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I. GENERAL INTRODUCTION 
I.1 INTRODUCTION 
Years of intensive research in pharmaceutical industry and academic have resulted in about 
300 biotechnology products which are approved in the US, thereby covering 16 medical areas 
and about 250 indications [1, 2]. Most protein based drugs are used in therapy of serious 
diseases such as diabetes, cancer or autoimmune diseases [3]. Especially a combination with 
conventional low molecular weight drugs results in a better treatment compared to the 
administration of one single therapeutic protein drug [4]. 
The key obstacle of any drug delivery system - especially in delivering proteins - is accurately 
defined by van de Weert et al. [4]: «The main aim […] is to deliver the drug to the active site at 
the right time, at a therapeutically effective concentration, at the highest patient 
convenience/compliance, with the lowest possible side effects and at the lowest possible 
costs». The key to a successful protein formulation and its delivery is therefore the knowledge 
of chemical, physical and biological properties of the protein, including immunogenicity, stability 
and pharmacokinetic properties. For example, the chemical and physical stability is influenced 
by pH, ionic strength, temperature and surface interactions [5].  
All these factors can be influenced by different formulation strategies. One may differentiate 
between formulation stabilisation using stabilisers or the direct modification of the protein 
structure. Stabilisation of proteins in the liquid and dry state (freeze-dried) is implemented using 
excipients, e.g. hydroxypropyl-beta-cyclodextrine (HP-β-CD) [6-8], sucrose [9-11], or by using 
surfactants. For instance, a well-known representative of this class are polysorbates [12-14]. 
Modifying the protein structure itself to improve its properties represents another strategy [5]. 
This includes the use of protein analogues with more promising properties, e.g. insulin lispro for 
type 2 diabetes or aldesleukin (IL-2 analogues) for therapy of renal cell carcinoma. Another 
approach is the attachment of fatty acids to the protein structure (acylation) which can increase 
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the half-life or the affinity to blood protein albumin. This principle has been applied for proteins 
like interferon-α [15] or desmopressin [16]. Likewise, the attachment of polyethylene glycol 
(PEGylation) or hydroxyethyl starch (HESylation) increases the half-life of proteins [5]. 
Additionally, these modifications improve the safety profile by shielding antigenic epitopes [17]. 
For example, a commercial product is PEG-interferon-α with an improved pharmacokinetic 
profile compared to native interferon-α [18]. To quote just one example, HESylation of Anakinra 
has been investigated by Liebner et al. [19, 20]. 
For protein and peptide based drugs, oral administration is still not possible (except for 
cyclosporine) since proteins and peptides are degraded by enzymes of the gastrointestinal tract, 
which results in poor bioavailability of the drugs [4, 21]. Furthermore, most proteins have a short 
half-life within the body due to hydrolysis and denaturation within the stomach. The intestinal 
mucosa of the small intestine is poorly permeable for larger molecules being an additional factor 
for poor bioavailability [22]. 
Alternative routes for protein administration have been studied such as buccal [23], rectal [24] 
nasal [25, 26], or pulmonary [27, 28] delivery. There is a need to develop a delivery system for 
proteins and peptides to the human body which show higher bioavailability and a longer half-
life, which consequently results in lower doses and fewer side effects. 
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I.2 CONTROLLED PROTEIN DELIVERY 
I.2.1 CURRENTLY MARKETED PEPTIDE AND PROTEIN DEPOTS 
So far, parenteral application of pharmaceutical proteins and peptides is indispensable due to 
their instability in the gastrointestinal tract and/or bioavailability limitations. To circumvent these 
problems, parenteral application of protein drugs including subcutaneous injection and 
intravenous infusion is common practice. As most proteins exhibit short half-lives compared to 
small molecule drugs [29], frequent administration is required which is associated with high 
costs in the health care system [30]. Therefore, depots have been investigated for parenteral 
administration to minimise dosing frequency and improve patients’ convenience.  
In 1990, Zoladex® was approved, which is a depot system containing the peptide Goserelin, a 
gonadotropin releasing hormone (GnRH) super agonist for the treatment of prostate cancer and 
breast cancer [31]. Zoladex® is available as a one-month or three-months depot formulation and 
is formulated within a poly-lactic-co-glycolic acid (PLGA) and poly-lactic acid (PLA) matrix. The 
approval of Zoladex® was the initial impulse for other GnRH analoga formulated within a 
PLGA/PLA matrix: Lupron Depot®, which is composed of a microparticulate system (PLA and 
leuprorelin acetate), was approved in 1993 for the treatment of prostate cancer, endometriosis, 
fibroids, and central precocious puberty (CPP) for children [32-35]. Also, Profact Depot® 
containing a GnRH analogon (buserelin acetate) is formulated in a PLA/PLGA matrix. The in-
situ forming depot Eligard® was launched in 2002 and contains leuprorelin acetate for treatment 
of prostate cancer [36, 37]. It is formulated in PLGA and N-methyl-2-pyrrolidon (NMP) and forms 
a depot once administered subcutaneously. So far, all depots described have in common that 
there are releasing peptides from a PLGA/PLA matrix.  
Also formulated as an injectable suspension of PLGA microparticles is Nutropin Depot®, which 
represents the only marketed product delivering the protein drug somatropin, a recombinant 
human growth hormone. It was approved by the FDA in 1999 for the treatment of growth failure 
due to a lack of adequate endogenous GH secretion [38]. Nutropin Depot® was intended to 
CHAPTER I 
4 
release somatropin over a period of one month, but was withdrawn in 2004 which was explained 
by «significant resources required by both companies (Alkmers Inc. and Genentech Inc.) to 
continue manufacturing and commercializing the product». Sandostatin LAR® represents a 
further depot based on PLGA microparticles for the treatment of acromegaly or tumors of the 
gastroenteropancreatic endocrine system. It contains octreotide acetate and is administered 
monthly.  
In 2011, the last approved depot for sustained delivery of a peptide was Bydureon®, which 
represents a further development of Byetta® (approved in 2007). Bydureon® contains the 
glucagon-like-peptide-1 (GLP-1) analoga exenatide and is encapsulated within PLGA 
microspheres [39]. Bydureon® is administered once a week for the treatment of diabetes type 2 
[40-42].  
In summary, all marketed products in which a protein drug is encapsulated within a matrix 
(without further direct modification) are based on PLGA/PLA matrices. Protein drugs 
encapsulated within such depots are rather small, ranging from approximately 1.2 kDa for the 
GnRH analoga to up to 22 kDa for somatropin, meaning that depots for monoclonal antibodies 
or other protein formats are not yet commercially available. 
 
I.2.2 MATRIX MATERIALS FOR CONTROLLED RELEASE OF PROTEINS AND 
PEPTIDES  
For sustained release of peptides and proteins, a wide variety of matrix materials has been 
described in literature, including a broad variation of synthetic (HEMA, PVA, EVA, PLGA/PLA, 
PEG) and natural polymers (alginate, chitosan, silk, casein, zein, cellulose derivates, collagen, 
triglycerides, phospholipids, cholesterol) forming implants, gels, micro- and nanospheres or 
films. In the following, the most recently used materials are briefly described with a special focus 
on PLA/PLGA matrices as they represent the most commonly used material and had been used 
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within this study as well. Lipids have also been investigated as parenteral sustained release 
depots and will be discussed separately (I.2.3).  
I.2.2.1 PLA/PLGA & PLGA COMPOSITES 
Although PLA/PLGA can be categorised as synthetic materials (which will be discussed in 
I.2.2.3), this paragraph is dedicated due to its intensive use. This polymer had been approved 
by regulatory agencies and is the only one being in use for marketed products (described 
above). Thus, research groups along the globe have investigated this matrix since decades. 
Between 1998 and 2008, predominantly the preparation of PLGA based microparticles for the 
sustained release of model proteins like bovine serum albumin (BSA) [43] but also 
pharmaceutical proteins such as erythropoietin [44-46] human growth hormone [47, 48], insulin 
[49], insulin-like growth factor-I [50], or bone morphogenetic protein-2 (BMP-2) [51] have been 
described. PLGA based implants [52, 53] and in-situ forming gels [54, 55] have been 
investigated as well. 
Along the preparation of PLGA based depots, the use of organic solvents is problematic in terms 
of protein stability as proteins tend to aggregate within a hydrophobic environment and at 
interfaces [56, 57]. The erosion of the matrix has negative effects on protein stability because 
degradation of PLA and PLGA results in an acidic microclimate, inducing a pH drop within the 
depot [58, 59]. Thus, chemical degradation, e.g. deamidation [60] and acylation [61], of the 
proteins has been observed.  
To overcome these drawbacks, two strategies had been pursued: the addition of excipients or 
the modification of the matrix itself. To prevent protein degradation, excipients like PEG [62, 63], 
HP-β-CD [64] or basic salts [53, 65] have been added. The modification of the matrix has been 
followed since 2007 as more and more literature can be found describing PLA/PLGA-
composites to overcome protein instability issues and to improve release kinetics. This includes 
conjugates with amino cyclodextrins [66], copolymers with monomethoxy-PEG [67], histidine 
[68], oligo(vinyl sulfadimethoxine) [69], or chitosan-graft-PLA micelles [70]. In addition, new 
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preparation methods like electrostatic adsorption of proteins onto PLGA nanoparticles have 
been investigated as described by Pakulska et al. [71] in 2016. Chang et al. investigated PLGA-
triacetin depots for sustained release applications of a fab-fragment [72] reporting on a sustained 
release of 80 days.  
In conclusion, it can be stated that PLGA based depots have been improved including both 
protein stability and release behaviour. Nevertheless, still major problems need to be addressed 
as protein instabilities [72] and incomplete release profiles [73] can still be found.  
I.2.2.2 NATURAL POLYMERS 
Natural polymers occur in nature and are often water-based. Examples of naturally occurring 
polymers are for example chitosan, collagen, silk, or cellulose.  
Chitosan have been extensively investigated within the last 10 years. Especially the preparation 
of particulate systems is reported, for instance nanoparticles and microparticles [74, 75]. 
Chitosan based depots have been described for tissue engineering applications of bone and 
cartilage. Hou et al. and Zhang et al. investigated the controlled release of NEL-like molecule-1 
(NELL-1) from chitosan nanoparticles [76] or chitosan/hydroxyapatite particles [76, 77] whereas 
BMP-6 was formulated within chitosan scaffolds [78]. In addition, the controlled release of insulin 
from chitosan microspheres [79], thermoresponsive chitosan hydrogels [80], chitosan-zinc 
copolymers [81], or chitosan composite hydrogels [82] has been described. However, chitosan 
has not yet been approved by regulatory agencies for parenteral applications.  
Alginate based depots are a further representative of natural polymers. Especially in recent 
publications, alginate composites rather than pure alginate based depots have been described. 
As already reported for chitosan depots, bone remodeling applications represent the major 
research field for alginate based systems. For instance, NELL-1 was encapsulated into apatite 
coated alginate/chitosan microparticles and was delivered for up to 30 days [83]. A 
thermoresponsive chitosan/dextran-polylactide/glycerophosphate hydrogel and selected 
alginate microspheres for the controlled release of BMP-2 for up to 42 days has been described 
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by Zhu et al. [84]. Likewise, Zuo et al. reported on heparin-conjugated alginate microspheres 
for the delivery of basic fibroblast growth factor (bFGF) addressing bone remodeling [85]. 
However, about a broader possible use of alginate scaffolds for sustained protein delivery has 
been reported as well [86]. Despite the application orientated research, research is still on-going 
towards a fundamental understanding of the underlying interaction mechanisms between 
proteins and alginate matrices as reported by Schweizer et al. [87]. They observed that ionic 
interactions between polyanions of the matrix and monoclonal antibodies occur which can be 
exploited for sustained release delivery. In 2016, Bazban-Shotorbani et al. reported on a new 
technology to synthesise alginate nanogels with tunable pore size for controlled protein delivery 
[88]. 
Another representative of the class of natural polymers is collagen. In the early 1990s, Marks et 
al. has already reported on dermal wound healing applications using fibroblasts seeded onto 
collagen matrices [89]. More recently, collagen and collagen composites have been described 
for tissue engineering applications. For instance, Friess et al. investigated the delivery of BMP-
2 from collagen sponges [90, 91]. The controlled release of BMP-2 from collagen fibers [92], 
collagen-hydroxyapatite scaffolds [93], and conjugated collagen scaffolds [94] have been 
utilised and show the potential of collagen in the field of bone regeneration.  
Beyond the «classical» polymers used for controlled release applications, silk represents a new 
and promising natural polymer and has been extensively studied within the last years. It should 
be stated that silk based depots can be divided into recombinant spider silk based systems and 
systems containing of the silk from the cocoons of Bombyx mori. Recombinant spider silk 
particles have been described by Hofer et al. releasing lysozyme for up to 28 days [28]. 
Furthermore, recombinant spider silk was used to produce films for controlled release 
applications. Agostini et al. studied the release of BSA from differently coated spider silk films 
that could deliver the protein in a close to zero order kinetic for 90 days. The other type of silk 
can be extracted from the cocoons of Bombyx mori as described by Hayden et al. [95]. A broad 
variety of depots has been described using this type of silk including hydrogels for intraocular 
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delivery of Bevacizumab [96], the sustained release of cytokines from films [97] or systemic 
investigations on monoclonal antibody stabilisation by silk biomaterials [98]. 
I.2.2.3 SYNTHETIC POLYMERS 
As an alternative to PLA/PLGA and natural polymers, synthetic materials have been studied as 
matrix material for controlled protein delivery.  
Among others, this includes polyanhydrides comprising fatty acids and sebacic acid, thereby 
enabling better controllable polymer properties. Polyanhydrides have been already studied 
since the early 1990s for controlled protein applications using model proteins such as BSA, 
ovalbumin or lysozyme [99-101]. Still, further research needs to be carried out addressing the 
molecular structure descriptors which appear to have the greatest impact on the release kinetics 
in order to optimise release behaviour [102]. 
The class of poly(ɛ-caprolactone) (PCL) represents a further synthetic polymer. PCL is a widely-
used polymer and has been approved by the FDA. It is a biocompatible and biodegradable 
polymer, which is non-toxic. PCL degradation does not create an acidic environment which 
could possibly negatively affect the integrity of encapsulated protein drug [103]. With PCL as 
matrix material, versatile depots can be produced including nanoparticles, fiber meshes or 
implants. For example, electrospun fiber meshes composed of PCL and polyethylene oxide 
(PEO) have been described for the controlled release of lysozyme for up to 300 hours. It was 
demonstrated that the initial burst can be reduced by adjusting the PCL/PEO ratio [104]. Within 
another publication, Rayaprolu et al. reported on BSA loaded PCL nanoparticles using D-α-
tocopheryl polyethylene glycol 1000 as an emulsifier [105]. By this, a sustained BSA release of 
5 days was achieved. Stanković et al. described long-term release of up to 170 days of various 
proteins and peptides including goserelin, lysozyme and carbonic anhydrase from hot melt 
extruded poly(ɛ-caprolactone-PEG)-b-poly(ɛ-caprolactone) multiblock-copolymer implants 
[106]. The structurally related polymer dihydroxyacetone-based poly(carbonate ester) has also 
been described for controlled release applications of BSA and lysozyme [107]. 
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Beyond the already known and established polymers (EVA, PVA, polyanhydrides, PCL), more 
and more very specific and unique polymers can be found in literature. As an example, the use 
of trimethylopropane ethoxylated-ethyl 2-mercaptoproprionate (TMPE-TL) or trimethylo-
propane ethoxylated ethyl thioglycolate (TMPE-TG) hydrogels has been described for the 
controlled delivery of bioactive horseradish peroxidase (HRP) for up to 16 days [108]. 
Furthermore, thermosensitive hydrogels consisting of multi-block Pluronic copolymers linked by 
lactide oligomers has been investigated delivering hGH over 13 days [109]. 
Generally, within the last few years, more and more sophisticated and highly complex release 
systems have been described in literature. This suggests that the «classical materials» have 
been replaced by completely new platform technologies or new composites with well-known 
materials. This opens entirely new research fields with innumerable possibilities. Just to name 
a few, within recent years it has been reported on glycidyl methacrylated dextran/gelatin 
hydrogel scaffolds [110], Diels-Alder hydrogels [111-113], nanogels made of hybrid 
hydroxyapatite nanoparticles with chitosan/polyacrylic acid [114], PEGylated fibrin gels [115], 
calcium phosphate based nanorods and nanowires for intracellular protein delivery [116], or 
photoactivated depots for the controlled release of insulin [117, 118]. 
It should be further mentioned that protein crystals for controlled release applications represent 
a very interesting and challenging research field at once [119-122].  
 
I.2.3 LIPID VEHICLES FOR CONTROLLED RELEASE OF PROTEINS AND PEPTIDES 
The Oxford Dictionary of Biochemistry and Molecular Biology defines lipids as biological 
substances that are generally hydrophobic in nature and in many cases soluble in organic 
solvents [123] such as fatty acids, phospholipids, sterols, sphingolipids, terpenes and others 
[124]. Other references divide this group of elements into different categories based on their 
chemistry, containing classes and subclasses of molecules, e.g. fatty acyls, glycerolipids, 
glycerophospholipids, sphingolipids, sterol lipids, prenol lipids, saccharolipids and polyketides 
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[125]. All definitions have one thing in common: lipids are predominantly hydrophobic but partly 
also have a hydrophilic component. Various types of lipids, many of them physiological 
substances such as triglycerides, cholesterol or phospholipids, have been investigated for lipid 
based implants [126]. 
As already mentioned before (I.1), oral application of proteins and peptides is in most cases not 
possible due to their degradation by the harsh conditions within the stomach and gastro-
intestinal tract [21]. Thus, efforts have been made to explore alternative administration routes 
for protein drugs for lipid-based carriers covering the pulmonary, transdermal or parenteral route 
[127-130]. 
I.2.3.1 SOLID LIPID NANOPARTICLES 
Solid lipid nanoparticles (SLNs) have attracted increasing attention as carrier for protein and 
peptide drugs. Mostly, SLNs are composed of physiological lipids, which make them an 
interesting alternative to synthetic polymers. Synthetic polymers have been used as common 
pharmaceutical excipient but also in food and cosmetic industry and thus considered to be save 
[131-133]. To prepare SLNs, the lipid raw material, emulsifier and water or solvent are needed. 
Commonly used lipids are triglycerides (e.g. Compritol® 888 ATO, Dynasan® 114), partial 
glycerides, steroids (cholesterol), fatty acids (trilaurin, trimyristin, tripalmitin), and waxes (cetyl 
palmitate) [134]. Various preparation methods are described in literature, e.g. ultrasonication, 
micro emulsion based technologies, solvent emulsification/evaporation, double emulsion 
methods, or spray drying methods. However, two main production techniques (high-pressure 
homogenisation and microemulsion-based techniques) are prevailed [135]. These techniques 
do not require potentially toxic organic solvents, which may also have deleterious effects on the 
protein drugs.  
Since the early 1990s, SLNs have been used as drug delivery system (DDS) for proteins and 
peptides including topical, oral, pulmonary and parenteral administration routes [136]. The use 
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of this vector as depot for protein drugs has been addressed within several publications, e.g. for 
yak interferon-α [137], insulin [138], or human recombinant epidermal growth factor [139].  
Within recent years, SLNs have gained more and more interest as DDS for peptides and nucleic 
acids. For instance, Sacchetti et al. described the use of SLNs to deliver the octapeptide 
LSCQLYQR for the treatment of resistant ovarian carcinoma. SLNs were formulated by a double 
emulsion method using stearic acid or Compritol® 888 ATO and different surfactants which 
resulted in SLNs being 130 nm to 1140 nm in size, all with a negative zeta potential [140]. 
However, SLNs showed substantial cytotoxic effect on ovarian carcinoma cells indicating that 
SLNs could carry efficiently the peptide to its target. In the course of an increased interest in the 
delivery of nucleic acids, SLNs have been used for RNA delivery [141]. For this purpose, usually 
cationic SLNs are needed due to the electrostatic interactions between negatively charged 
nucleic acids and positively charged lipids, which enables the formation of so-called lipoplexes 
[142-144]. As an example, it was demonstrated that cationic SLNs are capable to form 
complexes with DNA plasmids [143]. Jin et al. developed SLNs able to delivery siRNA to 
glioblastoma by overcoming the blood-brain-barrier with no apparent systemic toxicity [145]. 
Successful RNA delivery has also been described by Montana et al. using cationic SLNs as 
non-viral vectors for gene delivery [146]. Furthermore, lipid composites for nucleic acid delivery 
have been described as well [147, 148].  
I.2.3.2 SOLID LIPID IMPLANTS 
Within first publications describing solid lipid implants (SLIs) as DDS, SLIs were produced by 
compression or casting methods and were focused on fundamental questions, e.g. drug release 
mechanisms or solid-state behaviour of the lipids using exclusively small non-proteinaceous 
molecules. Then, model proteins have been encapsulated and in-vitro release behaviour was 
described followed by first in-vivo applications. Consequently, the composition of SLIs was 
optimised to prolong release periods ending up with the introduction of release modifiers, 
precipitating agents and pore formers. Compression as standard manufacturing technique was 
replaced by twin-screw (tsc)-extrusion, which has become the leading manufacturing technique 
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for SLIs so far. Applying tsc-extrusion to manufacture SLIs, research was carried out to prolong 
the release of proteins up to 240 days. Further, protein-lipid-interactions (which has been 
neglected up to now) has gained more and more interest because this aspect might play a major 
role in controlled protein release form lipid based DDS. Most recent, the field of possible 
applications was spread including vaccination, tumour therapy or intraocular applications. 
This «evolution» of SLIs within the last 20 years will be spotlighted more in detail in the following 
section. At this point it should be briefly mentioned that quite a significant number on 
publications is available addressing the «fundamental research» in the field of SLIs. This 
includes dissolution aspects [149-152], mathematical modeling [153-156], elucidation of 
underlying release mechanisms [157-159], solid-state behaviour of triglycerides [160-163], or 
casting as preparation method [164-166]. However, since all these publications used small 
molecules as model drugs rather than proteins and peptides, they are not enclosed within the 
following text. 
COMPRESSED SOLID LIPID IMPLANTS FOR PROTEIN AND PEPTIDE DELIVERY 
Compression represents a very fast, easy and inexpensive manufacturing technique and was 
the method of choice in the early stages of SLI manufacturing. Versatile lipids have been used 
to prepare compressed SLIs by applying hydraulic presses. Direct compression has been used 
by different research groups for approximately 20 to 25 years for controlled release applications 
of proteins and peptides [126, 167-170].  
In 1987, Wang et al. incorporated insulin in lipidic matrices consisting of different fatty acids, 
anhydrides of fatty acids, triglycerides and cholesterol [171]. SLIs were administered 
subcutaneously and controlled release of insulin was measured for approximately 1 month, as 
measured by the blood glucose level of diabetic Wistar rats. Moreover, the authors already 
reported on erosion of the SLI once administered subcutaneously, thereby already underlining 
the potential as biodegradable DDS [126].  
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On the sustained release of labelled BSA and hyaluronidase was reported by Vogelhuber et al. 
in 2003 using a compressed glycerol trimyristate matrix. In-vitro investigations revealed a high 
initial burst and incomplete protein release, which was explained by insufficient amounts of pore-
forming agents. In addition to in-vitro testing, the implants were tested under in-vivo conditions 
by subcutaneous implantation in mice showing a good in-vivo stability after 15 days [170, 172].  
The biocompatibility of lipid implants was addressed by Guse et al. [173] in 2006. The authors 
observed that a blend of glycerol tripalmitate with either lecithin or cholesterol showed good 
biocompatibility after subcutaneous implantation in mice while an increasing amount of lecithin 
led to increased inflammatory reactions at the site of administration. The incorporation of lecithin 
led to clearly visible signs of degradation which was not the case for cholesterol. 
Also published in 2006, Appel et al. investigated insulin loaded implants with the background of 
cartilage engineering [169]. Lipid matrix cylinders with dimensions of 2 mm x 2 mm were 
manufactured from glycerol tripalmitate by compression without further additives. SLIs were 
loaded with different concentrations of insulin (0.2 % to 2 %) and the bioactivity of released 
insulin was measured for up to 4 weeks. The authors reported that the bioactivity of 
encapsulated and released insulin was preserved as the weights of cartilaginous cell-polymer 
constructs increased compared to the control [169]. 
Compression as manufacturing technique was also used for the controlled release of 
interleukin-18 (IL-18), reported by Koennings et al. [174]. A cell culture assay was established 
for the bioactivity determination of released IL-18 showing a continuous release of 10 ng to 
100 ng IL-18 per day for up to 12 days. An incomplete release (< 35 %) of IL-18 from the 
matrices was explained by insufficient amounts of pore-forming agents (as stabiliser and pore 
forming agent, PEG was used). Furthermore, it was reported on an integrity loss with ongoing 
release, which would be related to protein degradation during incubation. Within a second 
publication, Koennings et al. addressed the sustained release of brain-derived neurotrophic 
factor (BDNF) with an additional focus on different manufacturing strategies [175]. Four different 
manufacturing techniques performed with the model protein lysozyme (all counting to 
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compression based approaches) were applied: (i) direct mixing of lyophilised lysozyme with lipid 
powder, (ii) a solid-in-oil dispersion of lyophilised lysozyme in tetrahydrofuran mixed with a 
solution of the triglycerides, (iii) a water-in-oil emulsion (the protein was dissolved in the aqueous 
phase and the lipid in dichloromethane), and (iv) a co-lyophilisation of lysozyme with PEG 6000 
prior to compression. Slowest release was observed for more than 60 days applying the water-
in-oil emulsion technique and the co-lyophilisation approach. Interestingly, the water-in-oil 
emulsion technique induced higher levels of aggregates, thus the co-lyophilisation technique 
was found to be most appropriate. Consequently, this technique was used for the preparation 
of BDNF loaded SLIs. In-vitro release studies revealed a sustained release of BDNF for up to 
30 days, although total amount of released protein was only 60 % [175].  
Starting in 2004 with the publication «Continuous release of rh-interferon a-2a from triglyceride 
matrices» by Mohl et al. [167], the research group of Prof. Winter addressed the topic of lipid 
based depots for controlled protein release. Mohl et al. described compressed SLIs consisting 
of glycerol tristearin, PEG 6000 and lyophilised rh-interferon α-2a. In contrast to Koennings et 
al., Mohl et al. reported on an almost complete release of incorporated rh-interferon α-2a (more 
than 90 %) over a period of 1 month. The authors further stated, that the release rate was 
controlled by the amount of PEG 6000, which was added to the formulation acting as a pore-
forming agent. In addition, compressed SLIs were stored for 6 months prior to in-vitro release 
in order to investigate the storage stability of the SLIs including protein stability and release 
[176]. After a 6-month storage, the release patterns were comparable to those from non-stored 
SLIs. Furthermore, rh-interferon α-2a was released in its monomeric form when HP-β-CD was 
used as stabiliser even after storage of the implants at room temperature. It turned out that the 
use of trehalose as excipient resulted in increased levels of aggregated and oxidized species 
after storage and release [176].  
The role of PEG as release modifier was investigated by Herrmann et al. [177]. The release of 
rh-interferon α-2a was monitored as a function of different PEG percentages within the 
formulation. For this, SLIs were prepared by compression comprising 0 to 20 % PEG. The 
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addition of PEG substantially changed both the protein release rate and the underlying mass 
transport mechanisms [177]. If no PEG was added, the release of rh-interferon α-2a was purely 
diffusion controlled. Contrarily, in PEG-containing SLIs the release rate remained constant over 
prolonged periods of time pointing into the direction that also other release mechanisms (which 
were not observed before) were involved. Interestingly, the release of PEG itself from SLIs 
persisted purely diffusion controlled, irrespective of the amount of PEG added. Herrmann et al. 
concluded that different mass transport mechanisms govern the release of rh-interferon α-2a 
out of the lipidic implant. Further work showed that at a physiological pH rh-interferon α-2a tends 
to precipitate in the presence of PEG which was reflected in the release kinetics [156, 178]. By 
this, it was shown for the first time that the release of pharmaceutical proteins can be controlled 
by an in-situ precipitation. 
The in-vivo rh-interferon α-2a release from compressed SLIs was studied by Schwab et al. [168]. 
SLIs were implanted subcutaneously in rabbits and sustained protein release was measured 
over 9 days. A modelling of the data revealed that the in-vivo release correlated closely with the 
in-vitro release. The lipase induced degradation of lipid implants was also investigated by 
Schwab et al. to obtain information about degradation time frames of SLIs once administered. 
SLIs were compressed from either 100 % of a single triglyceride or a blend of two of the following 
lipids: Dynasan® D112 (trilaurin), D114 (trimyristin), D116 (tripalmitin) or D118 (tristearin). The 
authors stated that the triglyceride D112 seems to play a major role in the degradation and 
erosion processes of the implants [179]. This is due to the melting point of D112, which is below 
the human body temperature leading to disintegration and loss of physical integration, which is 
also of special interest of the present work. 
Jensen et al. reported on the in-vitro release of insulin from compressed lipid implants being the 
first author after nearly 10 years using again compression as preparation technique [180]. The 
work described the investigation of UV imaging-based in-vitro methods to enable the 
visualisation of released drug to mimic the subcutis. Jensen et al. stated that «Insulin release 
from 10 % (w/w) implants into agitated solution was faster as compared to release into agarose 
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hydrogel. This was ascribed to the additional mass transfer resistance provided by the agarose 
hydrogel. » [180]. 
TWIN-SCREW EXTRUDED SOLID LIPID IMPLANTS FOR PROTEIN AND PEPTIDE DELIVERY 
Schulze et al. [181] introduced tsc-extrusion as manufacturing technique for lipid implants which 
meanwhile became one of our standard manufacturing techniques besides the direct 
compression technique described above [168, 175, 177].  
Lipid implants consisted of 10 % rh-interferon α-2a co-lyophilised with HP-β-CD and 10 % PEG 
6000 incorporated into a lipid matrix. The lipid matrix consisted of D118 with either H12 or E85 
both low melting lipids. Extrusion was performed at 40°C with a screw speed of 40 rpm. The 
authors stated that sustained release occurred in a sustained manner over 15, 40, or 60 days 
as a function of the composition [181]. Moreover, the preparation process did not affect the 
stability of rh-interferon α-2a which was studied by FT-IR and SDS-PAGE. 
Tsc-extrusion was systematically investigated by Sax et al. approaching the influence of melting 
events on the in-vitro release of lysozyme [182]. For this purpose, D118 was admixed with 
different low melting lipids (having slightly different melting points) and PEG 4000 or PEG 6000 
was added as pore forming agent. A more sustained release (for up to 240 days) of lysozyme 
was achieved when the amount of PEG was reduced. Interestingly, the inner structure of the 
implant changed during release as measured by DSC and XRPD. The authors explained that 
phenomenon by a partial melting of the lipid matrix. Thus, Sax et al. concluded that partial 
melting of the implants during in-vitro release was found to be a major factor for the controlled 
protein release being a useful tool to trigger release. To study this phenomenon more in detail, 
single molecule fluorescence microscopy revealed that two release pathways were present. 
Surprisingly, it was observed that «proteins were not only released via water-filled pores 
(created by dissolution of the pore-former), but surprisingly also through diffusion in a phase of 
molten lipid.» [183]. This represented a completely new finding which is crucial for the future 
development of lipid-based depots also being important for this thesis. 
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The in-vivo biodegradation was described in a rabbit model by Sax et al. [184]. Different 
formulated SLIs were implanted subcutaneously in rabbits and implant mass was measured for 
6 months. After 6 months, recovered implant mass was only 24 % in average. Furthermore, 
biodegradation was a function of formulation: the presence of pore forming agent resulted in 
higher mass loss and an accelerated degradation rate. The unique composition of a low melting 
and a high melting lipid was claimed to be responsible for the good biodegradability due to a 
partial melting of the implant at physiological temperatures. 
Neuhofer used this formulation investigated by Schulze et al. and Sax et al. for the 
encapsulation of the hydrophobic protein native interferon-β-1b (nIFN-β-1b) [185]. The 
sustained release of nIFN-β-1b was described for up to 10 days when surfactants (0.1 % SDS 
or 0.15 % laureth-12) were added to the release medium. Since almost no release was 
observed when no surfactants were added (approximately 5 % after 7 days), it was assumed 
that the high hydrophobicity and solubility effects might play a role for triggering the release of 
proteins. This hypothesis was strengthened by the more complete release of more hydrophilic 
PEGylated interferon-β-1b (60 % within 7 days). Thus, Neuhofer was the first studying possible 
interactions between the proteins and the matrix materials by adsorption experiments and QCM 
studies. QCM studies revealed a tendency to fewer protein adsorption of PEG-IFN-β-1b to a 
tristearin surface than nIFN-β-1b. This indicates a stronger affinity of nIFN-β-1b to hydrophobic 
surfaces [185]. 
Interactions between triglycerides and peptides were studied by Even focussing on interactions 
between peptides (being different in charge and hydrophobicity) and the lipids D114 (trimyristin), 
soybean lecithin and cholesterol [186]. Even found that adsorption to D114 was a function of 
hydrophobicity of the peptide.  
Moreover, Even et al. explored new application fields for SLIs. The authors described the in-
vivo investigation of SLIs as depot for vaccines [186] using the model antigen Quil-A in a mice 
model. Quil-A was released for 14 days and the overall immune response (CD4+ and CD8+ T-
cell proliferation, IgG production, cytokine secretion) revealed a successful proof of concept. 
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Addressing the field of immunotherapies, the peptide tyrosinase-related protein-2 (TRP-2), 
being an antigen in tumour therapy approaches, was successfully incorporated into SLIs and 
tested in mice. The in-vivo study showed that mice which received TRP-2 loaded implants had 
delayed tumour growth for 3 days compared to groups having received no TRP-2 [187]. Within 
this publication, Even et al. was the first one using the ZE-5 mini-extruder from Three-Tec for 
the production of tsc-extruded implants. They stated that «The type of extruder used to produce 
the implants had a major influence on implant properties and the release behaviour, 
demonstrating that extrusion parameters and lipid formulations have to be individually adapted 
to each extrusion device.» [187]. These aspects are of special interest of the present work since 
the ZE-5 mini-extruder was intensively used.  
 
I.2.4 INTRAOCULAR DELIVERY  
The treatment of several serious eye diseases, e.g. age related macular degeneration (AMD), 
is up to now associated with significant side effects due the penetration of the posterior segment 
of the eye by a needle [30, 96]. AMD is the leading cause of blindness in industrialised nations 
for people over 50 years [188]. The wet AMD accounts for only 15 % of all AMDs, but causes 
about 90 % of blindness [189]. The pathology is based on weak blood vessels underneath the 
macula and retina affecting a leakage of fluids (e.g. blood) into the eye and finally causing 
macular damage [190]. This causes the distribution of inflammatory markers (cytokines or 
VEGF) generating ischemia and inflammation, which leads to choroidal neovascularisation 
(CNV) [191]. New blood vessels grow irregular under the macula supporting rapid central vision 
loss. Furthermore, CNV has a strong link to increased expression of the VEGF gene [192]. 
Currently, the management with anti-VEGF drugs such as Bevacizumab (Avastin®), 
Ranibizumab (Lucentis®) and Aflibercept (Eylea®) are representing the state of the art therapy 
[193-197]. Besides the stress for the patient, the required monthly injections into the vitreous 
causes injection-related adverse effects like endophthalmitis [96]. Hence, it would be preferable 
to prolong the period between two intravitreal injections by using sustained release devices to 
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improve patient convenience, safety, and efficacy. With these limitations, efforts are being made 
to develop ocular inserts releasing therapeutic drugs over a long time to reduce application 
intervals. 
I.2.4.1 MARKETED PRODUCTS FOR INTRAOCULAR ADMINISTRATION 
Currently, there are four commercially available ocular implants providing long-term release 
from either biodegradable or non-biodegradable polymeric systems over several months to 
years.  
Vitrasert®, the first non-biodegradable intravitreal implant approved by the FDA in 1996, 
contains ganciclovir for the therapy of cytomegalovirus retinitis. It is consisting of a drug pellet, 
coated with PVA allowing drug release of 5 to 8 months [198]. The outer and inner permeable 
PVA layers sandwiching a discontinuous layer of impermeable EVA controlling the release. 
Other intravitreal devices based on this technology are on the market such as Retisert® from 
Bausch and Lomb which contains fluocinolone acetonide and is approved for the treatment of 
chronic non-infectious uveitis [199]. Iluvien™ is another injectable intravitreal insert which 
delivers a very low dose of the corticosteroid fluocinolone acetonide (0.5 µg to 0.2 µg/day) to 
the retina over a period of about 3 years [200]. The implant consists also of a drug-loaded core 
coated with a PVA layer and has a release opening. All these implants are non-biodegradable 
and need to be surgically removed.  
Ozurdex® is commercially available since June 2009 and was approved by the FDA for the 
treatment of macular edema [201]. The implant consists of a PLGA matrix, which degrades 
slowly to lactic acid and glycolic acid allowing the long-term release of dexamethasone of up to 
6 months [202-204]. 
In summary, it can be concluded that an ocular insert loaded with a therapeutic protein or 
peptide has not yet reached the market. 
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I.2.4.2 VEHICLES FOR INTRAOCULAR DELIVERY OF PROTEINS AND PEPTIDES 
The development of intravitreal inserts for the sustained release of therapeutic proteins and 
peptides is currently in the focus of research. Delivery platforms described in literature are 
multifaceted including implants, hydrogels and particulate systems affirming the efforts, which 
had been made within the last years. Interestingly, irrespective of the depot used within those 
studies, it is noteworthy that in most (but not all) cases Bevacizumab was used.  
In 1999, the first intravitreal controlled release application of a monoclonal antibody was 
described by Mordenti et al. [205]. Trastuzumab was encapsulated into PLGA microspheres 
and injected into rabbit eyes. The depot was well tolerated in the eye and suitable for ocular 
applications as no relevant side effects were reported. However, the total cumulative release of 
Trastuzumab was only 32 %, thereby indicating large portions of non-released and/or nonnative 
antibody [29]. 
The most represented dosage form are hydrogels and semisolid depots including thermo-
responsive hydrogels [206], Diels-Alder hydrogels [111], or silk hydrogels [96]. As an example, 
thermoresponsive hydrogels consisting of poly(N-isopropyl acrylamide) were cross-linked with 
PEG-diacrylate and Bevacizumab and Ranibizumab were encapsulated within this matrix. A 
sustained release for approximately 3 weeks was observed whereby the release rate was 
controllable by varying the cross-linking degree [206]. Bevacizumab had also been 
encapsulated within silk hydrogels, which were administered into rabbit eyes. Release 
concentrations were achieved after 90 days equivalent than those achieved at 30 days with the 
positive standard dose control (a single injection of 50 µl Bevacizumab intravitreally 
administered). Thus, a comparable therapeutic threshold based on a dosage administration 
schedule of one injection/month was achieved [96]. 
The sustained-release of a fab-fragment has been described by Asmus et al. Here, the authors 
considered the use of a hydrophobic polyester hexylsubstituted PLA (hexPLA) as matrix. The 
fab-fragment exhibited an excellent compatibility with the matrix and the protein was released for 
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6 to 14 weeks [207]. Furthermore, the antibody fragment structure remained intact during 
incorporation and release. 
A representative of particulate systems is described by Chen et al. where the encapsulation of 
connexin43 mimetic peptide into PLGA micro- and nanoparticles is broached for treatment of 
retinal ischaemia [208]. The use of PLGA based nano- and microspheres for Bevacizumab 
delivery was shown by Li et al. showing a sustained release for over 90 days [209].  
Another interesting approach is the use of nanostructured mesoporous silica films loaded with 
Bevacizumab. By this technique an in-vitro release of bioactive Bevacizumab over one month 
has been observed [210]. A fascinating but completely different technology has been described 
by Gooch et al. and Molokhia et al., the so-called capsule drug ring (CDR). The CDR is designed 
to serve as refillable reservoir and being placed within the capsular bag during cataract surgery 
with the ability to release Bevacizumab close to zero order kinetic [211, 212].  
I.2.4.3 LIPID BASED VEHICLES FOR INTRAOCULAR USE 
Only a few publications are available regarding the intraocular delivery of proteins from lipid 
based systems. The study of Abrishami et al. is one of the few describing the in-vivo 
performance of Bevacizumab encapsulated within a nanoliposomal formulation [213]. 
Liposomes were prepared by the dehydration-rehydration method and were scaled to nano size 
even though the exact diameter is not mentioned. However, the Bevacizumab containing 
liposomal formulation was tested in rabbit eyes and Bevacizumab concentration was monitored 
for 42 days. The depot was well tolerated over 42 days and Bevacizumab clearance was slower 
for the liposomal formulation compared to the soluble form.  
A single publication is available addressing the in-vivo performance of SLIs for intravitreal 
purposes. In 2014, Tamaddon et al. reported on SLIs consisting of a glyceride tripalmitate 
matrix. The implants had a diameter of 0.4 mm and were fabricated via a hot melt extrusion 
method. In-vitro release of clindamycin was up to 10 days and in-vivo biocompatibility was 
tested in rabbit eyes showing no abnormalities up to 2 months after implantation into the rabbit 
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eye [214]. Even though the SLIs did not contained a protein drug, the similarity to the SLIs 
described within this thesis is noteworthy. 
It is apparent, that lipid based intravitreal depots are in the early stages and that much more 
research should be done. On the other hand, this highlights that the work presented here is 
intended to exactly address this gap considering it as an incentive for further research. 
 
I.2.5 PROTEIN STABILITY CONSIDERATIONS FOR CONTROLLED RELEASE 
SYSTEMS 
The controlled release of pharmaceutical protein drugs is a key strategy to reduce both systemic 
side effects and the frequency of drug administration [71]. However, developing protein delivery 
systems which ensure both suitable release and at the same time maintaining the stability of 
the protein drug represents the major challenge [215]. Jiskoot et al. already underlined the 
importance of knowledge on possible protein instability and immunogenicity even before 
considering it for a sustained release depot. [216]. 
During a «life time» of a DDS, the proteins are exposed to multiple unfavorable conditions, e.g. 
during the manufacturing process, storage of the DDS prior to use and during release. 
Considering the great diversity and number of DDS for protein and peptide drugs, it is surprising 
that numerous publications do not pay any or not sufficient attention to this important topic.  
Generally, each single protein – even among the same subclass – has its own unique 
physicochemical «fingerprint» which needs to be taken into consideration when developing a 
DDS. For instance, each protein is unique by its isoelectric point (pI), surface charge distribution, 
hydrophobic patches or buffer capacity dedicated by its primary structure [29]. Moreover, when 
considering different protein formats such as bispecific antibodies, fab-fragments, PEGylated 
proteins or fusion proteins, these differences become even more enhanced.  
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A protein encapsulated within a DDS is even more exposed to additional stress conditions than 
a protein administered intravenous. These additional stresses can occur during 
encapsulation/manufacturing, storage, and in-vivo release.  
Harsh conditions can arise during encapsulation/manufacturing of the DDS and can be 
exemplarily illustrated by the production of PLGA particles where vigorous stirring and 
emulsification of a protein solution into a polymer solution is obligatory [60]. Moreover, proteins 
are exposed to organic solvents and interfaces and the high hydrophobicity of PLGA favours 
interactions [217]. Of course, these issues can also be encountered when other technology 
platforms than PLGA are used. For instance, in case of particular lipid-based DDS including the 
preparation of liposomes [218]. 
Once administered, e.g. subcutaneously, the protein need to retain its integrity at the 
administration site at the conditions prevailing in-vivo. In the case of subcutaneously 
administered DDS (e.g. in-situ forming gels), the depot retains the drug for long time periods at 
the administration site often exceeding their endogenous half-life [219]. This is because under 
in-vivo conditions, proteins tend to degrade much faster than under in-vitro storage conditions 
(2°C to 8°C). Additionally, after administration the protein is exposed to 37°C and the present 
of matrix degradation products, interstitial fluid, proteolytic enzymes, various cells and cellular 
by-products (reactive oxygen species) which could result in adverse side effects [216, 220]. 
Moreover, «stabilizers present within the original formulation rapidly dissipate and are usually 
not available to protect the drug during drug release inside the matrix» as stated by Schweizer 
et al. [29]. 
Despite protein instability considerations, also the immunogenicity aspects should be 
considered since a number of immunological risks are associated with the application of DDS 
including hypersensitivity reactions [221]. Moreover, pharmacokinetics, biodistribution and 
targeting capability can be negatively affected [220]. The highest risk are anti-drug-antibodies 
against the protein drug itself [222], its aggregates [223-226], the matrix material or targeting 
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ligands associated with the DDS. This could cause reactions and formation of membrane attack 
complexes or accelerated clearance as stated by Rojko et al. [227].  
Jiskoot et al. perfectly summarised this topic and formulated three approaches for the adequate 
characterisation of proteins in DDS to «obtain as complete a picture as possible of the quality 
of the drug product»: (i) characterisation of the protein encapsulated within the DDS, (ii) 
characterisation of released protein and (iii) characterisation of protein which remained within 
the depot [216].  
During this work, it was intended to take these approaches into consideration. 
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II. OBJECTIVES OF THE THESIS 
 
The applicability of parenteral depots has been studied intensively within the last two decades. 
Besides the thoroughly investigated PLA/PLGA depots [48, 73], those depots include PLGA-
composites [68, 70, 72], alginate [84], chitosan [76, 77, 80], silk [28, 96, 98], or casein [228], 
just to name a few. Due to the drawbacks of PLA/PLGA materials in terms of protein stability 
[49, 72, 229], lipid based depots have gained more and more importance as material for long 
term delivery of proteinaceous drugs. Preserving the integrity of incorporated proteins [176, 181] 
is the most valuable benefit over commonly used PLA/PLGA polymers.  
Previous works on triglyceride based implants have already demonstrated the suitability of such 
depots to maintain stability of both encapsulated and released protein [176, 181]. Furthermore, 
the long-term release of protein drugs from triglyceride implants was demonstrated by a rather 
simple and straightforward compression technique [167, 177]. Within our group, tsc-extrusion 
was established and meanwhile became one of the standard manufacturing techniques. It was 
shown that tsc-extruded SLIs exhibit a more sustained release and a more homogenous drug 
distribution compared to SLIs manufactured by direct compression [230]. For instance, long-
term release of protein drugs was successfully demonstrated for interferon α-2a, which was 
delivered for more than 60 days [181] and for lysozyme, for which a release of more than 
200 days was described [182]. Also, it has already been demonstrated that SLIs are a promising 
platform for various applications, e.g. vaccination [231], tumour therapy [187], subcutaneous 
administration [184], or intraocular use (data not published).  
The starting point of the present work was an established extrusion process on the MiniLab® 
Micro Rheology Compounder which was used for the sustained long-term release of different 
model proteins and therapeutic proteins [232]. Also, in-vivo investigations had revealed 
excellent biocompatibility after subcutaneous [184] and intravitreal administration (data not 
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published). Within those works, sustained release of different commercially available protein 
formats has not yet been reported. Also, protein stability and biological activity aspects had not 
been investigated systematically with regards to tsc-extrusion as manufacturing technique. 
Furthermore, the impact of different extrusion parameters (e.g. extrusion temperature, screw 
speed) on implant characteristics and release patterns had not been investigated systematically 
[182, 186, 233, 234]. 
Consequently, the present work was aimed to address the following objectives: 
(i) further optimisation of the manufacturing process (extrusion parameters, 
formulation) with a focus on intraocular use is described in chapter IV. For this, a 
new extruder (ZE-5 mini extruder) was acquired allowing to manufacture small 
batches. In a first step, the established process was transferred from a MiniLab® 
Micro Rheology Compounder to a ZE-5 mini extruder. It was aimed to optimise the 
process to reach delivery time frames of at least 3 months. Second, as a potential 
intraocular use was considered, reducing implant dimensions and increasing the 
protein load while ensuring release patterns and storage stability was intended. To 
study the impact of the incorporated protein on release patterns, different protein 
formats were used including three commercially available products: Ranibizumab 
(Lucentis®), Bevacizumab (Avastin®) and Aflibercept (Eylea®). Additionally, another 
model mAb was used. To further tailor the release, triglycerides were pre-melted 
prior to extrusion to intentionally change their thermal and physicochemical 
properties. 
(ii) A 3-month in-vivo study in rabbit eyes using Ranibizumab loaded SLIs was executed 
to evaluate the in-vitro-in-vivo release correlation and pharmacodynamic effects 
within a choroidal neovascularisation (CNV) model (chapter V).  
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(iii) Within chapter VI, the bioactivity of fractions released from SLIs of the natural 
complement regulator Factor H (mini-FH) was studied to obtain information on its 
biological activity once released. 
(iv) Further work included the systematic investigation on stability of released protein 
over the complete release duration covering colloidal, chemical and conformational 
stability (chapter VII). Comparison of stability profiles delivered from SLIs to PLGA-
based implants was performed. 
(v) Recent work pointed into the direction that not only the manufacturing settings 
influence release patterns but also the properties of the protein itself [185, 186]. 
Consequently, the influence of possible triglyceride-protein-interactions on protein 
stability was investigated within chapter VIII.  
(vi) Solid lipid extrusion (SLE) has been used previously within different works [162, 163, 
235-237]. However, the extrusion process itself and its impact on the lipid matrix and 
release patterns has not yet been described. It was therefore the aim of chapter IX 
to characterise the SLE process with regards to how changing process parameters 
affect the properties of the lipid matrix and the release patterns of the model mAb. 
Therefore, the impact of process parameters such as extrusion speed, temperature, 
and lipid composition on implant properties was investigated systematically. 
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III. MATERIALS AND METHODS 
III.1 MATERIALS 
III.1.1 PROTEINS 
In this thesis, the following proteins were utilised for the preparation of long-term release lipid 
depot systems: 
A monoclonal IgG1 antibody (mAb) formulated in a 10.5 mM sodium phosphate buffer at pH 6.4 
at a concentration of 17.3 mg/ml was utilised.  
Bevacizumab (Avastin®) is a recombinant humanised monoclonal IgG1 antibody that binds to 
human vascular endothelial growth factor (VEGF) [195, 238, 239] and has an approximate 
molecular weight of 149 kDa. Bevacizumab is formulated at a concentration of 25 mg/ml in a 
50 mM sodium phosphate buffer containing 60 mg/ml α, α-trehalose and 0.04 % polysorbate 20 
at a pH of 6.2.  
Ranibizumab (Lucentis®) is a recombinant humanised IgG1 monoclonal antibody fragment from 
Bevacizumab (Avastin®), inhibiting the biologic activity of VEGF [193, 196]. Ranibizumab has a 
molecular weight of approximately 48 kDa and is formulated in 10 mM histidine-HCl, 10 % α, α-
trehalose dihydrate and 0.01 % polysorbate 20 at pH 5.5. 
The recombinant fusion protein Aflibercept (Eylea®) consists of portions of human VEGF 
receptors and extracellular domains fused to the Fc portion of human IgG1 [191, 197]. It is a 
dimeric glycoprotein with a molecular weight of 97 kDa containing 15 % glycosylation which 
results in an overall molecular weight of 115 kDa. Aflibercept is formulated in 10 mM sodium 
phosphate at a concentration of 40 mg/ml, also containing 40 mM sodium chloride, 5 % sucrose 
and 0.03 % polysorbate 20 at pH 6.2. 
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Bevacizumab (Avastin®), Ranibizumab (Lucentis®) and Aflibercept (Eylea®) were kindly 
provided by the Moran Eye Center (Salt Lake City, Utah, USA). 
The C3-opsonin targeted complement inhibitor mini-FH having a molecular weight of 43.3 kDa 
[240, 241] was available as freeze-dried powder without further stabilisers. It was provided by 
the group of Dr. Christoph Schmidt from the Institute of Pharmacology and Natural Products 
and Clinical Pharmacology, Ulm University, Germany.  
 
III.1.2 TRIGLYCERIDES 
The triglycerides Dynasan® D118, Witepsol H12, H12 and H12A were a kind gift from Cremer 
Oleo (Hamburg, Germany). The high melting lipid D118 consists of nearly 100% tristearin, 
whereas the low melting lipids Witepsol H12, H12 and H12A are a mixture of trilaurin, trimyristin 
and tripalmitin (Table III-1).  
Table III-1: Properties of the triglycerides H12, H12A, Witepsol H12 and D118. 
 H12 H12A Witepsol H12 D118 
Hydroxyl value [mg KOH/g) 0.0 0.0 5.0 2.4 
C12 fatty acid (trilaurin) [%] 70.2 74.2 70.8 0.0 
C14 fatty acid (trimyristin) [%] 27.1 25.3 26.0 0.0 
C16 fatty acid (tripalmitin) [%] 2.3 0.2 2.4 0.0 
C18 fatty acid (tristearin) [%] 0.0 0.0 0.0 98.2 
Triglyceride content [%] 99.7 99.9 96.5 99.9 
Tonset [°C] 36.8 37.4 32.0 70.0 
Tmelting [°C] 43.1 42.4 39.9 72.7 
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III.1.3 POLY(D,L-LACTIC-CO-GLYCOLIC) 
The Poly(D, L-lactic-co-glycolic) (PLGA) Resomer® RG 502, Resomer® RG 502 H and 
Resomer® RG 755 S were purchased from Evonik Industries (Essen, Germany). Based on the 
different ratios of lactide to glycolide acid and different end groups, properties of PLGAs varied 
in their molecular weight, degradation time and chemical end groups (Table III-2). 
Table III-2: Properties of the Resomer® polymers RG 502, RG 502 H and RG 755 S. 
Type of 
Resomer® 
Molecular weight 
Ratio Poly(D,L-lactic-co 
glycolic) 
Degradation time 
frame 
End group 
RG 502 7.000 to 17.000 Da 50:50 < 3 months alkyl ester 
RG 502 H 7.000 to 17.000 Da 50:50 < 3 months free COOH 
RG 755 S 76.000 to 116.000 Da 75:25 < 6 months ester 
 
III.1.4 CHEMICALS AND SALTS 
All reagents and chemicals used within this work are listed in Table III-3. All chemicals and salts 
were of analytical grade. 
Table III-3: List of chemicals and salts used within this work. 
Substance Abbreviation purchased from 
4,4′-Dianilino-1,1′-binaphthyl-5,5′-
disulfonic acid dipotassium salt 
Bis-ANS Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Ammonium sulfate (NH4)2SO4 Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
di-Sodium hydrogen phosphate 
dihydrate p.A. 
Na2HPO4*2H2O AppliChem GmbH & Co. KG, Darmstadt, 
Germany 
Hydroxypropyl-β-cyclodextrine HP-β-CD Wacker Chemie AG, Burghausen, 
Germany 
Imidazole - Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
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n-Hexane - Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Piperazine - Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Polyethylene glycol 6000 PF PEG 6000 Clariant GmbH, Frankfurt am Main, 
Germany 
Potassium chloride KCl AppliChem GmbH & Co. KG, Darmstadt, 
Germany 
Potassium dihydrogen phosphate KH2PO4 Merck KGaA, Darmstadt, Germany 
Sodium azide NaN3 Merck KGaA, Darmstadt, Germany 
Sodium chloride NaCl Prolabo, Leuven, Belgium 
Sodium dihydrogen phosphate 
dihydrate 
NaH2PO4*2H2O AppliChem GmbH & Co. KG, Darmstadt, 
Germany 
Tris(hydroxymethyl)aminomethane Tris Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
 
III.2 METHODS 
III.2.1 PREPARATORY STEPS 
III.2.1.1 DIALYSIS 
Dialysis of the protein formulations was performed to deplete the formulations of buffer salts 
and stabilisers and to substitute them with hydroxypropyl-β-cyclodextrine (HP-β-CD). HP-β-CD 
was used as lyoprotectant to assure protein stabilisation during freeze drying and storage as 
reported previously for rh-interferon α-2a [176] and erythropoietin [242]. The protein bulk 
materials were dialysed against 50 mM sodium phosphate buffer pH 6.2 at 4°C by complete 
buffer exchange thrice resulting in 20 liters total buffer volume. The theoretical dilution factor 
was calculated with 1200. Dialyses was performed in a CelluSep® T1 tube from Orange 
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Scientific (Braine-l’Alleud, Belgium) with a molecular weight cut off (MWCO) of 3.5 kDa. After 
dialysis, the protein concentration was determined spectrophotometrically by applying an UV-
VIS spectrometer Agilent 8452 (Böblingen, Germany). The protein concentration was set to 
10 mg/ml and HP-β-CD was added to obtain a ratio of 1:1 [w/w], 2:1 [w/w] or 3:1 [w/w]. 
III.2.1.2 LYOPHILISATION PROCESS 
Aliquots of 2.0 ml of the formulations were filled into 10R vials and lyophilised using an Epsilon 
2-6D freeze dryer from Christ (Osterode, Germany) (Figure III-1). In brief, the solution was 
frozen to -50°C at a rate of 1°C/min and the temperature was held for 30 min. Primary drying 
was performed at a shelf temperature of -10°C and a pressure of 0.09 mbar for 24 h. Afterwards, 
the temperature was increased to 25°C within 4 h. Secondary drying was then performed at 
25°C for 7 h. After the cycle was finished, freeze dried samples were held at 5°C at 0.09 mbar. 
Product temperature was monitored with thermocouples placed at the edges and in the middle 
of the shelf. Finally, the freeze dryer was vented with filtered nitrogen gas to approximately 
800 mbar. Vials were stoppered and crimped after unloading. 
 
Figure III-1: Shelf temperature and pressure traces of an examplary freeze-drying run. Thermocouples were 
placed in the formulations to monitor the product temperature. 
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III.2.1.3 PRE-MELTING OF LIPIDS 
For specific experiments, lipids were pre-melted prior to extrusion by simultaneous melting of 
the high and low melting lipid at 80°C to obtain a homogenous molten mass. The molten mass 
was not further stirred. The melt was allowed to cool down to room temperature at approximately 
23°C. The solidified melt was ground using mortar and pestle, sieved (< 180 µm) and stored at 
4°C. 
 
III.2.2 PREPARATION OF IMPLANTS  
III.2.2.1 TSC-EXTRUSION OF SLIS ON A MINILAB® MICRO RHEOLOGY COMPOUNDER 
Applying the MiniLab® Micro Rheology Compounder (Thermo Haake GmbH Karlsruhe, 
Germany) the composition listed below was extruded according to the formulation described by 
Sax et al. [182]. Tsc-extrudates were prepared from a powder mixture comprising 10 % protein 
lyophilisate, 10 % PEG 6000 lyophilisate, 24 % H12 and 56 % D118. Equal masses of 
lyophilisates and triglycerides were weighed into a mortar and mixed to create a uniform powder 
mixture. Afterwards, remaining H12 and D118 was added to ensure a homogenous distribution 
of the single components. Extrusion was performed at 41°C with closed bypass channel, screw 
speed was adjusted to 40 rpm and the extruder outlet was set to 1.9 mm. Approximately 5 g of 
the material was fed into the barrel by compressing it manually. The obtained lipid strand was 
cut into pieces of approximately 20 mm resulting in an average weight of 67 mg per implant. 
III.2.2.2 TSC-EXTRUSION OF SLIS ON A ZE-5 MINI-EXTRUDER 
Formulations consisting of 10 % to 20 % protein lyophilisate and different ratios of the low 
melting lipid H12 and the high melting lipid D118 were extruded on a ZE-5 mini extruder. H12, 
D118 and lyophilised protein were weighed into a mortar and admixed by hand to create a 
uniform powder mixture. When extrusion was performed with pre-melted lipids, protein 
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lyophilisate was added to the sieved (< 180 µm) cooled down solidified melt and the powder 
mixture was homogenised manually using pestle and mortar. Tsc-extrusion was performed 
using a ZE-5 mini-extruder from Three-Tec (Seon, Switzerland) comprising three heating zones. 
Approximately 1 g of the powder mixture was fed manually into the barrel of the ZE-5 mini-
extruder and extrusion was performed between 33°C to 42°C. The rotation speed of the screws 
was set between 20 rpm to 80 rpm. The implant diameters were adjusted by applying outlet 
plates with 0.8 mm, 1.5 mm, 1.7 mm and 2.0 mm diameter, respectively. Extruded implants 
were cut into a length of 15 mm resulting in an implant weight of around 30.7 mg ±0.78 mg 
(1.5 mm diameter) and 39.3 mg ±0.96 mg (1.7 mm diameter). 
III.2.2.3 TSC-EXTRUSION OF SLIS ON ZE-5 MINI-EXTRUDER USING A FEEDING TUBE 
The inlet die to the ZE-5 mini-extruder barrel was equipped with a custom-made feeding tube 
of 22 cm length and 0.9 cm diameter and a custom-made pestle to feed the material into the 
barrel. The material was filled into the feeding tube (3 g) and the powder mixture was fed into 
the barrel by applying a constant weight on the pestle. Extrusion of various formulations (30 % 
to 70 % H12) was performed at extrusion temperatures ranging from 33°C to 42°C at different 
screw speeds (40 rpm to 80 rpm).  
III.2.2.4 DOUBLE EXTRUSION OF SLIS ON ZE-5 MINI-EXTRUDER WITH FEEDING TUBE 
In a first approach, extrudates with 10 % lyophilisate were produced using a lipid matrix 
consisting of 50 % H12 and 50 % D118 extruded at 35°C and 40 rpm. The lipid strand was 
ground, sieved (< 180 µm) and extruded a second time at 33°C, 35°C or 37°C.  
In a second approach, a formulation comprising 20 % protein lyophilisate and 80 % D118 was 
first extruded at 65°C. Afterwards, the extrudates were ground and sieved (< 180 µm), H12 was 
added to get a lipid matrix composed again of 50 % H12 and 50 % D118. Second extrusion was 
then performed at 35°C.  
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In a third approach, 20 % protein lyophilisate and 80 % H12 were extruded at 35°C within the 
first extrusion run. D118 was added to the ground and sieved (< 180 µm) extrudate to obtain a 
50:50 lipid matrix of H12 and D118 which was then extruded at 35°C a second time. During all 
double extrusion runs, rotation speed was set to 40 rpm.  
III.2.2.5 PREPARATION OF PLGA BASED IMPLANTS 
PLGA implants were prepared by mixing 10 % protein lyophilisate (1:1 [w/w] protein to HP-β-
CD) with 90 % Resomer® RG 502, Resomer® RG 502 H or Resomer® RG 755 S, respectively, 
in a mortar to obtain a homogenous powder blend. The powder mixture (approximately 1.5 g) 
was fed manually to the ZE-5 mini-extruder and extrusion was performed at 70°C at a screw 
speed of 60 rpm. Extruded PLGA rods with a diameter of 1.5 mm were cut into a length of 
15 mm resulting in a weight of 52.9 mg (±4.15 mg) and a protein load of 2.66 mg (±0.21 mg). 
 
III.2.3 PROTEIN RELEASE TESTS  
Extrudates (n=4) were cut into a length of 15 mm and were placed in 2.0 ml micro-centrifuge 
tubes (VWR, Radnor, PA, USA) and incubated at 37°C in a Certomat® IS (Sartorius BBI, 
Göttingen, Germany) horizontal shaker at 40 rpm in 1.0 ml PBS buffer pH 7.4 comprising 10 mM 
sodium phosphate, 137 mM NaCl and 2.7 mM KCl. At predetermined time points, the release 
medium was exchanged completely and tempered incubation medium was added. Protein 
concentration was analysed spectrophotometrically at 280 nm applying an UV-VIS 
spectrometer (Agilent 8453, Böblingen, Germany). For all proteins, linearity of measurements 
was established for a concentration range of 0.001 mg/ml to 1.0 mg/ml. 
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III.2.4 DETERMINATION OF IMPLANT PROPERTIES 
III.2.4.1 DYNAMIC SCANNING CALORIMETRY (DSC) 
Thermal properties of lipid raw material and implants were measured using a Netzsch DSC 204 
(Selb, Germany). Approximately 15 mg sample (accurately weighed) was weighed into 
aluminium sample pans and crimped before heating from 0°C to 90°C with a heating rate of 
5 K/min. Tonset, Tmelting and the melting energy of the lipids were assessed. 
III.2.4.2 X-RAY POWDER DIFFRACTION (XRPD) 
To determine lipid modifications and crystallisation events, XRPD was performed using an 
Empyrean powder diffractometer (PANalytical, Almelo, The Netherlands) equipped with a 
copper anode (45 kV, 40 mA, Kα1 emission at a wavelength of 0.154 nm) and a PIXceI3D 
detector. Approximately 100 mg of finely sieved sample material were placed onto the sample 
holder and analysed in the range of 0° to 50° 2-theta with steps of 0.05° 2-theta. 
III.2.4.3 SCANNING ELECTRON MICROSCOPY (SEM) 
The morphology of extrudate surfaces and cross sections were analysed either using a 
JSM6500F Field Emission Electron Microscope (Jeol, Eching, Germany) or a FEI Helios G3 UC 
(Hillsboro, Oregon, USA) without any further processing or coating. SEM micrographs were 
taken at an operating voltage of 2.0 kV at a magnification of 40x, 300x and 2500x (JSM6500F) 
or at a voltage of 1.5 kV at a magnification of 80x, 300x and 2000x (FEI Helios G3 UC). 
III.2.4.4 MECHANICAL PROPERTIES 
Mechanical properties of extrudates were analysed using a Texture Analyser TA XT2i (Stable 
Microsystems, Godalming, UK). Compressive strength was assessed by compressing the 
samples with a cylindrical piston having a diameter of 13 mm (Figure III-2 A). Settings were 
adjusted to a pre-test speed of 1.0 mm/s, test speed of 0.1 mm/s, post-test speed of 10 mm/s 
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and a trigger force of 0.05 N. The maximal force at the point of breakage was defined to be the 
compressive strength. 
 
Figure III-2: Experimental setup of (A) compressive strength and (B) bending strength. 
 
For analysis of bending strength, the sample was located on two holders being 10 mm apart 
from each other (Figure III-2 B). The sample was levitating were the piston touched the 
extrudate. Bending strength was measured by pressing a piston (4 mm in diameter) with a 
speed of 0.1 mm/s until the sample broke. The maximal force measured before the sample 
broke was defined as bending strength. Trigger force was set to 0.05 N. Per batch, experiments 
were performed six times at room temperature. 
III.2.4.5 TRUE DENSITY MEASUREMENTS 
Samples were cut into pieces with a length of approximately 5 mm, transferred to a measuring 
insert and weighed accurately before placing the insert into a helium pycnometer AccuPyc® 
1330 (Micromeritics, Norcross, USA). After the chamber was flushed ten times with helium, the 
replaced volume was measured six times. For each sample, triplicates were measured resulting 
in eighteen single measurements per sample. Based on these volumes and with the exact mass, 
true density was calculated. 
 
A B 
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III.2.5 METHODS USED FOR THE IN-VIVO STUDY IN RABBIT EYES 
III.2.5.1 MATERIALS 
The fab-fragment Ranibizumab (Lucentis®) was dialysed as described above (III.2.1.1). After 
dialysis, the protein concentration was determined spectrophotometrically by applying an UV-
VIS spectrometer Agilent 8452 (Böblingen, Germany). The protein concentration was set to 
10 mg/ml and HP-β-CD was added to obtain a ratio of 1:1 [w/w]. Afterwards, the solution was 
filtered into sterile 50 ml tubes (Sarstedt, Nürnbrecht, Germany) using a 0.22 µm sterile syringe 
filter (VWR, Radnor, PA, USA). The sieved (< 180 µm) triglycerides H12 and D118 were gamma 
irradiated with 30.5 kGy (Synergy Health, Allershausen, Germany).  
III.2.5.2 LYOPHILISATION PROCESS 
Samples of 2.0 ml of the sterile protein solution were filled into autoclaved 10R vials under 
aseptic conditions. Lyophilisation was performed using an Epsilon 2-12D freeze dryer from 
Christ (Osterode, Germany) following the lyophilisation protocol described in III.2.1.2. After the 
cycle was finished, freeze dried samples were held at 5°C at 0.09 mbar. Finally, the freeze dryer 
was vented with filtered nitrogen gas (0.22 µm) to approximately 800 mbar. Vials were 
stoppered and crimped after unloading. 
III.2.5.3 IMPLANT PREPARATION 
Parts of the ZE-5 mini-extruder that could potentially be in contact with the product were 
autoclaved, glass ware and further equipment was heat sterilised applying a GTA 50 heat 
steriliser (Medizin- und Labortechnik KG, Hamburg, Germany). Extrusion was performed as 
described above (III.2.2.2) at an extrusion temperature of 35°C and a screw speed of 40 rpm. 
To prevent any contamination of Ranibizumab loaded implants before, during or after the 
preparation process, extrusion was performed in a laminar air flow cabinet (Hera Safe, Kendro 
Laboratory Products GmbH, Germany) under aseptic conditions.  
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Figure III-3: Semicircle shaped Ranibizumab loaded implants manufactured under aseptic conditions. 
 
The lipid strand was formed manually with the aid of a sterile glass rod (9.4 mm in diameter) to 
obtain semicircle shaped rods fitting into a rabbit eye (Figure III-3). Finally, implants were placed 
into sterile 2.0 ml micro-centrifuge tubes (VWR, Radnor, PA, USA). 
III.2.5.4 CHOROIDAL NEOVASCULARISATION MODEL  
Neovascularisation was induced by an adeno-associated virus (AAV) mediated expression of 
vascular endothelial growth factor (VEGF) as previously described [243]. Recombinant AAV 
vector was chosen because it was extensively used in retina and other systems to deliver 
transgenes with little toxicity and inflammation [244]. To induce this into dutch-belted rabbit 
eyes, AAV-VEGF was injected subretinally. The AAV vector transfected the retinal pigmented 
epithelium to induct VEGF expression. Disease model induction was examined by fluorescein 
angiography. A fluorescein solution with 100 mg/ml was injected (100 µl) into the vitreous, 
enabling an imaging for up to 30 minutes. Although it was intended to induce choroidal 
neovascularisation, evidence suggested it was only retinal neovascularisation.  
III.2.5.5 IMPLANT INCISION AND RANIBIZUMAB PHARMACOKINETIC STUDY 
Semicircle shaped SLIs were inserted into dutch-belted rabbit eyes by a small incision. The 
rabbits were sacrificed after 14, 28, 42 and 84 days and Ranibizumab amounts were measured 
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in different compartments namely cornea, vitreous, lens, iris, retina/choroid, aqueous humor, 
conjunctiva, and sclera. Ranibizumab concentrations were measured using an enzyme-linked 
immunosorbent assay (ELISA) as already described [245, 246]. In brief, samples were diluted 
to be within the linear range of the assay (0.375 ng/ml to 12 ng/ml) using StabilCoat reagent 
(Surmodics Inc., Eden-Prairie, MN, USA) and 100 µl were aliquoted onto VEGF coated 96-well 
plates. The 96-well plates were incubated for 2 h at room temperature with agitation. To remove 
unbound Ranibizumab, plates were washed with 0.05 % Tween 20 in PBS pH 7.4. Bound 
Ranibizumab was detected using an antihuman IgG antibody labelled with horseradish 
peroxidase (HRP) (Pierce Biotechnology Inc., Rockford, IL, USA). The labeled antihuman IgG 
antibody was diluted 1:20.000 in StabilCoat reagent. Aliquots of 100 µl of the diluted antihuman 
IgG antibody were pipetted onto 96-well plates and incubated for 45 min at room temperature 
with agitation. Unbound IgG was removed by washing the plates 3 times with 0.05 % Tween 20 
in PBS pH 7.4. Chemiluminescence was triggered by the SuperSignal ELISA Pico 
Chemiluminescent Substrate (Pierce Biotechnology Inc., Rockford, IL, USA) and measured 
using a PHERAstar Microplate Reader (BMG Labtech, Durham, NC). Ranibizumab 
concentration of the samples was calculated from the standard curve.  
The induction of choroidal neovascularisation and the pharmacokinetic studies were performed 
by the Moran Eye Center, Salt Lake City, Utah, USA. 
 
III.2.6 PROTEIN STABILITY DETERMINATION 
III.2.6.1 DETERMINATION OF THE CONCENTRATION OF RELEASED PROTEIN FRACTIONS 
Vivaspin® 20 Ultrafiltration Tubes equipped with a PES membrane (Sartorius Stedim Biotech, 
Goettingen, Germany) with a MWCO of 50.000 Da for mAb and Bevacizumab, a MWCO of 
30.000 Da for Aflibercept or a MWCO of 10.000 Da for Ranibizumab were used to concentrate 
the released protein fractions. Tubes were filled with collected release medium and centrifuged 
CHAPTER III 
42 
at 8000 x g for 20 min at 20°C using a Sigma® 4K-15 centrifuge (Sigma, Osterode, Germany). 
Protein concentration was determined using a NanoDrop 2000 UV-VIS Spectrophotometer 
(Thermo Scientific, Wilmington, USA), and protein concentration was adjusted to 1.0 mg/ml with 
PBS pH 7.4 for further analysis. 
III.2.6.2 LIGHT OBSCURATION (LO) 
Subvisible particles were counted and allocated cumulative in a range of 1 µm to 200 µm by 
using a SVSS (PAMAS, Rutesheim, Germany). The system is equipped with an HCB-LD-25/25 
sensor which allows a detection of maximal 120,000 particles > 1 µm/ml. Before measurements, 
the system was rinsed with highly purified water until total particle count was less than 
30 particles per ml. For analysis, the system was rinsed with 0.5 ml sample followed by three 
measurements of 0.3 ml sample. Between each sample measurement, the system was flushed 
with 10 ml of highly purified water. If necessary, 250 µl of sample were diluted to 3.00 ml with 
highly purified water to not exceed the total particle count of 120,000. Data analysis was 
performed using the PAMAS PMA software and particle diameters in a range of > 1 µm to 
200 µm were assessed. If not otherwise noted, all results are given in cumulative particle count 
per ml of non-diluted sample. 
III.2.6.3 TURBIDITY 
Turbidity was measured using a Hach Lange Nephla nephelometer (Hach Lange GmbH, 
Düsseldorf, Germany). For measurements, 1.0 ml sample were pipetted in turbidity glass 
cuvettes with flat bottom. Each measurement was performed three times. The measured 
scattered light (wavelength = 860 nm) is given in FNU (formazine nephelometric units), detected 
in an angle of 90°. 
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III.2.6.4 SIZE EXCLUSION HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (SE-HPLC) 
Protein monomer content, fragments and high molecular weight (HMW) soluble aggregates 
were determined via SE-HPLC using a Waters 2695 Separations Module with a Waters 2487 
Dual λ Absorbance Detector (Waters, Milford, USA). Linearity of measurements was 
established for a concentration range of 0.01 mg/ml to 1.0 mg/ml. For separation, the flow rate 
was adjusted to 0.5 ml/min. A sample volume of 25 µl with a concentration of 1.0 mg/ml were 
injected onto a TSKgel G3000SWXL size exclusion column (300 mm x 7.8 mm; Tosoh Bioscience, 
Tokyo, Japan). The running buffer consisted of 50 mM sodium phosphate containing 300 mM 
NaCl and was adjusted to pH 7.0. 
III.2.6.5 ION EXCHANGE CHROMATOGRAPHY (IEX) 
For charge variant separation of the mAb and Bevacizumab, IEX was used according to a 
method previously described by Farnan et al. [247]. IEX was performed on a Waters 2695 
Separations Module with a Waters 2487 Dual λ Absorbance Detector (Waters, Milford, USA). 
For separation, 50 µl of sample (1.0 mg/ml) was injected onto a 4 mm x 50 mm Dionex ProPac® 
WCX-10G guard column coupled to an analytical 4 mm x 250 mm Dionex ProPac® WCX-10 
column. Mobile phases A and B consisted of 2.4 mM Trizma® Base, 1.5 mM imidazole and 
11.6 mM piperazine at a pH of 6.0 (mobile phase A) and 9.5 (mobile phase B), respectively. For 
separation of the different charge variants of mAb and Bevacizumab, the gradient of mobile 
phase B was adjusted for each protein (Figure III-4). The column was washed with 100 % eluent 
B for 5 minutes before it was equilibrated with 100 % eluent A for 5 minutes prior to the next 
injection. The flow rate was set to 1.0 ml/min. Eluted protein was monitored 
spectrophotometrically at 280 nm. 
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Figure III-4: Gradient of mobile phase B for charge variant separation of (A) mAb and (B) Bevacizumab. 
 
III.2.6.6 HYDROPHOBIC INTERACTION CHROMATOGRAPHY (HIC) 
For charge variant separation of Ranibizumab and Aflibercept, HIC was performed using a 
Waters 2695 Separations Module with a Waters 2487 Dual λ Absorbance Detector (Waters, 
Milford, USA). A sample volume of 50 µl with a concentration of 1.0 mg/ml was injected onto an 
analytical 4.6 mm x 250 mm Dionex MAbPac™ HIC-10 column for separation. Flow rate was 
adjusted to 1.0 ml/min and eluted protein was detected at 280 nm. Mobile phase A consisted of 
1.5 M ammonium sulfate and 50 mM sodium phosphate. Mobile phase B consisted of 50 mM 
sodium phosphate. Mobile phases were adjusted to pH 7.0. Prior to sample injection, the column 
was allowed to equilibrate with eluent A. For separation of the different charge variants of 
Ranibizumab and Aflibercept, for each protein the gradient of mobile phase B was adjusted 
(Figure III-5). Post-gradient, the column was washed with 100 % eluent B for 3 min before the 
composition was returned to 100 % A for 5 min in preparation for the next injection. 
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Figure III-5: Gradient of mobile phase B for charge variant separation of (A) Ranibizumab and (B) Aflibercept. 
 
III.2.6.7 NON-REDUCING DENATURATING SODIUM DODECYL SULFATE – POLYACRYLAMIDE 
GEL ELECTROPHORESIS (SDS-PAGE) 
Non-reducing denaturating SDS-PAGE was used to monitor aggregation and fragmentation of 
the proteins. Analysis was performed using a XCell SureLock™ Mini-Cell Electrophoresis 
System (Novex by Life Technologies, Carlsbad, CA, USA). For separation and resolution of the 
mAb, Bevacizumab and Aflibercept, NuPAGE® Novex® 3-8 % Tris Acetate Protein Gels 1.0 mm 
x 10 wells and NuPAGE® Tris-Acetate SDS Running Buffer were used. Separation was 
accomplished at a constant voltage of 150 V and a running time of 50 to 55 min using a Bio Rad 
PowerPac 200 (Bio-Rad Laboratories, Hercules, CA, USA).  
Ranibizumab was analysed using NuPAGE® Novex® 4-12 % Bis-Tris Protein Gels 1.0 mm x 
12 wells and NuPAGE® MOPS SDS Running Buffer. For separation, a constant voltage of 
200 V for approximately 50 min was applied.  
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All samples were diluted with NuPAGE® LDS Sample Buffer to an initial concentration of 
37.5 µg/ml and were denatured at 90°C for 5 min. Each well was loaded with 12 µl sample 
resulting in a total mass of 0.45 µg protein per well. Gels were stained with the SilverXPress® 
Silver Staining Kit according to the manufacturer’s recommendations. The performance of the 
system was monitored by a BSA sensitivity control. Each gel was loaded with 1.80 ng and 
0.36 ng BSA, respectively. Gels were stained until both bands became visible before staining 
was stopped by adding the stopping solution. Molecular weight of protein bands was calculated 
using a molecular weight marker on each gel. For the mAb, Bevacizumab and Aflibercept the 
HiMark™ Pre-stained Protein Standard was used, while for Ranibizumab the Mark12™ 
Unstained Standard was used. 
III.2.6.8 CAPILLARY GEL ELECTROPHORESIS 
As an orthogonal method to classical non-reducing denaturating SDS-PAGE, capillary gel 
electrophoresis applying an Agilent 2100 Bioanalyzer system (Agilent, Santa Clara, CA, USA) 
was carried out for Ranibizumab. The system offers a fast and reliable separation, sizing and 
quantification of proteins in a range of 14 kDa to 230 kDa. Due to these limitations, analysis of 
mAb, Bevacizumab and Aflibercept was not performed. Ranibizumab samples were analysed 
under non-reducing conditions using a Protein 230 Kit (Agilent, Santa Clara, CA, USA). 
According to the Agilent Protein 230 Assay Protocol, 4 µl of sample (1.0 mg/ml) and 2 µl of 
sample buffer were admixed and incubated at 95°C for 5 min. After samples were allowed to 
cool down, 84 µl highly purified water were added and 6 µl were then pipetted into the sample 
wells of the protein chip. The protein chip was prepared by loading it with the gel-dye mix, 
destaining solution und molecular weight marker according to the protocol provided by the 
manufacturer. The chip was then placed into the system and analysis was started immediately.  
In addition, capillary gel electrophoresis was performed under reducing denaturating conditions 
for all proteins. Analysis was performed as described above except one adjustment: before 
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adding 2 µl of sample buffer to 4 µl sample, the sample buffer was spiked with 1 M Dithiothreitol 
(DTT) solution resulting in 4.83 mM/µl DTT. 
III.2.6.9 CAPILLARY ISOELECTRIC FOCUSING (CIEF)  
Imaged capillary isoelectric focusing (cIEF) was conducted using an iCE280 instrument coupled 
with a PrinCE Microinjector (ProteinSimple, San Jose, CA, USA), where the molecules are 
detected across the whole IEF column (capillary). UV light at a wavelength of 280 nm was 
focused on the UV-transparent capillary and images were captured at regular intervals by aid 
of a charge-coupled device (CCD) camera. Prior to analysis, the fused, silica-coated (FC) 
cartridge was installed according to the provider’s instructions. Reservoirs for the anode were 
filled with 0.08 M phosphoric acid (in 0.1 % methylcellulose, electrolyte kit, ProteinSimple, San 
Jose, CA, USA) and for the cathode with 0.1 M sodium hydroxide (in 0.1 % methylcellulose, 
electrolyte kit, ProteinSimple).  
During analysis of Ranibizumab and Bevacizumab (0.5 mg/ml), isoelectric focusing of the 
samples took place by pre-focusing for 1 min at 1500 V followed by focusing for 5 min at 3000 V. 
The focusing process was monitored while images were captured every 30 sec. The UV 
absorption image was analysed using the software ChromPerfect (Version 5.5.6). Protein 
sample was mixed with carrier ampholytes, methyl cellulose, and water as reported in Table 
III-4. The sample mixtures were vortexed and spun using a bench top centrifuge (Espresso, 
Thermo Fisher Scientific, Waltham, MA, USA) for 3 min at 10.000 rpm. An aliquot of 150 µl of 
the supernatant was transferred into an iCE280 glass vial insert (300 µl, ProteinSimple, San 
Jose, CA, USA). Finally, the glass vial insert was spun for 1 min at 7.500 rpm to remove air 
bubbles (potentially causing “spikes” in the electropherogram). Glass vial inserts were then 
loaded into a sample holder and placed into the temperature-controlled auto sampler. 
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Table III-4: Overview of experimental conditions and composition of Ranibizumab and Bevacizumab samples 
used for cIEF. 
 
Servalytes 
pH 2-9 [µl] 
Low pI marker 
5.85 [µl] 
High pI marker 
10.1 [µl] 
MC 1 % 
[µl] 
MQ 
[µl] 
Sample 
[µl] 
Final 
volume [µl] 
Ranibi-
zumab 
4.0 1.0 1.0 50.0 94.0 50.0 200.0 
Bevaci-
zumab 
4.0 1.0 1.0 50.0 94.0 50.0 200.0 
 
III.2.6.10 FOURIER TRANSFORM INFRARED SPECTROSCOPY (FT-IR) 
To determine the conformation of proteins, a Bruker Tensor 27 FT-IR Spectrometer (Bruker 
Optics, Ettlingen, Germany) equipped with a BIO ATR II cell was used. The mercury cadmium 
telluride detector was allowed to cool down prior to each measurement by cooling it with liquid 
nitrogen for one hour. The beam path was purged with nitrogen and the temperature was kept 
constant at 25°C. Sample concentration was 1.0 mg/ml and 30 µl of sample was used for each 
determination. Each spectrum was recorded in 100 scans between 1000 cm-1 to 4000 cm-1 
whereat a blank spectrum was subtracted. The collected spectra were Fourier transformed 
using the Opus software (Version 6.8, Bruker Optics, Ettlingen, Germany). The spectra were 
further normalised and the second derivative was calculated using the smoothing algorithm with 
17 smoothing points. Each sample was recorded in triplicates and mean spectrum was 
calculated. 
III.2.6.11 EXTRINSIC FLUORESCENCE 
Extrinsic fluorescence was measured using a Cary Eclipse Spectrofluorimeter (Varian, Santa 
Clara, CA, USA). Samples were diluted with PBS pH 7.4 to an initial concentration of 100 µg/ml 
and 50 µl of a 2 mM Bis-ANS solution were added. For measurements, 50 µl were transferred 
into a submicro fluorescence glass cuvette (Hellma Analytics, Müllheim, Germany). Each 
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sample was scanned in triplicates in steps of 5 nm with an excitation wavelength of 390 nm and 
an emission wavelength of 400 nm to 600 nm. 
III.2.6.12 INDUCTIVELY COUPLED PLASMA ATOMIC EMISSION SPECTROSCOPY (ICP-AES) 
To test the raw materials and implants towards metal impurities, ICP-AES was performed using 
a ICP AES VISTA RL radial equipped with a CCD dual detector and a SPS 5 auto sampler 
(Varian, Santa Clara, CA, USA). Prior to analysis, the samples were stored in 10R vials at 4°C. 
For analysis, approximately 2 mg of sample (accurately weighed) was dissolved in 1.5 ml 
concentrated HNO3 at 110°C and was diluted with highly purified water to a final concentration 
of 3 % [v/v]. Each sample was measured ten times at two different wavelengths to identify 
possible impurities with aluminium (Al), cobalt (Co), chrome (Cr), copper (Cu), iron (Fe), 
manganese (Mn), nickel (Ni), lead (Pb) and tin (Zn) against standard solutions of known 
concentrations. Plasma temperature was set to 10.000 K and flow rate was adjusted to 
1.0 ml/min. 
 
III.2.7 ONLINE PRESSURE MEASUREMENT DURING EXTRUSION 
To monitor the pressure within the extruder barrel during an extrusion run, the outlet plate was 
equipped with a custom-made resistance strain gauge (nanoFaktur GmbH, Ettlingen, 
Germany), which was inserted into the outlet plate (Figure III-6). Thus, it was ensured that the 
sensor did not change the dimensions of the barrel and had no influence on extrusion 
performance. It was possible to measure directly the force in real time when the material was 
pressed against the outlet plate by the rotating screws. The signal of the resistance strain gauge 
was amplified using a data logger SensorData Easy (Soemer Messtechnik GmbH, Lennestadt, 
Germany) and was recorded with the software H&B DOP 4P (Hauch & Bach, Lynge, Denmark).  
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Figure III-6: Images of the barrel of the ZE-5 mini-extruder equipped with the custom-made resistance strain 
gauge manufactured by nanoFaktur GmbH, Ettlingen, Germany.  
 
For calibration of the sensor, defined weights ranging from 0.5 kg to 50 kg were attached 
(weights were hanging downwards) to the outlet plate. The correlation between applied weight 
and read out of the data logger was found to be linear (R2 = 0.9987) and was converted into 
extrusion pressure in kPa by dividing the force (in Newton) by the area the material was 
compressed to (6.127*10-5 m2) shown on Figure III-6 D. For all experiments, extrusion runs were 
performed in triplicates. 
 
III.2.8 RABBIT ERYTHROCYTE HEMOLYSIS ASSAY 
The rabbit erythrocyte hemolysis assay was performed to determine the biological activity of the 
mini-FH released from SLIs. The protein mini-FH is a C3-opsonin targeted complement inhibitor 
with a molecular weight of 43.3 kDa [240]. The assay was performed by the group of Dr. 
Christoph Schmidt from the Institute of Pharmacology and Natural Products and Clinical 
Pharmacology, Ulm University, Germany, as previously described [241]. In brief, 10 µl human 
C 
B A 
D 
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serum containing Mg-EDTA was mixed with 20 µl sample in PBS pH 7.4 and 10 µl of a rabbit 
erythrocyte suspension in PBS/Mg-EDTA. The final serum concentration was 25 %. The mixture 
was incubated for 30 min at 37°C before it was stopped by adding 120 µl PBS/EDTA with a 
concentration of 5 mM on an ice bath. Hemolysis was determined via optical density 
measurement of 100 µl of the supernatant at 405 nm using a spectrophotometer. 
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IV. IN-VITRO RELEASE STUDIES FROM LIPID AND 
PLGA IMPLANTS 
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IV.1 INTRODUCTION 
Within the last years, controlled release of pharmaceutical proteins from implantable/insertable 
devices has received more and more attention. The need for such devices can easily be 
illustrated using the example of intraocular treatment of AMD with anti-VEGF drugs such as 
Ranibizumab (Lucentis®), Bevacizumab (Avastin®), or Aflibercept (Eylea®). To date, anti-VEGF 
drugs are the standard treatment for AMD [248], but their frequent application causes high costs 
on the health care system [30]. Besides the stress for the patient, the required monthly injections 
- for example of Lucentis® - into the vitreous causes injection-related adverse effects like 
endophthalmitis [96]. Hence, it would be preferable to prolong the period between two 
intravitreal injections by using sustained release devices to improve patient convenience, safety, 
and efficacy. For this study, anti-VEGF drugs were used, namely the recombinant humanised 
monoclonal IgG1 antibody Bevacizumab (Avastin®), the fab-fragment Ranibizumab (Lucentis®) 
and the recombinant fusion protein Aflibercept (Eylea®). Furthermore, another IgG1 antibody 
(model mAb) was used as well. 
Since the early 2000s, lipid based drug delivery systems have gained more and more interest 
as platform for sustained release of proteins [167, 173, 174, 249, 250]. Lipid implants were 
shown to have excellent properties for in-vivo applications as demonstrated by good 
biodegradability and biocompatibility [184]. Moreover, long-term release of protein drugs was 
successfully demonstrated: interferon α-2a was delivered for more than 60 days [181], and 
sustained release of lysozyme was described for more than 200 days [182]. To date, several 
research groups are working on lipid based depots including implants for sustained 
erythropoietin release as described by Appel et al. [169] and Jensen et al. [180], or the 
intravitreal use of clindamycin phosphate loaded lipidic implants as published by Tamaddon et 
al. or using solid lipid nanoparticles (SLNs) for an immense variety of application possibilities 
[134, 141, 214, 251, 252]. 
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Preserving the integrity of incorporated proteins such as interferon α-2a [176, 181] or brain-
derived neurotropic factor (BDNF) [175], is the most valuable benefit over the commonly used 
and well investigated PLA/PLGA polymers. Indeed, these polymers provide a biodegradable 
system as well, but erosion/degradation of the polymer creates difficulties associated with the 
biodegradation process: a drop in pH and an increase in osmotic pressure, particularly inside 
the matrix, often results in degradation products caused by acylation, deamidation or 
aggregation [49, 253, 254], and incomplete release [54, 68, 242, 255]. 
Within our group, Schulze et al. [181] introduced tsc-extrusion as manufacturing technique for 
lipid implants, which meanwhile became our standard manufacturing technique besides direct 
compression or casting methods described in early studies [168, 175, 177]. Compared to 
release profiles of compressed implants, we observed a more sustained release of extruded 
implants in addition to a more homogenous drug distribution [256]. Tsc-extrusion was already 
used in several of our studies [182, 183, 233], allowing the manufacturing of triglyceride blends 
of a low melting and a high melting lipid at comparatively low temperatures of 42°C [181, 183]. 
The overall aim of the present chapter was to establish formulation and extrusion settings which 
result in an implant that ensures a long-term release of at least 3 months and is sufficiently small 
for intravitreal use. To reach this goal, the following steps were performed:  
(i) reproduction: Reproduction of existing data [232] as a proof of concept using a 
MiniLab® Micro Rheology Compounder. 
(ii) transfer: A transfer from a MiniLab® Micro Rheology Compounder to a ZE-5 mini-
extruder to reduce the batch size was carried out.  
(iii) optimisation: As the release profile was not identical for the same formulation 
extruded on different extruders, the formulation and extrusion settings were 
adapted to the ZE-5 mini-extruder. 
(iv) increase of protein load: Since an adequate amount of drug substance should 
be provided when release time frames of several months are considered, 
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increasing protein load was attempted by three different approaches. The 
increase of the protein lyophilisate percentage, the change of protein lyophilisate 
composition, and the change of implant diameter were tested.  
(v) Storage stability: storage stability of extruded SLIs was determined to ensure 
that implants guarantee comparable release characteristics particularly after 
storage. Therefore, lipid implants were stored for 4 and 12 weeks after 
production at 4°C prior to in-vitro release. Due to potential changes in lipid 
modifications occurring upon storage, lipid characteristics were also assessed. 
Protein stability of released protein of stored and non-stored was analysed as 
well and will be presented in chapter VII. 
(vi) Pre-melting of lipids: The effect of melting point, melting energy and lipid 
modifications on release patterns and storage stability of SLIs was studied. For 
this, H12 and D118 were simultaneously molten at 80°C, the molten mass was 
allowed to cool down before it was ground and sieved (< 180 µm) prior to 
extrusion.  
Additionally, PLGA based extrudates were produced using different polymers (Resomer® RG 
502, RG 502 H and RG 755 S) in order to compare those data with release profiles obtained 
from SLIs. PLGAs with different degradation time frames were used for two reasons: first, to 
evaluate the impact of depot erosion in addition to diffusion and second, to determine the impact 
of different end groups on release profiles. Protein stability aspects of protein released from lipid 
and PLGA matrices will be addressed within chapter VII. 
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IV.2 RESULTS AND DISCUSSION 
IV.2.1 LYOPHILISATE STABILITY STUDY  
SLIs were produced via tsc-extrusion where the protein was embedded within the lipid matrix 
as a lyophilisate. HP-β-CD was used as lyoprotectant to assure protein stabilisation during 
freeze drying and storage as reported previously for rh-interferon α-2a [176] and erythropoietin 
[242]. Furthermore, it was described by Ressing et al. that HP-β-CD increased stability and 
activity of IgG antibodies compared to samples which were formulated with dextran or sucrose 
[257]. The stability of the proteins within the freeze-dried matrix was determined to ensure 
sufficient protein stability at the point of SLI production. The stability of freeze-dried protein was 
investigated over 24 weeks since stability of released protein was extensively studied within this 
work (chapter VII). However, produced lyophilisates were used within 8 weeks. 
IV.2.1.1 DIALYSIS AND LYOPHILISATION 
The protein bulk was dialysed as described above (III.2.1.1) to deplete the formulations of buffer 
salts and stabilisers and to substitute them with 50 mM sodium phosphate pH 6.2.  
Table IV-1: Monomer content of the protein bulk (mAb), marketed formulation and after dialysis. 
 Monomer content before dialysis [%] Monomer content after dialysis [%] 
mAb 97.74 (±0.15) 97.42 (±0.19) 
Ranibizumab 99.97 (±0.01) 100.00 (±0.00) 
Bevacizumab 96.10 (±0.56) 95.37 (±0.06) 
Aflibercept 98.62 (±0.06) 98.56 (±0.01) 
 
This was essential because all proteins were formulated with different stabilisers (III.1.1) which 
could potentially have an impact on release behaviour, for instance trehalose, sodium chloride, 
or sucrose. 
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After dialysis, the monomer content was measured by SE-HPLC showing no negative impact 
caused by the dialysing procedure (Table IV-1). The protein concentration within the dialysed 
formulations was adjusted to 10 mg/ml and HP-β-CD was added to obtain a ratio of 1:1 [w/w], 
2:1 [w/w] or 3:1 [w/w]. 
IV.2.1.2 PHYSICAL STABILITY OF PROTEINS 
Freeze-dried samples were stored at 4°C for 24 weeks and samples were taken at pre-
determined time points after 2, 4, 8, 12 and 24 weeks. Lyophilisates were reconstituted with 
highly purified water (0.2 µm filtered) to obtain a protein concentration of 1.0 mg/ml. 
 
Figure IV-1: (A) Light obscuration measurements and (B) turbidity measurements of reconstituted samples 
measured after 0, 2, 4, 8, 12 and 24 weeks of storage at 4°C.  
 
The formation of subvisible particles upon storage was measured using LO and turbidity (Figure 
IV-1). The samples were not diluted prior to measurements. For mAb, cumulative particle count 
and turbidity was found to have the highest values ranging between 716 (±24) and 1979 (±46) 
cumulative particle count per ml and 1.47 FNU (±0.06 FNU) and 2.12 FNU (±0.14 FNU) turbidity 
over the observation period. An increase in cumulative particle count and turbidity upon storage 
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was not observed. This also applies to Aflibercept, where no increase of both cumulative particle 
count and turbidity was observed. LO results for Ranibizumab and Bevacizumab showed a 
continuous increase, starting after approximately 8 weeks of storage and a final maximal particle 
count of 559 (±81) for Ranibizumab and 587 (±36) for Bevacizumab after 24 weeks of storage. 
The corresponding turbidity measurements after 24 weeks where measured at 0.52 FNU 
(±0.03 FNU) and 0.89 FNU (±0.14 FNU). Turbidity measurements did not show a continuous 
increase over the storage period. 
Table IV-2: Monomer content before lyophilisation and after reconstitution of the lyophilisates with highly 
purified water (0.22 µm filtered) at week 0 and week 24. 
 
Monomer content before 
lyophilisation [%] 
Monomer content at week 
0 after lyophilisation [%] 
Monomer content at week 
24 after lyophilisation [%] 
mAb 97.74 (±0.15) 97.55 (±0.06) 96.01 (±0.05) 
Ranibizumab 99.97 (±0.01) 100.00 (±0.00) 100.00 (±0.00) 
Bevacizumab 96.10 (±0.56) 95.45 (±0.04) 94.26 (±0.69) 
Aflibercept 98.62 (±0.06) 98.33 (±0.02) 97.89 (±0.29) 
 
Table IV-2 illustrates the monomer content of samples before lyophilisation and after 
reconstitution directly after the freeze-drying run (week 0) and after a storage of 24 weeks at 
4°C. There is no major difference in monomer content before and after lyophilisation, meaning 
that the lyophilisation process did not negatively impacted protein stability. Upon storage of the 
freeze-dried product, the monomer content decreased maximally by 1.54 % for mAb. 
Ranibizumabs` monomer content stayed constantly at 100 %. In addition to SE-HPLC, non-
reducing SDS-PAGE was performed to determine possible aggregates and fragments which 
were not detected by SE-HPLC. For mAb, the loss of 1.54 % monomer upon storage was most 
likely caused by aggregation rather than fragmentation, as aggregates having a size of 
approximately 250 kDa were observed (Appendix, Figure XII-1). The same trend was observed 
for Bevacizumab and Aflibercept. For both proteins, aggregates with an approximate size of 
CHAPTER IV 
60 
260 kDa (Bevacizumab) and 224 kDa (Aflibercept) were detected directly after lyophilisation 
(Appendix, Figure XII-3 and Figure XII-4). In contrast, for Ranibizumab mainly fragments with a 
size of about 25 kDa were detected (Appendix, Figure XII-2) but no aggregation occurred over 
the storage period. However, for all proteins degradation was found to be negligible. 
Based on the results for physical stability assessed by LO, turbidity, SE-HPLC and SDS-PAGE, 
it can be concluded that all proteins were physically stable over the storage period of 24 weeks. 
Slightly elevated particle counts were observed for Ranibizumab and Bevacizumab as well as 
minor degradation products for all proteins obtained by SDS-PAGE. Since the lyophilisates were 
further processed within 8 weeks, physical stability was considered as sufficient. 
IV.2.1.3 CHEMICAL STABILITY OF PROTEINS 
In addition to physical stability, lyophilisates were further analysed towards chemical stability. 
After reconstitution with 0.22 µm filtrated highly purified water to a concentration of 1.0 mg/ml, 
chemical stability was measured by IEX (mAb and Bevacizumab) and HIC (Ranibizumab and 
Aflibercept) and the change of main charge variant percentage was determined. Samples were 
analysed directly after lyophilisation and after a 24-week storage showing a small decrease of 
main charge variant percentage for all proteins.  
Table IV-3: Percentage of main charge variant after reconstitution of the lyophilisates with highly purified 
water (0.22 µm filtered) at week 0 and week 24. 
 
Percentage of main charge variant  
at week 0 [%] 
Percentage of main charge variant  
at week 24 [%] 
mAb 43.79 (±0.61) 41.37 (±0.05) 
Ranibizumab 99.37 (±0.02) 96.22 (±0.20) 
Bevacizumab 70.83 (±1.24) 68.12 (±0.95) 
Aflibercept 95.91 (±0.35) 95.02 (±0.30) 
 
IN-VITRO RELEASE STUDIES FROM LIPID AND PLGA IMPLANTS 
61 
Table IV-3 illustrates that Ranibizumab samples showed highest loss after 24 weeks (3.15 % 
±0.20 %), whereas the main charge variant of Aflibercept decreased only by 0.89 % (±0.30 %). 
The chemical stability was considered as sufficient because the lyophilisates were further 
processed within 8 weeks. 
 
IV.2.2 EXTRUDER TRANSFER 
The sustained long-term release of a mAb was already described by Sax over a period of 
approximately 150 days [232]. First, an experiment was carried out to reproduce these data. All 
formulation and extrusion parameters were adjusted exactly to those used within the previous 
experiments. SLIs consisted of 10 % protein lyophilisate, 10 % PEG 6000 lyophilisate, 24 % 
H12 and 56 % D118. Extrusion temperature was set to 41°C at a screw speed of 40 rpm using 
a MiniLab® Micro Rheology Compounder (Thermo Haake GmbH Karlsruhe, Germany). In-vitro 
release was executed at 37°C. 
Sax reported on a sustained release of mAb over 150 days in a linear fashion without any burst 
events [232]. Figure IV-2 A represents the release profile obtained by the reproduction 
experiment. The mAb was released in an almost linear manner over approximately 170 days. 
An initial burst release was not observed. Both release curves of mAb - reported in 2012 by Sax 
and described within the present work - are comparable to each other, leading to the conclusion 
that tsc-extrusion as preparation method can be considered as reliable and reproducible.  
The main drawback of the MiniLab® Micro Rheology Compounder is a minimal batch size of 
approximately 5 g. To reduce the batch size from 5 g to 1 g, the identical formulation was 
extruded using a ZE-5 mini-extruder from Three-Tec (Seon, Switzerland), to test if the 
developed formulation was transferable to a different extruder ensuring the same release 
patterns. 
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Figure IV-2: In-vitro release of mAb from SLIs extruded using a (A) MiniLab® Micro Rheology Compounder 
and a (B) ZE-5 mini-extruder from Three-Tec. Formulation of SLIs and extrusion settings were identical.  
 
Therefore, the exact formulation listed above was extruded with identical settings used before. 
The release profile of mAb is illustrated in Figure IV-2 B. A linear release over the first 28 days 
delivering approximately 85 % of total incorporated protein can be observed, followed by a 
phase where no more protein was delivered. Comparable release profiles using both extruders 
were not achieved. To clarify why release rates were so dramatically different, SLIs were further 
investigated towards mechanical properties and optical appearance.  
Compressive strength and true density of implants were determined. The results are depicted 
in Table IV-4, showing that both compressive strength and true density were lower for SLIs 
manufactured with the ZE-5 mini-extruder. This points into the direction that implants were 
compressed less with the ZE-5 mini-extruder compared to the MiniLab® Micro Rheology 
Compounder (for further details on considerations about extrusion pressure and its impact on 
release patterns, please see chapter IX). This allows the incubation medium to penetrate faster 
into the lipid matrix and may be one explanation for the accelerated release.  
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Table IV-4: Compressive strength and true density of SLIs manufactured with both extruders. Formulation 
and extrusion parameters were identical. 
 Compressive strength [N] True density [g/cm3] 
MiniLab® Micro Rheology Compounder 1.75 (±0.072) 1.085 (±0.005) 
ZE-5 mini-extruder 1.42 (±0.015) 1.069 (±0.002) 
 
To prove this hypothesis, SEM micrographs of freshly extruded SLIs were acquired (Figure 
IV-3). The surface of SLIs manufactured with the MiniLab® Micro Rheology Compounder were 
characterised by a non-porous and smooth surface without obvious irregularities (the 
irregularities which can be seen in the right lower part of Figure IV-3 A are due to breakage 
caused by handling).  
 
Figure IV-3: SEM micrographs of SLIs extruded with a (A and B) MiniLab® Micro Rheology Compounder and 
(C and D) a ZE-5 mini-extruder from Three-Tec. Displayed are implants` surfaces at a magnification of 40x 
and 300x.  
 
Only at a magnification of 300x, the surface appeared slightly rough and uneven; the platelet-
like structures are non-molten lipids (Figure IV-3 B). In contrast, SLIs produced with the ZE-5 
A 
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mini-extruder exhibited a surface with numerous pores and channel-like structures. Looking 
more closely on surface morphology, pores with a size of approximately 20 µm were present as 
well as irregularities with a diameter of up to 80 µm (Figure IV-3 D). 
 
IV.2.3 SETUP OPTIMISATION ON ZE-5 MINI-EXTRUDER 
Since the release of mAb was accelerated and implant properties were found to be different 
when extruding the identical formulation on different extruders, optimisation was necessary. 
It was aimed to increase the pressure within the extruder barrel by the following approaches: (i) 
elongating the outlet die, (ii) using a smaller outlet die and (iii) increasing the screw speed. 
Release experiments were performed with mAb only and were discontinued after 28 days 
because difference in release was already noticeable after this time.  
IV.2.3.1 ELONGATION OF OUTLET DIE 
In a first approach, the outlet die of the barrel was elongated (Figure IV-4). With respect to fluid 
mechanics, it is understood that an elongation should lead to an increase in pressure within the 
barrel and therefore generating a denser lipid matrix releasing the mAb in a slower fashion. 
 
Figure IV-4: Pictures of the outlet plate of the ZE-5 mini-extruder with elongated outlet die. The elongated 
outlet die was custom-made and was produced by the LMU workshop. 
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The formulation and extrusion parameters were kept as before: 10 % protein lyophilisate, a lipid 
matrix of 30 % H12 and 70 % D118. Extrusion was performed at 41°C at 40 rpm. Importantly, 
already at this early stage of setup optimisation, PEG 6000 was avoided, as it can promote 
protein degradation [258, 259]. This represents one of the major advantages of the lipid implants 
described here.  
 
Figure IV-5: Cumulative release of mAb delivered from SLIs with a diameter of 2.0 mm. The extruder barrel 
was either equipped with or without an additional elongation of the outlet die.  
 
As Figure IV-5 indicates, release rate of mAb was slowed down by equipping the outlet plate 
with an additional elongated outlet die, especially within the first days. For instance, after 7 days, 
37.2 % mAb was liberated compared to 23.9 % when the extruder was equipped with the 
elongated outlet die. Although it was possible to slow down the release, it was intended to tailor 
release further. Therefore, the implant diameter was reduced to increase pressure within the 
barrel even more. 
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IV.2.3.2 REDUCTION OF IMPLANT DIAMETER 
The implant diameter was reduced from initially 2.0 mm to 0.8 mm for two reasons: first, by 
increasing the pressure within the barrel, a further slowdown was intended and second, to obtain 
implant dimensions suitable for intraocular use.  
 
Figure IV-6: Cumulative release of mAb delivered from SLIs with different diameters ranging from 2.0 mm to 
0.8 mm. The outlet plate was equipped with an additional elongation of the outlet die. 
 
By reducing the implant diameter, it was possible to reduce the release further and additionally 
linearise it. For both implant diameters, 1.5 mm and 0.8 mm, a linear release over the first 
28 days was observed. However, because the cumulative percentage of mAb released was 
only reduced by 14 % (78.0 % for 2.0 mm compared to 61.9 % for 0.8 mm) after 28 days, 
optimisation of extrusion settings was further continued.  
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IV.2.3.3 ADJUSTMENT OF SCREW SPEED 
Adjustment of screw speed was performed with 1.5 mm implant diameter because protein load 
was too low for 0.8 mm diameter, especially when considering long-term release of several 
months.  
The screw speed was varied from 10 rpm to 80 rpm, meanwhile all other extrusion parameters 
were not changed. Figure IV-7 illustrates the impact on the release of mAb: the slowest release 
can be observed for 40 rpm (22.3 % after 7 days). After 7 days, 72.5 % mAb was released at 
80 rpm and 39.8 % at 10 rpm. Thus, it can be concluded that for this specific formulation using 
the ZE-5 mini-extruder the optimal extrusion settings were so far identified. The reason for the 
faster in-vitro release from implants extruded at 60 rpm and 80 rpm was most likely that implants 
were more porous comparing to slower screw speeds. This aspect is described within chapter 
IX.3.3.2.  
 
Figure IV-7: Cumulative release of mAb delivered from SLIs using different screw speeds ranging from 
10 rpm to 80 rpm. The outlet plate was equipped with an additional elongation of the outlet die. 
 
As an interim summary, it can be stated that all adjustments improved the release profile of mAb 
as the release rate was slowed down and release was linearised. However, since the release 
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rate was still too fast and far away from the desired 3 months, it was decided to change the 
system more profoundly by changing the lipid composition.  
IV.2.3.4 CHANGE OF LIPID COMPOSITION 
While changing the lipid composition of the extrudates, the percentage of protein lyophilisate 
was kept constant at 10 % and screw speed was adjusted to 40 rpm. First, lipid composition 
was changed from 30 % H12 stepwise to 50 % H12 (reduction of D118 from 70 % to 50 %) at 
a constant extrusion temperature of 41°C (Figure IV-8 A). Then, at a lipid composition of 50:50, 
the extrusion temperature was reduced from 39°C to 37°C and 35°C (Figure IV-8 B). For this 
experiment, release of mAb was monitored over 14 days. 
 
Figure IV-8: Cumulative release of mAb from SLIs consisting either of (A) different lipid compositions 
applying the same extrusion temperature or (B) a 50:50 lipid blend extruded at 39°C, 37°C or 35°C.  
 
In Figure IV-8 A the release profiles of mAb delivered from SLIs consisting of different lipid 
matrices are depicted. The most promising release was observed for the 50:50 formulation, as 
especially during the initial phase a very slow release was observed. The overall release after 
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14 days was comparable, but due to the very slow release within the first days, the 50:50 
formulation was chosen for further investigations.  
The 50:50 formulation was therefore extruded at different temperatures ranging from 35°C to 
39°C. A lower extrusion temperature was not feasible, as no continuous and homogenous lipid 
strand was formed. Higher extrusion temperatures than 41°C resulted in a molten lipid mass 
not forming a solid matrix. Slowest release of mAb was detected for an extrusion temperature 
of 35°C: after 14 days, only 14.8 % mAb were released compared to 56.3 % when 37°C were 
applied.  
It was also tested if the H12 percentage could be increased even more (up to 90 %), but it turned 
out that a too high percentage of H12 leads to a disintegration of SLIs at the incubation 
temperature of 37°C, resulting in burst release (data not shown). Therefore, the optimal 
formulation and extrusion settings were identified as: 10 % protein lyophilisate, 45 % H12, 45 % 
D118 extruded at 35°C and 40 rpm. 
 
Figure IV-9: Cumulative release of mAb and Ranibizumab from SLIs consisting of a 50:50 lipid blend. 
Extrusion temperature was set to 35°C and screw speed was 40 rpm. The protein load was set to 5 % 
resulting in 1.53 mg (±0.06 mg) protein per implant. 
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This setup was also tested incorporating Ranibizumab into SLIs (Figure IV-9). Appropriate 
release profiles over 126 days for both tested proteins were obtained from a formulation 
consisting of 45 % H12 and 45 % D118 with 10 % protein lyophilisate (1:1 [w/w]), resulting in a 
protein load of 1.53 mg (±0.06 mg) per implant. The release profile of mAb is characterised by 
triphasic release behaviour without any initial burst release. An initial phase for the first 28 days, 
releasing approximately 22.9 µg protein per day, is followed by a phase lasting from day 28 to 
day 100 where in average 8.2 µg/day protein was released. During the last phase, (lasting from 
day 100 until day 126) only small amounts of protein were released (approximately 5 %; 
2.7 µg/day). In total, approximately 85 % of incorporated protein was released. 
Results from the Ranibizumab release study showed qualitatively the same triphasic release 
behaviour (Figure IV-9). During the first phase lasting for 4 weeks, 53 % of incorporated protein 
was released (28.9 µg/day) followed by an almost linear phase lasting from day 28 to day 110 
in which approximately 34% of incorporated protein (equivalent to 6.5 µg protein per day) was 
liberated. In general, Ranibizumab release was faster compared to mAb and discontinued after 
110 days at approximately 90 % of total protein amount. For both proteins, no burst release 
occurred.  
Lipid implants were intentionally formulated without any pore forming agents. This, however, 
raises the question how proteins were set free. Even if the lipid matrix was strongly compressed, 
compacted and molten together by the extrusion process and applied temperature, micro-
channels and tiny pores were still present, allowing the incubation medium to penetrate into the 
matrix as observed by SEM (Figure IV-10). Micrographs of the surface, taken with a 
magnification of 40x, showed a dense and smooth surface (Figure IV-10 A). Small pores having 
a size of 5 µm to 10 µm can be observed at 300x as displayed in Figure IV-10 C. Slightly larger 
pores and channels ranging between 10 µm to 25 µm can be found in the cross-section 
micrographs (Figure IV-10 D). Based on these observations, it can be assumed that the lipid 
implants contained an interconnected pore network, even if no pore forming agents were 
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incorporated. The protein lyophilisate itself will generate channels and pores in-situ due to its 
water solubility.  
 
Figure IV-10: SEM micrographs of the surface and cross-section of lipid implants after extrusion and prior 
to incubation are shown. Micrographs (A) and (C) displaying the surface of the implant at magnifications of 
40x and 300x, (B) and (D) are the corresponding micrographs of the cross sections, also taken at 40x and 
300x. 
 
IV.2.3.5 DISCUSSION OF PROPERTIES OF THE LEAD FORMULATION 
In previous studies, a matrix with a protein load of 10 % protein lyophilisate, 10 % PEG 6000, 
24 % H12 and 56 % D118 [181, 182] was extruded at 41°C and showed promising long-term 
release of lysozyme [182] and a monoclonal antibody [232] and was therefore the starting point 
for our study. Based on this formulation, screening studies were performed to identify the most 
promising formulation and settings on the ZE-5 mini-extruder. The most appropriate formulation 
for the ZE mini-extruder comprised 10 % protein lyophilisate and a lipid matrix consisting of 
50 % H12 and 50 % D118; no PEG was added. An adequate extrusion temperature was 
determined at 35°C. Thus, a manufacturing setup was established to ensure the production of 
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SLIs which provide a constant and almost complete release (up to 95 %) of incorporated protein 
without any burst effects.  
The intentional absence of PEG as a precipitant represents one of the major features of the 
developed formulation. It has been reported that PEG can slow down the release and minimise 
the initial burst due to precipitating events [177]. Sax et al. [182] already demonstrated that long-
term release of proteins from SLIs without addition of PEG is feasible. The controlled release of 
lysozyme was reported for 230 days in which 80 % of protein was released. This study was 
performed with the rather small and robust protein lysozyme. Now, we demonstrated that SLIs 
can be produced without any further excipients showing no initial burst and ensuring long-term 
release of more complex and sensitive molecules such as monoclonal antibodies. Furthermore, 
as PEG can promote protein degradation [258, 259], avoiding PEG is favorable concerning 
protein stability, especially when release time frames of several months are considered. 
Furthermore, a reduction of the extrusion temperature to 35°C is beneficial as it reduces thermal 
stress on the protein. 
The observed release curves of the proteins are a result of different release mechanisms 
complementing each other. It is well known that release from lipid matrices is mainly controlled 
by diffusion, (see Guse et al. and Koennings et al. [158, 260]). Furthermore, release can be 
influenced by the addition of hydrophilic pore forming agents, e.g. PEG [160, 177, 178] or 
trehalose [216] to modify release patterns. Once the implant is placed into the incubation 
medium, hydrophilic components dissolve quickly and are released through an interconnected 
pore-network. In 2012, Sax et al. described an additional release pathway of proteins from a 
lipid matrix which relies on a partial melting of the low melting lipid within the matrix [182]; the 
molecules diffuse in a phase of molten lipid [234]. It was shown, that both melting points (Tonset 
and Tmelting) of the low melting lipid are very important parameters playing a major role in 
triggering protein release. Due to the similarity of our lipid matrix described here with the system 
Sax et al. characterised, we assume that also in our study Tonset and Tmelting of the low melting 
lipid are crucial parameters affecting release patterns. Therefore, the obtained long-term 
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release profiles for mAb and Ranibizumab are most likely an interplay of different release 
mechanisms mentioned above.  
 
IV.2.4 INCREASE OF PROTEIN LOAD  
Since an adequate amount of drug substance should be provided when release time frames of 
several months are considered, an increase of protein amount per implant was intended. 
Increasing protein load was attempted by three different approaches: (i) increase of the protein 
lyophilisate percentage, (ii) change of protein lyophilisate composition and (iii) change of implant 
diameter. 
IV.2.4.1 PROTEIN RELEASE FROM IMPLANTS WITH INCREASING AMOUNTS OF PROTEIN 
LYOPHILISATE 
With a protein load of 5 % and the minimal dimensions of the implants, total protein content of 
one single implant was on average approximately 1.53 mg. The percentage of protein was 
increased stepwise from initially 5 % to 7.5 % and 10 % to encapsulate more protein per implant. 
Lyophilisates comprised a mixture of protein and HP-β-CD in a ratio of 1:1 [w/w]. Consequently, 
the amount of lipids was reduced from 90 % to 80 %, while the lipid composition and extrusion 
settings were kept constant.  
With increasing amounts of protein lyophilisate, the release of proteins was accelerated. For 
mAb, a substantial burst release was seen for the formulations containing 7.5 % and 10 % 
protein, respectively: after 1 day, 22.0 % mAb was released from the formulation comprising 
7.5 % protein, whereas 23.1 % protein was quantified released from the formulation with 10 % 
mAb (Figure IV-11 A). For comparison, after 1 day only 4.4 % mAb was released from the lead 
formulation. Release stopped after 56 days of incubation for the formulations with 7.5 % and 
10 % protein content between 85 % to 87 % of total protein load.  
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Ranibizumab release from the different formulations is illustrated in Figure IV-11 B. The release 
profiles for the formulations with 7.5 % and 10 % protein load were characterised by a high initial 
burst release: 12.8 % (7.5 % protein load) and 17.9 % (10 % protein load) were already released 
after 1 day compared to the lead formulation with 5 % protein content (2.3 % after 1 day). 
Additionally, release stopped 6 weeks earlier when protein content was increased. 
Bevacizumab release was also accelerated with increasing lyophilisate percentage as 
illustrated in Figure IV-11 C. The comparatively short release duration of approximately 21 days 
for the lead formulation was even accelerated, especially during the first days of release. After 
1 day, 38.8 % and 47.5 % were released from the formulations containing increased lyophilisate 
percentages compared to 11.8 % released from the lead formulation. Additionally, release 
stopped already after 14 days (7.5 % protein load) and 7 days (10 % protein load).  
Qualitatively, similar observations were made for Aflibercept release, showing a faster release 
with increasing percentage of protein lyophilisate (Figure IV-11 D). 
In summary, for all proteins release was observed to be faster, especially during the initial 
phase. Therefore, this attempt was not further pursued. The more water soluble lyophilisate 
generated a larger pore-network in-situ by dissolution leading to faster release rates. This is in 
accordance with previous results described by Mohl et al. for interferon α-2a [167]. Up to 20 % 
of PEG 6000 was added to the lipid matrix before lipid implants were manufactured by 
compression. The same phenomena was also observed by Sax et al. for lysozyme [182] where 
a higher proportion of PEG 4000 resulted in faster release rates. However, care must be taken 
when considering pore-forming effects of excipients, especially in terms of PEGs. The addition 
of PEG can lead to either an in-situ precipitation of the protein [178] or a larger pore-network 
[177] depending on the protein. The increase of lyophilisate exclusively generates a larger pore-
network.  
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Figure IV-11: Cumulative release of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept from 
SLIs. Lipid implants were produced with different percentages of protein lyophilisate in a 1:1 [w/w] 
formulation with HP-β-CD resulting in a final protein load of 5 %, 7.5 % and 10 % per implant. Please note 
that the x-axis is scaled differently.  
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IV.2.4.2 PROTEIN RELEASE FROM LIPID IMPLANTS WITH DIFFERENT LYOPHILISATE 
COMPOSITIONS 
In a next attempt, the composition of the protein lyophilisate was changed to increase protein 
load per implant. The protein ratio within the lyophilisate was increased from 50 % to 75 %, 
whereas the percentage of lipid portion was retained constant at 90 %. Due to the poor release 
patterns of Bevacizumab and Aflibercept, the following experiments were carried out with mAb 
and Ranibizumab only. 
Figure IV-12 A and Figure IV-12 B display the release of mAb and Ranibizumab with lyophilisate 
formulations 1:1 [w/w] and 3:1 [w/w]. This time, the sustained release profiles were not 
significantly altered (no burst observed), and sustained release lasted equally long as for the 
low dose lead formulation. By changing the lyophilisate composition, 50 % more protein could 
be incorporated into the lipid implant without negatively affecting the release patterns. 
 
Figure IV-12: Cumulative release profiles of (A) mAb and (B) Ranibizumab from lipid implants. Protein 
lyophilisate percentage was kept at 10 % while the lyophilisate formulation was changed from 1:1 [w/w] 
protein:cyclodextrine ratio to 3:1 [w/w]. Protein load per implant was thus increased from 1.53 mg (±0.06 mg) 
to 2.40 mg (±0.23 mg). 
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The ratio of water-soluble (lyophilisate) to water insoluble (lipids) components stayed constant. 
Consequently, the micro structure of the lipid implant (pores and interconnected channels) of 
the implant was retained better. Figure IV-13 shows that both formulations, either comprising 
the 1:1 [w/w] protein lyophilisate (Figure IV-13 A) or the 3:1 [w/w] protein lyophilisate (Figure 
IV-13 B) have a comparable appearance of the micro structure in the cross sections. Due to a 
reduction of the stabilising agent, protein stability must be studied with care.  
 
Figure IV-13: SEM micrographs of lipid implants after extrusion and prior to incubation. Micrographs 
displaying the cross section of SLIs manufactured with (A) 1:1 [w/w] protein lyophilisate and (B) 3:1 [w/w] 
protein lyophilisate at magnifications of 40x. 
 
IV.2.4.3 PROTEIN RELEASE FROM IMPLANTS WITH DIFFERENT DIAMETERS 
Another aspect towards increasing protein load was to change implant dimensions rather than 
varying the composition. The diameter was increased from 1.5 mm to 1.7 mm. Thus, the surface 
area was increased by 14 % and the implant volume by 25 %, resulting in an increased 
(approximately 25 %) protein mass per implant.  
A diameter of 1.7 mm is still suitable for potential intravitreal incision and was realised by 
changing the outlet die of the ZE-5 mini-extruder. A further decrease of release rates was 
expected, based on the hypothesis that an increase in implant diameter increases diffusion path 
lengths. 
Figure IV-14 indicates that both proteins were released within the same time frame and fashion 
from implants being 1.5 mm or 1.7 mm in diameter. For mAb, a biphasic release behaviour 
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comprising an initial phase of 4 weeks followed by a phase lasting from day 28 to day 100 was 
noticeable. The cumulative release of mAb released from 1.7 mm implant was slightly faster 
compared to 1.5 mm even though approximately 85 % to 90 % of total incorporated protein was 
released in both cases (Figure IV-14 A). Ranibizumab release was monitored over 154 days, 
showing that from both diameters release discontinued nearly after 120 days at 90 % to 95 % 
of total protein load (Figure IV-14 B). 
 
Figure IV-14: (A) displays the cumulative release profile of mAb, (B) shows cumulative Ranibizumab release. 
Implant diameter was increased from 1.5 mm to 1.7 mm comprising the 3:1 [w/w] lyophilisate formulation.  
 
Release of both proteins from the larger diameter was faster than expected. Due to larger 
diffusion pathways of molecules diffusing out of the matrix, release was expected to be 
prolonged. In contrast to hot melt extrusion (HME), triglycerides were not completely molten 
during extrusion. Applying an extrusion temperature of 35°C induced merely a softening and 
sintering of the lipids, especially of the low melting lipid H12. Because of the semisolid state of 
the material, compression and compacting were the major mechanisms of implant formation. It 
can be speculated that during extrusion of SLIs with 1.7 mm diameter, the material was less 
compacted than at 1.5 mm which overcompensated the impact of larger diffusion pathways. 
However, this aspect requires further investigations.  
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IV.2.4.4 SUMMARY ON ATTEMPTS TOWARDS PROTEIN INCREASE 
Overall, it was successfully demonstrated that protein load can be increased without negatively 
impacting the desired release time frame of 4 months. As illustrated in Table IV-5, protein load 
was increased from initially 1.53 mg to 3.00 mg per implant by changing the lyophilisate 
composition and implant diameter. This results in an increase of protein load by nearly 100 %. 
The desired release kinetic was not influenced by that. Assuming a sustained release of 
120 days, the daily delivery rate was increased from approximately 11 µg/day to 23 µg/day.  
Table IV-5: Protein load per implant and average released protein per day in dependency of the different 
formulations and settings. A release time frame of 120 days and 90 % of total released protein was basis for 
calculations. 
Diameter 1:1 [w/w] lyophilisate formulation 3:1 [w/w] lyophilisate formulation 
 Total protein load 
per implant 
Average released 
protein per day  
Total protein load 
per implant 
Average released 
protein per day 
1.5 mm 
1.53 mg 
(±0.06 mg) 
10.93 µg 
2.40 mg 
(±0.23 mg) 
18.23 µg 
1.7 mm 
2.00 mg 
(±0.05 mg) 
14.93 µg 
3.00 mg 
(±0.08 mg) 
22.58 µg 
 
IV.2.5 IMPACT OF IMPLANT STORAGE  
IV.2.5.1 IN-VITRO RELEASE PATTERNS 
A major aspect concerning lipid based drug delivery matrices is their stability regarding 
properties and release patterns upon storage. It is well known that triglycerides exist in different 
modifications [261], such as α-, β- or β’-modifications which have an impact on properties like 
melting behaviour or crystallinity/amorphous state [181, 261]. Additionally, triglycerides can 
undergo an aging process upon storage, namely the conversation from the thermodynamically 
unstable α-modification to the more stable β-modification. These conversions can be prevented 
by curing of the implants at defined temperatures [233]. The system described here, consisted 
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of a binary triglyceride blend. Therefore, those aspects were of special interest as they can 
possibly change release patterns. 
Lipid implants consisted of 45 % D118, 45 % H12 and 10 % protein lyophilisate with both 1:1 
[w/w] and 3:1 [w/w] formulations resulting in a final protein load of 5.0 % and 7.5 %, respectively. 
For the following experiments, mAb and Ranibizumab were used only. 
 
Figure IV-15: Cumulative release profiles of (A) mAb and (B) Ranibizumab directly after production (week 0) 
and after storage of 4 and 12 weeks at 4°C prior to in-vitro release.  
 
Release studies were performed either directly after production (week 0) or after storage for 
4 weeks or 12 weeks at 4°C in micro-centrifuge tubes. Release profile was then monitored over 
126 days for both proteins (Figure IV-15). Displayed are the results for the formulation with 1:1 
[w/w] lyophilisates, illustrating that release patterns were not affected by the storage; both 
proteins retained their characteristic release profiles. Comparable release curves were obtained 
for the 3:1 [w/w] lyophilisate formulation for both proteins (data not shown). Consequently, it can 
be concluded that SLIs can be stored for at least 3 months at 4°C prior to use ensuring same 
release properties. These observations are in line with results from a previous storage study of 
lipid implants described by Mohl et al. [176]. 
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IV.2.5.2 STABILITY OF TRIGLYCERIDES IN THE LIPID MATRIX UPON STORAGE 
DSC was performed to identify possible alterations in melting points and/or melting energy 
indicating changes in lipid modifications or crystal growth.  
 
Figure IV-16: Melting curves of lipid implants consisting of 10 % protein lyophilisate, 45 % H12 and 45 % 
D118 after storage for 0, 4 and 12 weeks at 4°C. 
 
Thermograms (Figure IV-16) obtained after 0, 4 and 12 weeks did not show differences in the 
course of the melting curves. The maximum melting points (Tmelting) are summarised in Table 
IV-6. Tmelting of H12 was measured between 42.70°C and 43.23°C; the same was observed for 
D118. Melting energy was assessed as it is an indicator for the presence of amorphous lipids 
[233]. The melting energies for H12 and D118 remained constant upon storage, meaning no 
shifts in amorphous/crystallinity status of both triglycerides occurred (Table IV-6). No changes 
in Tmelting and melting energy values occurred, signifying that both triglycerides remained in their 
thermodynamically stable modifications. 
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Table IV-6: Tmelting and melting energy of H12 and D118 upon storage for 0, 4 and 12 weeks at 4°C. 
Time point 
Tmelting 
H12 [°C] 
Tmelting 
D118 [°C] 
Melting energy  
H12 [J/g] 
Melting energy 
D118 [J/g] 
week 0 42.70 (±0.46) 69.43 (±0.42) 75.74 (±3.21) 86.64 (±3.85) 
week 4 43.10 (±0.46) 70.10 (±0.26) 76.19 (±1.68) 89.95 (±1.51) 
week 12 43.23 (±0.42) 70.17 (±0.29) 74.40 (±0.65) 90.27 (±1.59) 
 
Figure IV-17 A shows the XRPD patterns of H12 bulk material revealing two strong reflections 
at 2θ=20.9° d=0.42 nm and at 2θ=23.2° d=0.38 nm which are typical for orthorhombic chain 
packaging of the β’-modification [181]. The D118 bulk material diffraction patterns were 
characterised by three main reflection peaks at 2θ=19.4°, 2θ=23.2° and 2θ=24.3° (Figure IV-17 
B) typical for the β-modification [167] with the corresponding short spacings at 0.46 nm, 0.38 nm 
and 0.37 nm. The reflection peak at 2θ=21.0° d=0.42 nm represents a small percentage of α-
modification. 
 
Figure IV-17: (A) shows diffraction patterns of H12 bulk material, (B) represents D118 bulk material diffraction 
patterns. 
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As displayed in Figure IV-18, the reflections of extruded SLIs are intermediates from those of 
pure H12 and D118, respectively [181]. The distinct diffraction lines at 2θ=19.6°, 23.4° and 24.5° 
match to the crystal spacings of the β-modification of D118 discussed above. At an angle of 
2θ=23.4° d=0.38 nm, an overlay of the H12 β’-modification and the β-modification of D118 can 
be observed due to similar appearance at this angle. However, the XRPD patterns of the stored 
implants and the non-stored ones were identical. 
 
Figure IV-18: Patterns of lipid implants after storage for 0, 4 and 12 weeks at 4°C. For a better visualisation, 
the plots are displayed vertically. 
 
Identical XRPD patterns of stored and non-stored implants (Figure IV-18) indicate that the same 
modifications were present. Due to comparable diffraction patterns observed before and after 
storage it can be concluded that H12 stayed in its β’-modification whereas D118 was present in 
the β-modification, also previously observed by Schulze et al. for implants containing interferon-
α and PEG [181]. 
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IV.2.6 PRE-MELTING OF TRIGLYCERIDES 
The impact of storage on SLI characteristics has already been described in chapter IV.2.5 
showing no aging of the triglycerides and therefore no changes in release patterns and thermal 
characteristics.  
The present chapter is aimed to investigate the effect of different lipid modifications (coming 
along with different thermal characteristics of the lipids) on release patterns. For this, H12 and 
D118 were simultaneously molten at 80°C intentionally inducing unstable lipid modifications. 
Then, the molten mass was allowed to cool down before it was ground and sieved (< 180 µm) 
prior to extrusion. It was systematically investigated if the «pre-melting» has an impact on 
properties of lipid raw material and of extruded implants including thermal and physical 
properties as well as release patterns. In the following, the standard extrusion technique already 
described will be named as «conventional extrusion». 
SLIs were manufactured with both extrusion techniques (conventional extrusion and extrusion 
with pre-melted lipids) using the established settings (50:50 lipid blend, 35°C extrusion 
temperature, 40 rpm, 1.5 mm x 15 mm). First, the characteristics of pre-melted lipid itself were 
investigated followed by investigating the impact on release patterns. Then, SLIs were stored 
for 0, 4 and 12 weeks at 4°C and thermal properties and release patterns were monitored. 
IV.2.6.1 IMPACT OF PRE-MELTING ON LIPID CHARACTERISTICS 
The pre-melted lipid raw material was prepared according to III.2.1.3. As a benchmark, thermal 
characteristics from SLIs extruded with the standard settings for conventional extrusion were 
studied. 
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Table IV-7: Tonset and Tmelting of H12 and D118 of freshly pre-melted raw material and after extrusion using pre-
melted lipids. As a comparison, Tonset and Tmelting of H12 and D118 applying the conventional extrusion 
technique are listed. 
 Pre-melting 
Pre-melting and 
extrusion 
Conventional  
extrusion 
H12onset [°C] 32.55 (±0.71) 32.56 (±0.21) 34.10 (±0.99) 
H12melting [°C] 39.05 (±0.92) 41.00 (±0.14) 42.80 (±0.70) 
D118onset [°C] 64.53 (±1.14) 65.83 (±0.76) 63.93 (±1.12) 
D118melting [°C] 71.33 (±1.46) 71.60 (±0.20) 69.43 (±0.42) 
 
In Table IV-7, the values for Tonset and Tmelting for H12 and D118 are summarised. The pre-melting 
reduced Tonset of H12 by 1.6°C from 34.1°C to 32.6°C. Also, Tmelting of H12 was shifted from 
42.8°C to 39.1°C. Equally, Tonset and Tmelting for D118 were slightly higher after pre-melting 
(approximately 1.5°C). Since the extrusion and the incubation temperatures are very close to 
the melting points of H12, they are of special interest. Therefore, pre-melting might substantially 
influence the release patterns since the melting point of the low melting lipid is a crucial 
parameter in terms of controlled release [183]. It is also worth to note, that Tmelting of pre-melted 
material was impacted by the extrusion process: Tmelting was 2°C higher than before extrusion. 
This means, that the applied temperature of 35°C (which is about 2.5°C higher than the Tonset of 
H12) already impacted the thermal characteristics of the pre-melted lipids. To study the impact 
of pre-melting not only on melting points but also on release patterns, SLIs were manufactured 
using both extrusion techniques (see IV.2.6.2). 
XRPD was used to analyse lipid modifications. Diffraction patterns of extruded SLIs using both 
extrusion techniques and of the pre-melted lipids prior to extrusion are shown in Figure IV-19. 
The diffractograms of pre-melted lipid raw material (trace 1) and SLIs manufactured with those 
(trace 2) show no qualitative differences indicating that extrusion itself did not alter lipid 
characteristics, e.g. crystallinity. However, for SLIs produced with conventional extrusion (trace 
3), patterns changed signifying that the pre-melting step altered lipid modifications.  
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Figure IV-19: Diffraction patterns of pre-melted lipids prior to extrusion and of extruded SLIs produced with 
both conventional extrusion and extrusion with pre-melted lipids. 
 
IV.2.6.2 IMPACT OF PRE-MELTING ON IN-VITRO RELEASE 
SLIs were manufactured with freshly prepared pre-melted lipids to eliminate possible aging 
effects of the raw material on release patterns. Both extrusion techniques, conventional 
extrusion and extrusion with pre-melted lipids (Figure IV-20), were used. The extrusion settings 
and the composition of the lead formulation was used.  
Figure IV-20 illustrates the cumulative release of mAb from SLIs using both extrusion 
techniques. Release was slowed down using pre-melted lipids. The triphasic release behaviour 
for the conventional extrusion technique was not observed anymore, instead the release was 
more linear over a longer period. A sustained and almost linear release can be described lasting 
from the very first day to day 140; an initial burst was not noticed. Between day 140 and day 
200, little amounts of mAb were still released. An overall biphasic rather than a triphasic release 
behaviour was observed. Therefore, the release time frame could be extended from 
approximately 120 days to 200 days without changing the overall composition. 
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Figure IV-20: Cumulative release of mAb released from SLIs manufactured using the () conventional 
extrusion technique and () extrusion with pre-melted lipids.  
 
In 2012, Sax et al. described a release pathway of proteins from a lipid matrix which relies on a 
partial melting of the low melting lipid within the matrix [182]; the molecules diffuse in a phase 
of molten lipid [234]. It was shown, that Tonset and Tmelting of the low melting lipid are very 
important parameters playing a major role in triggering protein release. A nearby explanation of 
the prolonged release in our case could be that at the incubation temperature of 37°C the H12 
is already partially molten due to the low Tonset (Table IV-7) and thereby «closing» the pores and 
interconnected pores within the lipid matrix in-situ. Thereby, the molecules are hindered to 
diffuse out of the depot which results in prolonged release periods. The pre-melted lipids were 
exposed twice to a thermal input, which reduced the melting point of H12 and thereby softened 
and changed the flowability of the material. Measurements of the extrusion pressure supposedly 
favours that hypothesis: within the extruder barrel a pressure of 975 kPa (±74 kPa) for 
conventional extrusion was measured and 556 kPa (±41 kPa) were measured when pre-melted 
lipids were manufactured (see chapter IX).  
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INCREASE OF PROTEIN LOAD OF SLIS EXTRUDED WITH PRE-MELTED LIPIDS 
By pre-melting of the lipids, it was possible to prolong and linearise the sustained release profile 
of mAb from 120 days to almost 200 days. Due to the very promising results, it was further 
investigated, if the protein load could be increased as previously described for SLIs produced 
with the conventional extrusion technique (IV.2.4) and if this technique is also applicable for the 
other proteins used.  
 
Figure IV-21: Cumulative release profiles of mAb from implants being (A) 1.5 mm and (B) 1.7 mm in diameter. 
Protein lyophilisate percentage was kept at 10 % while the lyophilisate formulation was changed from 1:1 
[w/w] protein:cyclodextrine ratio to 3:1 [w/w]. SLIs were prepared with pre-melted lipids. 
 
The approach to increase the percentage of lyophilisate was not successful (Appendix, Figure 
XII-5) since accelerated release rates were observed for all proteins with increasing percentage 
of lyophilisate. Simultaneously to the approaches already discussed in IV.2.4 for SLIs produced 
with conventional extrusion technique, the lyophilisate composition was changed from 1:1 [w/w] 
to 3:1 [w/w] to encapsulate 50 % more protein within the same amount of lyophilisate. The 
implant diameter was increased from 1.5 mm to 1.7 mm as well. Both approaches were 
performed with mAb and Ranibizumab. Release patterns for both proteins were not negatively 
influenced by the attempts (Figure IV-21 and Figure IV-22). It was therefore possible to 
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encapsulate 3 mg mAb and Ranibizumab into an SLI and deliver it over approximately 200 days 
using pre-melted lipids.  
 
Figure IV-22: Cumulative release profiles of Ranibizumab from implants being (A) 1.5 mm and (B) 1.7 mm in 
diameter. Protein lyophilisate percentage was kept at 10 % while the lyophilisate formulation was changed 
from 1:1 [w/w] protein:cyclodextrine ratio to 3:1 [w/w]. SLIs were prepared with pre-melted lipids. 
 
IV.2.6.3 IMPACT OF PRE-MELTING ON STORAGE STABILITY OF SLIS 
As pre-melting had a strong impact on thermal characteristics (Table IV-7), lipid modifications 
(Figure IV-19) and the associated prolonged release, it was tested if triglycerides underwent an 
aging process upon storage. Since possibly unstable lipid modifications were induced (and 
therefore a change of crystallinity/amorphous status was induced), aging of triglycerides also 
affecting release patterns may be possible.  
To systematically investigate the storage effect, SLIs were manufactured with both extrusion 
techniques (conventional extrusion and extrusion with pre-melted lipids) using the established 
settings (50:50 lipid blend, 35°C extrusion temperature, 40 rpm, 1.5 mm x 15 mm). SLIs were 
stored for 1, 2, 4 and 12 weeks at 4°C and were analysed towards thermal characteristics and 
release patterns. 
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IMPACT OF STORAGE ON THERMAL CHARACTERISTICS OF SLIS 
After a storage of 1, 2, 4 and 12 weeks, SLIs were analysed towards Tonset and Tmelting of both 
lipids (Figure IV-23). Figure IV-23 A represents the melting points of H12 measured over 
12 weeks upon incubation of SLIs produced with both extrusion techniques. 
 
Figure IV-23: Overview of Tonset and Tmelting of both lipids (A) H12 and (B) D118. Implants were manufactured 
using both extrusion techniques, conventional extrusion and extrusion with pre-melted lipids. 
 
For conventional extrusion, both values remained rather constant over time (Tonset: 33.2°C to 
33.5°C; Tmelting: 42.7°C to 43.2°C). This is also valid for SLIs produced with pre-melted lipids 
because Tmelting values stayed constantly at 40.2°C over time. The value for Tonset decreased 
from 32.5°C (week 0) to 32.1°C (week 12). Generally, changes of melting points as a function 
of the different extrusion techniques were not apparent for H12 melting points.  
Tonset and Tmelting of D118 incorporated into the SLIs was also monitored over 12 weeks (Figure 
IV-23 B). Applying conventional extrusion, Tonset and Tmelting of D118 decreased by approximately 
2°C during incubation time. Due to no obvious differences in release profiles after storing SLIs 
produced with conventional extrusion (Figure IV-15), a change in melting points was not 
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expected raising the question if the melting points of D118 (and H12) are affecting the release 
at all. The same trend was also observed for extrusion with pre-melted lipids: both melting points 
dropped by approximately 1°C within 12 weeks. The thermal characteristics of D118 changed 
more than those of H12 even though H12 is the low melting lipid and its melting points are very 
close to the extrusion and incubation temperature. It seems that a correlation between melting 
points and release patterns is not present probably due to the complexity of the system where 
other parameters are affecting the release (extrusion temperature, extrusion pressure, screw 
speed). 
 
Figure IV-24: Overview of melting energies of both lipids manufactured within SLIs. Implants were 
manufactured using both extrusion techniques, conventional extrusion and extrusion with pre-melted lipids. 
 
In addition to melting points, the melting energy was assessed as it is an indicator for the 
presence of amorphous lipids [233]. In Figure IV-24 the melting energies of H12 and D118, 
manufactured with both extrusion techniques and stored over 12 weeks, are displayed. 
Regarding conventional extrusion, melting energies of H12 and D118 demonstrated rather 
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constant values (H12: 75 J/g to 78 J/g; D118: 85 J/g to 90 J/g). Contrarily, for pre-melted lipids 
ΔH increased by 10 J/g (from 63 J/g to 72 J/g) for H12 and decreased from 105 J/g to 95 J/g 
concerning D118. The melting energies of both lipid components changed due to the pre-
melting procedure. In general, a change in melting energy indicates a change in amorphous 
state of the lipids while a decrease designates an increase in amorphous amounts [233].  
The crystallinity status of stored and non-stored SLIs was evaluated as well but results did not 
show any changes in XRPD patterns for both extrusion techniques (Appendix Figure XII-6 and 
Figure XII-7). 
IMPACT OF STORAGE ON RELEASE PATTERNS OF SLIS  
In addition to thermal characteristics, release patterns of stored and non-stored SLIs were 
evaluated to determine if the changes in melting points, melting energy and lipid modification 
have an impact on release patterns. SLIs extruded with conventional extrusion technique did 
not show any differences in release behaviour upon storage (Figure IV-15). 
 
Figure IV-25: Cumulative release of mAb from SLIs extruded with pre-melted lipids and after a storage of 0, 
4 and 12 weeks at 4°C. Lipid implants were produced with different protein lyophilisate compositions: either 
in a ratio of (A) 1:1 [w/w] or (B) 3:1 [w/w]. 
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Figure IV-25 displays the release of mAb from SLIs stored for 0, 4 and 12 weeks at 4°C prior to 
release. SLIs were extruded with pre-melted lipids. Compared to the release profile obtained 
from non-stored SLIs (week 0), release was accelerated after a 4-week storage. Especially 
during the initial phase, substantially higher release rates were observed. For instance, after 
7 days, 8.4 % mAb was released from non-stored SLIs but 25.9 % and 50.3 % from SLIs stored 
for 4 weeks and 12 weeks, respectively (Figure IV-25 A). These accelerated release rates are 
present over the complete release time of 160 days. Observations made for the 1:1 [w/w] 
lyophilisate hold also true for the 3:1 [w/w] lyophilisate (Figure IV-25 B). 
 
Figure IV-26: Cumulative release of Ranibizumab from SLIs extruded with pre-melted lipids and after a 
storage of 0, 4 and 12 weeks at 4°C. Lipid implants were produced with different protein lyophilisate 
compositions: either in a ratio of (A) 1:1 [w/w] or (B) 3:1 [w/w]. 
 
Interestingly, Ranibizumab release patterns were much less affected by storage: especially over 
the first 28 days, the characteristic release profile was retained for both lyophilisate 
compositions (Figure IV-26). Starting from day 28, release rates were accelerated from stored 
SLIs. A difference in release rates of 4-week stored and 12-week stored SLIs cannot be 
observed as it was the case for mAb described previously.  
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Therefore, not only the properties of the lipids affecting release patterns, also the proteins itself 
which are encapsulated within the depot. This is one of the most important aspects within this 
work and will also be addressed in chapter VIII. 
IV.2.6.4 SUMMARY ON PRE-MELTING OF TRIGLYCERIDES AND THEIR IMPACT ON IMPLANT 
PROPERTIES 
It can be summarised that the melting points, melting energies and crystallinity of the lipids was 
changed by the pre-melting technique. By a simultaneous pre-melting of both lipids prior to 
extrusion, it was demonstrated that release was prolonged for up to 200 days tested with mAb 
and Ranibizumab. However, when storing SLIs, differences between conventionally extruded 
SLIs and SLIs manufactured with pre-melted lipids can be observed (especially for melting 
energy). XRPD diffraction patterns stayed unchanged over time signifying no change in 
modifications for both extrusion techniques. Nevertheless, in terms of release patterns, major 
differences were apparent (even protein dependent). Thus, it seems that a straightforward 
correlation of thermal and physical characteristics and release patterns cannot be made 
probably due to the complexity of the system. Other parameters, e.g. extrusion temperature, 
extrusion pressure, screw speed, or other effects occurring during release (wettability) may 
affect the release more than expected. Since the only major difference of conventional extruded 
SLIs to those extruded with pre-melted lipids is the melting energy, the question raises if that 
might be the most crucial parameter for the different release behaviours observed. 
The fact that also a protein dependent difference in release patterns was observed, points into 
the direction that this topic is much more complex than previously thought. In other words: the 
very promising release profiles obtained with this simple and straightforward technique, makes 
this topic even more attractive for further research. For instance, the process of melting both 
lipids simultaneously together offer great potential as the rate of heating, the final temperature 
or the cooling rate can be varied most likely impacting the properties of the lipids.  
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IV.2.7 PROTEIN RELEASE TESTS FROM PLGA MATRICES 
This section describes the release of proteins from different PLGA matrices including Resomer® 
RG 502, RG 502 H and RG 755 S. It was aimed to evaluate how proteins are released from 
PLGA matrices and to compare those data with release profiles obtained from SLIs. PLGAs 
with different degradation time frames were used for two reasons: first, to evaluate the impact 
of depot erosion in addition to diffusion, and second, to determine the impact of different end 
groups on release profiles. 
For this, PLGA implants were prepared by mixing 10 % protein lyophilisate (1:1 [w/w] 
protein:HP-β-CD) with 90 % Resomer® RG 502, Resomer® RG 502 H or Resomer® RG 755 S 
in a mortar to obtain a homogenous powder blend. The powder mixture (approximately 1.5 g) 
was fed manually to the ZE-5 mini-extruder from Three-Tec® (Seon, Switzerland) and extrusion 
was performed at 70°C at a screw speed of 60 rpm. In-vitro release was performed at 37°C. 
The stability of released protein from PLGA matrices was assessed additionally and is described 
within chapter VII. 
IV.2.7.1 RELEASE FROM RESOMER® RG 755 S MATRICES 
Resomer® RG 755 S was chosen since the estimated degradation time frame of this PLGA 
(equipped with an ester as end group) is about 6 months. The polymer is characterised by a 
ratio of 75:25 and with a molecular weight of 76,000 to 116,000 Da (Table III-2). This rather long 
degradation time allows to exclude erosion as additional release mechanism because no 
considerable erosion was observed during in-vitro release experiments of SLIs.  
For all proteins, no initial burst was observed. For mAb, a sustained released over approximately 
98 days was observed delivering 9.8 % over this time (Figure IV-27). After this time, release 
stopped. For all other proteins, release rates were very slow delivering almost no protein (0.2 % 
to 3.1 % after 126 days). Due to the very low release rates and the beginning degradation of 
the PLGA matrix, the experiment was stopped after 126 days.  
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Figure IV-27: Cumulative release of () mAb, () Ranibizumab, () Bevacizumab and () Aflibercept from a 
Resomer® RG 755 S matrix. Please note, that for better visualisation the y-axis is scaled from -5 % to 20 %. 
 
The pH was monitored over the complete incubation time as erosion of the polymer would 
impact on the release kinetics. It was expected that a major decrease in pH value would indicate 
the erosion of the polymer because the PLGA is hydrolysed in its components lactic and glycolic 
acid creating an acidic pH. During this incubation of the PLGA extrudates, the incubation 
medium was not exchanged. 
As Figure IV-28 Illustrates, the pH of all solutions stayed rather constant at pH 7.4 over the first 
42 days and decreased slightly to approximately 6.5 after 98 days. A major drop in pH can be 
observed between day 98 and day 126 for all proteins down to pH 2.5 to 3.0 signifying the 
starting degradation of the PLGA matrix. After 98 days, the PLGA extrudates started to degrade 
but no release was seen (Figure IV-27). This leads to the assumption that the non-released 
protein (90 % to 100 % of incorporated protein) precipitated within the PLGA matrix.  
Because generally no protein was released from this particular Resomer®, another Resomer® 
with a degradation time frame of approximately 3 months was chosen.  
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Figure IV-28: Overview of pH measured within the incubation medium in which PLGA extrudates were 
incubated. Extrudates were loaded with () mAb, () Ranibizumab, () Bevacizumab and () Aflibercept 
lyophilisate. 
 
IV.2.7.2 RELEASE FROM RESOMER® RG 502 AND RG 502 H MATRICES 
In a next experiment, Resomer® RG 502 and Resomer® RG 502 H were used both with a ratio 
of 50:50 and a molecular weight of 7,000 to 17,000 Da. The estimated degradation time frame 
of those PLGAs is less than 3 months (Table III-2). Two different polymers were chosen to study 
the effect of different end groups on the release behaviour: Resomer® RG 502 comprises an 
esterified end group, Resomer® RG 502 H is equipped with a free carboxyl group.  
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Figure IV-29: Cumulative release of () mAb, () Ranibizumab, () Bevacizumab and () Aflibercept from 
(A) Resomer® RG 502 and (B) Resomer® RG 502 H matrices. Please note, that for better visualisation the y-
axis is scaled from -5 % to 20 %. 
 
Figure IV-29 provides an overview of sustained release of the proteins delivered from Resomer® 
RG 502 (Figure IV-29 A) and Resomer® RG 502 H (Figure IV-29 B). For Resomer® RG 502, a 
cumulative release of mAb and Ranibizumab can be observed. Both proteins were released 
without initial burst and release was almost linear over the complete incubation period of 
84 days. In total, 14.4 % mAb and 8.9 % Ranibizumab was released after 84 days meaning that 
85.6 % mAb and 91.1 % Ranibizumab remained within the polymer. A release of Bevacizumab 
and Aflibercept has not taken place. The release experiment was stopped after 84 days 
because the PLGA matrix totally disintegrated. This corresponds to the estimated degradation 
time frame of this polymer (< 3 months). 
A sustained release from Resomer® RG 502 H depot was only noticed for mAb. After 84 days, 
6.2 % mAb were released and 93.8 % remained within the PLGA matrix. The other proteins did 
not show any release (Figure IV-29 B).  
A possible explanation that in some cases a sustained release was not noticed could be due to 
precipitation of the encapsulated protein already within the depot. The degradation of the 
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polymer creates a pH drop and an increase in osmotic pressure which results in aggregation of 
the encapsulated proteins [49, 253, 254] and incomplete release [54, 68, 242, 255]. This 
phenomenon is even more pronounced when the end group is a carboxylic acid which would 
correspond with our results (Figure IV-29). To prove this hypothesis, the pH was measured over 
the complete incubation time.  
 
Figure IV-30: Overview of pH measured within the incubation medium in which PLGA extrudates were 
incubated. Extrudates were loaded with () mAb, () Ranibizumab, () Bevacizumab and () Aflibercept 
lyophilisate and PLGA matrix consisted of either (A) Resomer® RG 502 or (B) Resomer® RG 502 H. 
 
Measurements of pH confirm the hypothesis that pH dropped faster at the Resomer® RG 502 H 
based extrudates due to the free carboxylic group (Figure IV-30 B). It is important to note, that 
the incubation medium was not changed during pH measurements whereas the incubation 
medium has been exchanged when release was measured. Therefore, a direct correlation of 
release patterns (and their explanations) and the change of pH is not given.  
It was further analysed if incomplete release (and the associated protein aggregation) was 
caused by the acidic microclimate within the PLGA matrix or by the acidic pH of the surrounding 
medium (chapter VII). 
CHAPTER IV 
100 
IV.2.7.3 COMPARISON OF OUR RESULTS TO CURRENT STATUS OF RESEARCH 
The very incomplete release profiles observed during this study are corresponding to release 
profiles of proteins described in literature. For instance, the release of erythropoietin (EPO) from 
PLGA depots also showed incomplete release [45, 46, 242]. This is also true for different protein 
formats including BSA [255], insulin [49], recombinant human growth hormone (r-hGH) [47, 48] 
or insulin-like growth factor-I [50]. In most cases, the proteins encapsulated within PLGA depots 
showed poor release patterns namely incomplete release and/or substantial initial burst release. 
To overcome this problem, different strategies had been pursued, for instance PLGA 
composites such as PLGA-triacetin depots [72] or conjugates with amino cyclodextrine [66]. 
Also, the addition of excipients has been investigated like PEG-block-oligo(vinyl 
sulfadimethoxine) [69], PEG-poly(l-histidine) [43] or Mg(OH)2 [52]. In some cases, protein 
release was improved which was reflected by a reduced burst release and a more continuous 
and complete release.  
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IV.3 CONCLUSION 
The sustained long-term release of different protein formats from SLIs including therapeutically 
relevant proteins was successfully demonstrated. A controlled release over approximately 
4 months of a mAb and the fab-fragment Ranibizumab was achieved. Both protein drugs were 
delivered in a sustained fashion without any initial burst release events for about 110 to 
120 days. It is the first time that long-term release of two different molecules from SLIs have 
been reported. The formulation and extrusion settings previously developed within our group 
were further improved. The most appropriate formulation for the ZE-5 mini-extruder comprised 
10 % protein lyophilisate and a lipid matrix consisting of 50 % H12 and 50 % D118; no PEG 
was added. An adequate extrusion temperature was determined at 35°C. This allows the 
production of SLIs which provided a constant and almost complete release (up to 95 %) of 
incorporated protein without any burst effects.  
Several advantages in terms of the extrusion process were accomplished by an optimisation of 
the process: First, the avoidance of PEG as precipitant represents the most valuable 
improvement as it is known for its potential negative impact on protein integrity [262] and its 
allergic potential [263-265]. Also, the implant diameter was reduced by 25 % from 2.0 mm to 
1.5 mm without negatively impacting the release duration. Furthermore, a manufacturing setup 
using extremely mild processing conditions and a most elegant excipient composition was 
established. By introducing the ZE-5 mini-extruder as new extruder, the minimum batch size 
was reduced by 80 %. Moreover, the protein load was increased to 3.00 mg protein per implant 
without negatively affecting the desired release time frame. It was also ensured that extruded 
SLIs can be stored for at least 3 months without impacting their properties considering release 
patterns, thermal properties and status of crystallinity, respectively.  
Finally, it was possible to develop a depot releasing the fab-fragment Ranibizumab over 
110 days in-vitro from SLIs being small enough for intravitreal use (the excellent stability profile 
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of released Ranibizumab will be discussed in chapter VII). Based on these very good results, 
an in-vivo study in rabbit eyes was performed (chapter V). 
 
Beyond the principal scope of this chapter, the possibilities offered by triglycerides as depot 
were further investigated. Both triglycerides were pre-melted together prior to extrusion to 
change their properties and to study the effects on release patterns. By this, a prolongation of 
the release profiles of mAb and Ranibizumab was demonstrated. Release duration of mAb was 
prolonged by approximately 63 % up to 200 days and Ranibizumab release was extended to 
160 days being 40 % longer compared to conventional extrusion. Additionally, the release was 
further linearised by this approach. However, it was not yet possible to associate the improved 
release profiles to individual lipid characteristics (e.g. melting points, melting energy or status of 
crystallinity) and release was substantially different when SLIs were stored prior to release. To 
systematically investigate those aspects, more research is necessary. 
As a head to head comparison to lipid implants, PLGA implants having the same size and shape 
were manufactured using different Resomer® polymers. A sustained release of maximal 15 % 
and 10 % over 84 days was observed for the mAb and Ranibizumab, respectively, before the 
PLGA matrix completely degraded; no Bevacizumab or Aflibercept were released at all. As no 
burst release was seen when PLGA matrices degraded, incorporated protein most likely 
precipitated already within the depot.  
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V. IN-VIVO STUDY IN RABBIT EYES 
V.1 INTRODUCTION 
The intravitreal release of therapeutic peptides and proteins drugs is currently one of the most 
intensively investigated research areas. Table V-1 provides an overview of research which has 
been carried out in this field. Irrespective of the type of depot used within these studies, it is 
noteworthy that in most cases Bevacizumab was used. The depots already described in 
literature are highly diverse in terms of their size, method of production, and use of excipients. 
Reports can be found on implants [266], micro- and nanospheres [208, 209, 213], or hydrogels, 
which represent the most commonly used platforms including thermo-responsive hydrogels 
[206, 267], hydrogels prepared by Diels-Alder-reaction [112], or silk hydrogels [96]. In recent 
years, also more sophisticated depots have been investigated, for instance electrochemically 
prepared mesoporous silicon oxide [210], hexyl-substituted PLA [207], a capsule drug ring 
device [211, 212, 268], or stimuli-responsive nanomaterials [269, 270], just to name a few. If 
disclosed at all, Bevacizumab or a single-chain VEGF antibody fragment (most likely 
Ranibizumab) were used. 
Also, new in-vitro models mimicking the vitreous have been described. Loch et al. introduced a 
vitreous model to obtain data on permeability coefficients of ophthalmic drugs, simulating the 
vitreous body or simulating drug distribution once administered into the eye [271-273]. Patel et 
al. reported on an ex-vivo vitreous humor model to evaluate or even predict protein stability after 
intravitreal administration [274, 275].  
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Table V-1: Literature overview of controlled release systems for intravitreal peptide and protein release. 
LIPID BASED DELIVERY PLATFORMS 
Peptide or protein Analytical 
technique 
Delivery platform in-vitro 
release  
Reference comment 
Bevacizumab ELISA Nanoliposomes not available Abrishami et al. 
(2009) [213] 
• intravitreal injection of liposomes 
• encapsulated bevacizumab was well 
tolerated through 42 days in rabbits  
• clearance of this drug in vitreous from 
liposomal formulations was slower than 
soluble form. 
OTHER DELIVERY PLATFORMS 
Peptide or protein Analytical 
technique 
Delivery platform in-vitro 
release 
reference comment 
Bevacizumab ELISA Silk hydrogel up to 90 days Lovett et al. 
(2015) [96] 
• concentrations in vitreous humor after 
90 days equivalent to those levels for the 
positive control at 1 month 
 
single-chain VEGF 
antibody fragment 
SE-HPLC, SDS-
PAGE 
Semi-solid 
hexylsubstituted 
poly(lactic acid) (hexPLA) 
 
up to 98 days Asmus et al. 
(2015) [207] 
• structure was kept intact during 
incorporation and release 
connexin43 mimetic 
peptide 
retinal ischaemia–
reperfusion rat 
model 
 
PLGA nano- and 
microparticles 
up to 
120 days 
Chen et al. 
(2015) [208] 
• promising results for Cx43 down-regulation 
and RGC rescue in acute injury mode 
Bevacizumab MTT, 3-D 
angiogenesis 
culture 
Thermoresponsive 
hydrogel 
up to 60 days Hu et al. (2014) 
[267] 
• after 1 month of intravitreal injection, the 
histomorphology of rabbit’s retina was 
preserved 
• released bevacizumab inhibited anti-
angiogenesis in 3-D cultures 
 
Bevacizumab ELISA Nanostructured 
mesoporous silica (SiO2) 
films 
 
up to 30 days Andrew et al. 
(2011) [210] 
• antibody released in its active form over 
1 month; approx. 98 % of drug released 
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Peptide or protein Analytical 
technique 
Delivery platform in-vitro 
release 
reference Comment 
Bevacizumab induced choroidal 
neovascularization 
(CNV) in rat eyes 
PLGA nanoparticles not available Pan et al. (2011) 
[276] 
• reduction in CNV area suggests successful 
creation of formulations while retaining 
bevacizumab’s active antiangiogenic 
properties 
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V.2 IN-VIVO STUDY IN RABBIT EYES WITH PLACEBO LIPID IMPLANTS 
In 2012, a study using placebo SLIs was performed to assess the biocompatibility and 
biodegradability of SLIs inserted into rabbit eyes. SLIs were produced aseptically using a 
MiniLab® Micro Rheology Compounder (Thermo Haake GmbH Karlsruhe, Germany). The 
formulation consisted of 30 % H12 and 70 % D118, screw speed was set to 40 rpm and 
extrusion temperature was adjusted to 41°C. SLIs were inserted into rabbit eyes by a small 
incision, and biocompatibility and biodegradability were assessed over 84 days. 
 
Figure V-1: SLIs inserted into the vitreous of rabbit eyes. The pictures were taken at pre-determined time 
points starting from (A) day 14 and then after (B) 28 days, (C) 42 days, (D) 56 days, (E) 70 days and (F) 
84 days. 
 
The pictures displayed in Figure V-1 show SLIs inserted into the vitreous of rabbit eyes. The 
macroscopic appearance was monitored over 84 days. Within this observation period, no 
adverse effects, e.g. inflammation, irritation or swelling occurred. It was therefore concluded 
that SLIs show very good biocompatibility in rabbit eyes, thereby underlining their potential for 
use as an intravitreal depot. After the SLIs were removed from rabbit eyes after 7, 30 and 
90 days, the mass of explanted SLIs was assessed and compared to the original masses to 
monitor the implant degradation. After 90 days, SLIs were degraded by 25.6 % on average. The 
degradation profile was found to be linear (R2 = 0.9766), which resulted in a theoretical 
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degradation time frame of approximately 1 year. The data of this study have not yet been 
published. 
Based on the promising results obtained by the biocompatibility/biodegradability study, it was 
decided to perform a study with Ranibizumab loaded SLIs. Therefore, a formulation was 
developed (see chapter IV.2.3) which ensured the sustained release of Ranibizumab over 
approximately 110 days from SLIs being 1.5 mm in diameter, which is still a suitable diameter 
for intraocular use. Additionally, protein stability of released Ranibizumab was found to be 
excellent, making it to the most promising candidate (chapter VII.2.1) for this study.  
The in-vivo study in rabbit eyes was performed by the Moran Eye Center, Salt Lake City, Utah, 
USA. 
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V.3 CHOROIDAL NEOVASCULARISATION (CNV) MODEL  
Neovascularisation was induced as described in III.2.5.4. It was induced by an adeno-
associated virus (AAV) mediated expression of vascular endothelial growth factor (VEGF) [243, 
277]. AAV-VEGF was injected subretinally to induce neovascularisation in dutch-belted rabbit 
eyes. An increased expression of VEGF in the retina is sufficient to induce retinal 
neovascularisation [277].  
 
Figure V-2: Isolectin staining of flatmounts for choroidal neovascularisation lesions. Illustrated are the (A) 
choroid control, the (B) choroid lesions induced, (C) the control of retina, and the (D) increased retina vessel 
proliferation.  
 
A fluorescein solution with 100 mg/ml was injected (100 µl) into the vitreous, enabling an 
imaging for up to 30 min. Figure V-2 illustrates that neovascularisation was successfully induced 
as choroidal lesions (Figure V-2 B) and an increased proliferation of retina vessels were 
observed (Figure V-2 D) compared to the controls (Figure V-2 A and Figure V-2 C). Although it 
was intended to induce choroidal neovascularisation, evidence suggested only retinal 
neovascularisation was achieved. 
A 
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V.4 RESULTS AND DISCUSSION 
V.4.1 IN-VITRO RELEASE OF RANIBIZUMAB 
In-vitro release of Ranibizumab was evaluated additionally to in-vivo release. Thus, it was 
possible to perform an in-vitro-in-vivo correlation. Extrusion of aseptically SLIs was performed 
as described previously (III.2.5). The semicircle shaped SLIs had a final weight of 32.93 mg 
(±2.39 mg) and in average 1.65 mg (±0.12 mg) Ranibizumab were loaded onto an implant. 
 
Figure V-3: In-vitro release of Ranibizumab from the same batch which was manufactured for the in-vivo 
study.  
 
Results from Ranibizumab release study (Figure V-3) showed qualitatively comparable release 
behaviour as described before (chapter IV.2.3). During the first phase lasting for 4 weeks, 51 % 
of incorporated protein was released (30.1 µg/day), followed by a phase ranging from day 28 to 
day 112 in which approximately 36 % of incorporated protein equivalent to 7.1 µg protein per 
day was liberated. No burst release occurred, after 3 days of incubation only 4.8 % of 
Ranibizumab was released. 
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V.4.2 MACROSCOPIC OBSERVATIONS 
SLIs were inserted into the vitreous of dutch-belted rabbits by a small incision. The vitreous was 
examined after 15, 22, 30, 51, 63 and 87 days after implantation of the SLI. Both placebo SLIs 
and Ranibizumab loaded SLIs were inserted.  
Differences between placebo and Ranibizumab loaded SLIs were not observed, therefore the 
following descriptions do not distinguish between them.  
 
Figure V-4: Pictures of dutch-belted rabbit eyes where retinal neovascularisation was not induced (negative 
control). Ranibizumab loaded SLIs were inserted and the eyes examined after (A) day 6, (B) day 22, (C) day 
30, (D) day 51, (E) day 63 and (F) day 87.  
 
Within the observation period of 87 days, no adverse reactions or impairments like inflammation, 
encapsulation, swelling, or redness occurred. Also, the inserted SLIs stayed at the side of 
implantation (Figure V-4). Therefore, it can be concluded that the SLIs were well tolerable and 
biocompatible.  
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Figure V-5: Pictures of retinal neovascularisation induced dutch-belted rabbit eyes. SLIs were inserted and 
the eyes examined after (A) day 6, (B) day 22, (C) day 30, (D) day 51, (E) day 63 and (F) day 87. 
 
Figure V-5 illustrates that also in some cases small pieces of SLIs floating in the vitreous were 
observed right from the beginning. This means that those small parts of the implant broke apart 
most likely already during to the incision procedure.  
 
Figure V-6: Pictures of retinal neovascularisation induced dutch-belted rabbit eyes. SLIs were inserted and 
the eyes examined after (A) day 6, (B) day 22, (C) day 30, (D) day 51, (E) day 63 and (F) day 87. 
 
Also, a breakage of the complete implant was noticed. As shown in Figure V-6, during the first 
22 days of observation, no anomalies were observed, but at day 30 it was observed that the 
complete SLI broke apart into two pieces. This points into the direction that the breakage 
occurred during the incubation and was not caused by the incision as mentioned above. 
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In total, in 28.5 % of examined rabbit eyes a haze or debris of the cornea was observed after 
1 month. The percentage increased over time ending up at 66.7 % where a haze/debris was 
noticed after 3 months. The migration of the SLI into the anterior chamber was observed for 
25.0 % after 1 month and for 45.8 % after 2 months.  
Compared to the biocompatibility/biodegradability study from 2012, SLIs used here were 
mechanically less stable. Breakage and disintegration observed within the present study (Figure 
V-6) had not been observed in 2012 (Figure V-1). There are several reasons for this 
observation: dutch-belted rabbit eyes are smaller than those of New Zealand rabbits used in 
2012. Therefore, more force is required to place implants into the vitreous, possibly damaging 
the SLIs. Implants used here were smaller in diameter (1.5 mm) than the ones used previously 
(2.0 mm). Furthermore, a different formulation was used, comprising a higher percentage of 
H12 which could have possibly affected the mechanical stability of the SLIs. This aspect was 
further evaluated in detail and will be described below (V.4.5). As no difference was observed 
between placebo and Ranibizumab loaded implants in the current study, it is unlikely that the 
presence of Ranibizumab caused implant breakage. 
Further reasons leading to the break-up of implants could be external/environmental factors. As 
published by Lorget et al. [278] and Schwartz et al. [279], the temperature within rabbit eyes is 
not exactly 37°C as it was the case for in-vitro conditions. It is known that the temperature 
ranges from 35.8°C to 38.2°C in rabbit eyes, and that temperatures within the vitreous of rabbits 
are higher in comparison to mini pig or monkey eyes. Furthermore, «significant regional 
differences […] particularly between the lateral and the medial locations where the delta was 
approximately 2.5°C in the rabbit» are described [278]. The average temperature in the lower 
vitreous is 37.5°C, which is the region were the implants were located. Based on our previous 
studies, it is known that the percentage of H12 substantially impacts mechanical stability of SLIs; 
at a very high percentage even causing complete disintegration at 37°C (IV.2.3.4). To 
determine, if a higher external temperature than 37°C could cause a mechanical weakening of 
the implants (and therefore causing a break-up), a study was performed discussed in V.4.5.  
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V.4.3 PHARMACOKINETIC STUDY 
Released Ranibizumab was quantified according to III.2.5.5. In the following, the 
pharmacokinetic data from four different eyes are presented representing the pharmacokinetic 
profile of Ranibizumab within this study. Table V-2 provides an overview of Ranibizumab 
amounts in nanograms (ng) which was quantified within the different compartments of those 
eyes after the first months. 
Table V-2: Overview of Ranibizumab amounts measured within the different rabbit eye compartments 
1 month after implantation of SLIs. Amounts are given in ng. 
Compartment Eye 437 L Eye 437 R Eye 438 L Eye 438 R 
Cornea 53.13 35.59 72.90 4.85 
Vitreous 8.52 0.72 22.91 1.21 
Lens 137.29 106.07 483.63 41.68 
Iris 3.89 2.30 46.94 3.77 
Retina/choroid 1.21 3.77 5.35 2.67 
Aqueous humor 31.21 90.60 189.74 15.72 
Conjunctiva 0.60 0.48 1.21 0.84 
Sclera 3.28 1.94 48.40 3.77 
Total 239.15 241.46 871.10 74.51 
 
The overall quantified amount of Ranibizumab varied between 871 ng (eye 438 L) and 75 ng 
(eye 438 R). Nonetheless, the overall amount of quantified Ranibizumab was very similar to 
each other regarding the other two eyes (239 ng and 241 ng). Most Ranibizumab was found in 
the lens (192.2 ng ±198.3 ng), cornea (41.6 ng ±28.9 ng), and aqueous humor (81.8 ng 
±78.9 ng) in all examined eyes.  
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Table V-3: Overview of Ranibizumab amounts measured within the different rabbit eye compartments 
2 month after implantation of SLIs. Amounts are given in ng. 
Compartment Eye 433 L Eye 433 R Eye 434 L Eye 434 R 
Cornea 0.00 0.00 7.65 46.75 
Vitreous 0.00 0.00 0.00 0.06 
Lens 0.85 0.00 97.76 103.50 
Iris 282.35 347.06 260.21 262.21 
Retina/choroid 0.00 0.00 2.46 27.75 
Aqueous humor 0.20 0.77 83.47 222.79 
Conjunctiva 0.00 0.00 8.31 0.00 
Sclera 1.13 0.00 17.22 37.80 
Total 284.53 347.83 477.08 700.87 
 
The same results were observed for Ranibizumab quantified after 2 months (Table V-3): the 
overall amount of released Ranibizumab ranged from 285 ng (eye 433 L) to 701 ng (eye 434 
R). The highest levels of Ranibizumab were measured within the lens (50.5 ng ±57.9 ng) and 
aqueous humor 102.3 ng (±112.2 ng). This time, also notable amounts were found in the iris 
(288.0 ng ±40.7 ng). 
After 3 months, no noticeable amounts of Ranibizumab were quantified any more.  
Ranibizumab concentrations were further measured within the retina/choroid after 1 month and 
2 months as shown in Table V-4. The target concentration for total inhibition of proliferation was 
observed at Ranibizumab concentrations ≥ 1.3 nM which are 62 ng/g. The necessary 
Ranibizumab concentration to inhibit the biological activity of VEGF by 50 % (IC50) was 
measured with 11 ng/g to 27 ng/g (data provided by Moran Eye Center, Salt Lake City, Utah, 
USA).  
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Table V-4: Overview of Ranibizumab concentrations in retina/choroid in ng/g after 1 and 2 months for all 
eyes.  
 1 month [ng/g] 2 months [ng/g] 
Target concentration for 
total inhibition [ng/g] 
Eye 1 15.59 0.00 
62 
Eye 2 56.27 0.00 
Eye 3 50.66 27.81 
Eye 4 120.03 376.47 
 
The data presented in Table V-4 indicate, that after 1 month at all eyes the concentration 
reached the IC50 of VEGF. In the case of eye 4, the target concentration of 62 ng/g was 
exceeded as 120 ng/g Ranibizumab were measured. After 2 months, only for two eyes 
measurable concentrations were calculated with 28 ng/g and 376 ng/g Ranibizumab. As 
observed previously, concentrations were found to greatly vary from each other. 
The in-vivo release of Ranibizumab was monitored over 3 months. Measurable amounts were 
found at the 1-month time point at all compartments and partly after 2 months. After 3 months, 
no noticeable amounts of Ranibizumab were quantified any more. Within the retina/choroid, 
especially after 1 month, concentrations were measured being above the IC50 of VEGF, partly 
even exceeded the concentration of total proliferation inhibition. However, in-vivo release was 
largely complete after 4 weeks and thus faster than measured in-vitro. Therefore, an in-vitro-in-
vivo correlation could not be established. 
V.4.4 COMPARISON OF OUR RESULTS TO CURRENT STATUS OF RESEARCH 
Abrishami et al. [213] describes the encapsulation of Bevacizumab within phospholipid based 
liposomes using the well-known film method which was used previously to encapsulate versatile 
drugs into liposomes [231, 280-283]. The liposomes were further processed to reach the 
nanoscale. Liposomal encapsulated Bevacizumab was injected intravitreally into rat eyes and 
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concentration was determined over 42 days by ELISA. The authors stated, that the 
Bevacizumab concentration was measured up to five times higher in rat eyes which received 
liposomal encapsulated Bevacizumab compared to those where Bevacizumab was 
administered in an aqueous solution. This points into the direction that the encapsulated 
Bevacizumab was prevented from clearance better than the soluble drug showing the beneficial 
effects of liposomes as carrier. However, a disease model was not tested within this work. 
A silk hydrogel as potential depot for intravitreal delivery of Bevacizumab was described by 
Lovett et al. in 2015 [96]. The concentration of Bevacizumab released from silk hydrogels was 
measured over 90 days within the vitreous humor of dutch-belted rabbit eyes. Bevacizumab 
concentrations measured at day 90 were equivalent or greater than those analysed at day 30 
after administration of the positive (standard dose) control, which was a single injection of 
1.25 mg Bevacizumab. Again, a disease model was not considered.  
Nanostructured mesoporous silica films represent another option. Here, Bevacizumab was 
released in its active form over approximately 1 month, but was only measured in-vitro [210]. 
Hu et al. reports on the anti-angiogenetic effect of Bevacizumab released from thermo-
responsive hydrogels [267]. Those gels consisted of block copolymers of methoxy-PEG-block-
PLGA cross-linked with 2,2-bis (2-oxazoline) (BOX). This special polymer can reverse the sol-
gel-sol phase transition. The mPEG-PLGA-BOX gel was injected intravitreally into rabbit eyes 
and released Bevacizumab was collected after 1 month. The bioactivity of released 
Bevacizumab was tested by different assays including the human umbilical vein endothelial 
cells (HUVECs) assay, Macaca mulatta retina epithelial cells (RF/6A) assay and 3-D 
angiogenesis assay. It was found that anti-angiogenesis took place, therefore demonstrating 
the bioactivity of released Bevacizumab. 
The performance of Bevacizumab in a CNV rat model induced by laser photocoagulation has 
been reported by Pan et al. [276]. Within the study, different long-acting Bevacizumab 
formulations (PEG-bevacizumab conjugate and PLGA-encapsulated bevacizumab) were 
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compared to Bevacizumab as an aqueous solution. The authors reported on a reduction of CNV 
area for all long-acting Bevacizumab formulations compared to the aqueous Bevacizumab 
solution. The authors concluded that a reduction in CNV area suggests successful formulations 
while retaining bevacizumab’s active antiangiogenic properties. 
A study describing the in-vivo behaviour of Ranibizumab released from a depot in a disease 
model was not found in literature. 
Biocompatibility issues were not reported in the studies described above. Also, within our study, 
biocompatibility of lipid implants was excellent since no adverse reactions or inflammation was 
observed over 3 months. Within our study, a sustained release of Ranibizumab over at least 
28 days was measured. Partly, also after 42 days Ranibizumab was still released which 
corresponds to the deliver time frames described by Abrishami et al. [213] and Hu et al. [267]. 
Other references reported on longer release durations [96]. Since the breakage of SLIs occurred 
rather early within our in-vivo study, a further examination (e.g. histological examination) was 
not performed. By this, a comparison to published data is not possible.  
 
V.4.5 MECHANICAL STABILITY OF IMPLANTS 
During the in-vivo study, breakage of SLIs was observed, which did not occur during the 
biocompatibility study performed in 2012. A reason for this might be temperature gradients being 
present in rabbit eyes, which has been already reported [278, 279]. Those gradients are ranging 
from 35°C to 38°C and could therefore negatively impact mechanical properties of the implants, 
hence leading to breakage. Additionally, a higher percentage of the low melting lipid H12 was 
used within the study, which most likely influenced mechanical properties of the SLIs.  
To verify these hypotheses, a study was performed focusing on the mechanical properties of 
SLIs. In a first experiment, implants of the same formulation used within the in-vivo study were 
incubated at different temperatures (35°C, 37°C, 39°C) and bending strength was measured 
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after 7 days and 28 days, respectively. Second, the composition of the lipid matrix of SLIs was 
varied (30 % to 50 % H12) and bending strength of implants was determined after an incubation 
at 37°C for 7 days and 28 days. All formulations tested here comprised 10 % protein 
lyophilisate. Implants were placed in 1.0 ml PBS pH 7.4 and were incubated in a Certomat IS 
(Sartorius BBI, Göttingen, Germany) horizontal shaker at 40 rpm. After 7 days and 28 days, 
SLIs were removed, dried in a vacuum chamber for 24 h at 25°C at 10 mbar (Memmert GmbH 
& Co KG, Schwabach, Germany) and bending strength was determined. 
 
Figure V-7: Bending strength of lipid implants consisting of 10 % protein lyophilisate, 45 % H12 and 45 % 
D118 incubated at 35°C, 37°C and 39°C over 28 days. Bending strength was measured prior to release (day 
0) and after 7 days and 28 days of release, respectively. 
 
Figure V-7 displays the bending strength of SLIs incubated at 35°C, 37°C and 39°C. Irrespective 
of the incubation temperature, bending strength decreased upon incubation. Most importantly, 
mechanical stability was less the higher the incubation temperature was. After 28 days of 
incubation, bending strength was measured with 0.88 N (±0.06 N), 0.76 N (±0.03 N) and 0.66 N 
(±0.05 N) for the incubation temperatures 35°C, 37°C and 39°C, respectively. Thus, a 
correlation between mechanical stability and incubation temperature can be described. 
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Figure V-8: Bending strength of lipid implants consisting of 10 % protein lyophilisate and different lipid 
matrices comprising 30 % and 50 % H12 were incubated at 37°C over 28 days. Bending strength was 
measured prior to release (day 0) and after 7 days and 28 days of release, respectively. 
 
Second, SLIs were tested including both the exact lipid matrix used within the biocompatibility 
study from 2012 (30 % H12, 70 % D118) and the study described here (50 % H12, 50 % D118). 
The results of these experiments are displayed in Figure V-8. The formulation with 30 % H12 
was mechanically more resistant than SLIs containing 50 % H12. As more mechanically stable 
SLIs were used for the biocompatibility study than used within the present study, the breakage 
which occurred within this study can be explained. Both aspects (temperature and implant 
composition) could be a possible explanation of SLI breakage occurring during the in-vivo study 
and the faster release in-vivo compared to in-vitro release.  
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V.5 CONCLUSION 
Ranibizumab loaded SLIs were inserted into dutch-belted rabbit eyes and the in-vivo release 
was monitored over 3 months additionally to macroscopic observations.  
In 2012, excellent biocompatibility of placebo lipid implants inserted into the vitreous of New 
Zealand rabbits was reported. Over 90 days, no inflammation, encapsulation or other adverse 
reactions and complications were observed, thereby highlighting the great potential of lipid 
implants for intravitreal applications. 
Within our study, biocompatibility of lipid implants inserted into dutch-belted rabbit eyes was 
excellent, since no adverse reactions or inflammation was observed over the complete 
observation time of 3 months. After 2 months, in 45.8 % a break-up of implants occurred and in 
2/3 of rabbit eyes a haze/debris was noticed after 3 months. Associated with the partial break-
up of implants, in-vivo release was found to be faster than in-vitro going in line with high standard 
deviations. In-vivo release was tested over 3 months, but no more Ranibizumab was released 
after 8 weeks. 
It was hypothesised that the formulation used here was mechanically more sensitive compared 
to the one used in 2012 for two reasons. First, the formulation used here, comprised a relatively 
high percentage of H12. Second, the temperature within dutch-belted rabbit eyes might be 
higher than 37°C possibly impacting mechanical properties of SLIs. We could confirm that both 
the relatively high percentage of H12 and slightly higher incubation temperatures (modelling 
elevated temperatures within the rabbit eye) than 37°C do negatively impact mechanical stability 
of SLIs. It is therefore likely that this was the reason for implant break-up and faster in-vivo 
release. Furthermore, another possible reason could be that due to the CNV induction the 
temperature within the rabbit eyes changed and hence influenced the mechanical stability of 
the implants additionally. 
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VI. BIOLOGICAL ACTIVITY OF RELEASED MINI-FH 
FROM LIPID IMPLANTS 
VI.1 INTRODUCTION 
This chapter describes the sustained release of the protein mini-Factor H (mini-FH) from SLIs 
and the determination of its biological activity following the release from the depot. Mini-FH is a 
protein having a molecular weight of 43.3 kDa and is a C3-opsonin targeted complement 
inhibitor for potential use against paroxysmal nocturnal hemoglobinuria (PNH) [240, 241]. PNH 
is characterised by haemolytic anaemia caused by the expansion of hematopoietic progenitor 
cells. In turn, PNH results in anaemia, hemoglobinuria, fatigue, and other hemolysis-related 
disabling symptoms [284-287]. Currently, Eculizumab is the only therapy available for patients 
suffering from PNH [288, 289]. Schmidt et al. recently described a novel therapeutic approach, 
which involves C3-opsonin targeted complement inhibitors, which are engineered from parts of 
the natural complement regulator Factor H (FH) or the complement receptor 2 (CR2) [240, 241]. 
The FH inhibitor class includes three variants of the so-called mini-FH which was used within 
this experiment. Schmidt et al. observed that mini-FH was more efficient in preventing 
complement activation on PNH erythrocytes which represents a promising therapeutic 
alternative [241]. 
PNH is a disease of the so-called alternative pathway (AP) [290-292] as it is also the case for 
wet AMD [293]. That is the reason why AP inhibitors (like mini-FH) are first tested in the «model 
disease» PNH before they are subsequently tested in other AP-mediated disease models as it 
is the case here. Currently, mini-FH is also being tested in canine and monkey eyes (not 
published). Meanwhile, other AP inhibitors than mini-FH have already been tested in AMD 
animal models. It is described that «Targeted complement inhibitors such as TT30 and its 
homologs have not only shown promising potential in PNH, but also in a variety of other AP-
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mediated clinical conditions ranging from collagen induced arthritis and ischemia/reperfusion 
injury to AMD» [294, 295]. Further, Schmidt et al. stated that «in the case of AMD, mini-FH may 
have particular advantages» [240]. In the case of chronic and progressive eye diseases (as it is 
the case for AMD), the loss of vision and neovascularisation of the retinal tissue is strongly 
associated with the complement regulation by Factor H. Factor H was identified as a major 
binding protein for lipid peroxidation, which is a marker of oxidative stress accumulating under 
various diseases conditions including AMD as described by Weismann et al. [296, 297]. 
The aim of this chapter is to evaluate the potential of mini-FH loaded SLIs as depot for the 
treatment of AP-mediated diseases like wet AMD. The preparation of mini-FH loaded SLIs and 
their in-vitro release behaviour is described in the following. Additionally, the biological activity 
of released mini-FH was measured by a rabbit erythrocyte hemolysis assay. The assay was 
performed by the group of Dr. Christoph Schmidt at the Institute of Pharmacology and Natural 
Products and Clinical Pharmacology, University of Ulm, Germany.  
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VI.2 RESULTS AND DISCUSSION 
VI.2.1 IN-VITRO RELEASE OF MINI-FH 
Lipid implants were produced using a ZE-5 mini extruder. The lipid matrix consisted of 50 % 
H12 and 50 % D118, mini-FH load was adjusted to 5 %, resulting in a final protein load of 
1.45 mg (± 0.03 mg) per implant. Mini-FH was available as freeze-dried powder without any 
further excipients. Extrusion temperature was set to 35°C and screw speed was adjusted to 
40 rpm. 
 
Figure VI-1: Cumulative release of mini-FH from SLIs being 1.5 mm x 15 mm in size. Protein load was set to 
1.45 mg (± 0.03 mg) per implant. 
 
According to the in-vitro incubation protocol described in chapter III.2.3, extrudates were placed 
into 2.0 ml micro centrifugation tubes, 1.0 ml PBS pH 7.4 was added and release was monitored 
at 37°C and 40 rpm using a Certomat IS (Sartorius BBI, Göttingen, Germany) horizontal shaker. 
Released mini-FH was measured spectrophotometrically at 280 nm applying an UV-VIS 
spectrometer (Agilent 8453, Böblingen, Germany). Linearity of measurements was established 
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for a concentration range of 0.001 mg/ml to 0.5 mg/ml (R2 = 0.9997). The samples were stored 
at -80°C directly after protein concentration was measured. 
Cumulative mini-FH release was monitored over 98 days. In total, 43.7 % of total incorporated 
mini-FH was released. The release curve did not show an initial burst, and the first phase was 
followed by a phase lasting until day 14 (25.4 µg mini-FH per day were delivered during this 
phase). Starting from day 14, release rate was slower (approximately 3.3 µg/day) lasting until 
day 98. After 98 days of release, the experiment was stopped because only minimal amounts 
of mini-FH were released. Those amounts would not be sufficient for biological activity 
determination. In contrast to the other proteins tested within this thesis (Figure IV-11), mini-FH 
was not completely released. In total, approximately 45 % of incorporated mini-FH were 
released. The non-recovered fraction of 55 % was probably still incorporated within the lipid 
matrix as this was already described for other proteins using triglyceride based SLIs [185]. As 
this phenomenon is more pronounced for hydrophobic proteins [185], it can be assumed that 
mini-FH is a rather hydrophobic protein. However, this was not evaluated within the present 
study and should be addressed in the future. 
 
VI.2.2 BIOLOGICAL ACTIVITY OF RELEASED MINI-FH 
Released mini-FH was collected at predetermined time points and frozen at -80°C prior to 
biological activity measurements. The biological activity of released mini-FH was determined as 
previously described [241]. In brief, 10 µl human serum containing Mg-EDTA was mixed with 
20 µl sample in PBS pH 7.4 and 10 µl of a rabbit erythrocyte suspension in PBS/Mg-EDTA. The 
final serum concentration was 25 %. The mixture was incubated for 30 min at 37°C and reaction 
was stopped with 120 µl PBS/EDTA (5 mM) on an ice bath. Hemolysis was determined via 
optical density measurement of 100 µl of the supernatant at 405 nm using a spectrophotometer. 
Rabbit erythrocytes lyse in presence of active human serum due to the complement activation 
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and formation of membrane attack complexes on rabbit erythrocytes. Mini-FH inhibits the 
human complement system and therefore protects rabbit erythrocytes.  
 
Figure VI-2: Hemolysis in dependence of mini-FH concentration. Positive and negative control in this 
experiment are displayed as open circles or filled triangles.  
 
Figure VI-2 displays the mini-FH reference curve at a concentration range of 12.5 nM to 
1600 nM and the controls (negative and positive). The reference of 100 % is defined by reagent 
red blood cells (rRBCs) in MQ water, having the same volume and ratio as the samples. The 
positive control (total hemolysis) consisted of rRBCs diluted with human serum without the 
addition of any inhibitors, e.g. mini-FH. The value of total hemolysis is slightly above 100 % (5 % 
to 9 %) which is within the error limit of the assay. The negative control was a dilution of the 
serum where 5 mM EDTA were added. In the absence of Mg2+ ions (present in EDTA), the AP 
of the cascade does not function, although all complement proteins are present. 
Mini-FH data points were analysed in duplicates, whereas the positive and negative control 
were analysed in quadruplicates.  
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Figure VI-3: Hemolysis of mini-FH released from SLIs determined over 98 days. 
 
The hemolysis percentage in dependence of mini-FH released from SLIs is illustrated in Figure 
VI-3. It can be observed that hemolysis was measured between 2.6 % and 3.1 % within the first 
14 days of release meaning a complete inhibition of hemolysis occurred pointing into the 
direction of a strong biological activity of released mini-FH. Mini-FH released on day 21 still 
revealed clear biological activity (14.3 % inhibition of hemolysis). Samples taken between day 
28 and day 98 showed a hemolysis of 92.3 % and 81.2 %. This leads to the conclusion that 
released mini-FH lost its biological activity upon release compared to the fractions released 
within the first 21 days. Nevertheless, still after 98 days of in-vitro release, mini-FH comprised 
biological activity. 
The biological activity of proteins released from lipid based systems has been described in 
literature before. For instance, Koennings et al. described the biological activity of the brain-
derived neurotrophic factor (BDNF), released in-vitro from compressed implants over 1 month. 
The biological activity of BDNF was measured with up to 60 % intact protein assessed by ELISA 
[175]. Also, the activity of released interleukin-18 (IL-18) from compressed lipid implants was 
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observed over 12 days, showing a progressive integrity loss down to 20 % to 40 % [174]. Even 
et al. demonstrated that the in-vivo release of the peptide TRP-2 delayed tumor growth for 
3 days compared placebo groups, indicating that TRP-2 was biologically active [187]. 
Despite SLIs, solid lipid nanoparticles (SLNs) as delivery platform have been used as well. 
Human thymidylatesynthase inhibitor peptide, an octapeptide, was encapsulated within SLNs 
and apoptosis was measured using a cell culture model over 4 h once the SLNs were spiked to 
the cell media. The increase of apoptosis percentage observed indicated that SLNs could carry 
the peptide efficiently to its enzymatic target in its biologically active form [140]. In 2009, 
Abrishami et al. reported on the encapsulation of Bevacizumab within nanoliposomes [213]. 
Nanoliposomes were administrated intravitreally into rabbit eyes and Bevacizumab 
concentration was assessed by ELISA over 42 days, showing that the clearance of 
Bevacizumab from nanoliposomes was slower than from the soluble form and that Bevacizumab 
was still active. 
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VI.3 CONCLUSION 
The protein mini-FH was encapsulated within SLIs and release was monitored over 98 days in 
a sustained fashion. Release started to level off after 70 days of incubation. However, even after 
98 days, small amounts of mini-FH were still released from SLIs. The biological activity of 
released mini-FH was determined, showing a clear biological activity over the first 21 days. 
Furthermore, mini-FH released between day 56 and day 98 still exhibited biological activity. 
In literature, lipid based systems have already been described for the sustained release of 
biologically active peptides and proteins [140, 187, 213]. To the best of our knowledge, none of 
those reports assessed the biological activity over a period of more than 42 days. Here, mini-
FH biological activity was measured over a time frame of 98 days which is unique. These 
findings underline the great potential of lipid based implants, as they can ensure long-term 
release of proteins but at the same time preserve biological activity of encapsulated protein.  
The present study demonstrated the feasibility of SLIs for long-term release of the complement 
factor mini-FH over several weeks. Based on these promising results, future work should 
progress with evaluating the source of incomplete mini-FH release, in-vitro release optimisation 
(further tailoring of release, more complete release) and consequently the in-vivo performance 
of the system, e.g. in rabbit eyes. 
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VII. STABILITY OF RELEASED PROTEIN 
FRACTIONS FROM LIPID AND PLGA MATRICES  
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VII.1 INTRODUCTION 
Developing protein delivery systems ensuring the stability of the protein drug remains a 
challenge [215]. Extensively investigated delivery systems for protein delivery are PLGA based 
systems [45, 71, 242], PLGA composites [68, 298] or other polymers like chitosan [79] including 
different delivery platforms such as hydrogels [111], nanogels [88, 114] or silk [96]. Protein drugs 
investigated for controlled release include model proteins, for instance bovine serum albumin 
(BSA) [114], lysozyme [175] or pharmaceutical proteins, e.g. erythropoietin (EPO) [45, 242], 
insulin [68, 79, 298], goserelin (Zoladex®) or monoclonal antibodies like bevacizumab [96].  
Table VII-1 and Table VII-2 display a review of controlled release systems for peptides and 
proteins delivered from lipidic and non-lipidic depots which address protein stability (Table VII-1) 
and bioactivity aspects (Table VII-2) of encapsulated and/or released protein. The references 
provided in the tables illustrate that significant research has been performed in this field within 
the last years, while the focus was mainly on PLGA based depots or hydrogels. Beyond 
«classical» analytical techniques to characterise proteins, e.g. SE-HPLC, SDS-PAGE or CD, 
also the bioactivity of released proteins (Table VII-2) have been investigated. Nonetheless, little 
research has been performed with respect to lipidic depots.  
In the past, only a few studies have reported on protein stability after encapsulation into the 
matrix [68, 242], but stability of the released protein has often not been taken into account. But, 
protein stability and activity should be addressed more intensively in future, as a drug delivery 
system is useless when the delivered protein comprises no acceptable stability and biological 
activity, respectively.  
More recently, several papers have been published also addressing protein stability and activity 
aspects of released protein for insulin [49] exenatide [217] or a fab-fragment [72] delivered from 
PLA/PLGA microspheres [49, 217] or PLGA-triacetin depots [72]. A major focus was on 
chemical degradation of insulin and exenatide during release from PLA/PLGA microspheres. 
The authors demonstrated deamidation of insulin [49] and acylation for exenatide [217] in the 
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time frame of 18 to 20 days upon release. Contrarily, stability of a fab-fragment released over 
approximately 80 days from a PLGA-triacetin based depot was described to be promising even 
though relative antigen binding capacity dropped to 80 % and peak area measured by IEX was 
found to be halved after 12 weeks of release [72].  
Moreover, reports can be found on biological activity [63, 77, 84] and binding capacity [72] of 
released proteins of different size and structure, e.g. NEL-like molecule-1 (NELL-1), bone 
morphogenetic protein-2 (BMP-2), platelet-derived growth factor (PDGF-AA) or a fab-fragment 
from modified chitosan particles [77] or hydrogels [63, 84]. Irrespectively of the different delivery 
depots and proteins studied, biological activity and antigen binding capacity was found to be 
retained even after several weeks of release.  
For lipid based (mainly triglycerides) depots, which have been investigated since the early 
2000s, research has been focused on release profiles and underlying release mechanisms 
[155, 157, 158, 182, 299], the solid-state behaviour for the lipids [161, 163], effect of release 
modifiers [149, 160, 177, 178] or in-vivo-in-vitro correlations [168] of various drugs including 
small molecular drugs [163, 236, 299], model proteins [182] and pharmaceutical proteins [178]. 
However, protein stability aspects have not been investigated in depths until now. Analysis of 
encapsulated and released protein from lipidic systems has been described for the first time in 
2004 [167]. The integrity of rh-interferon α-2a after incorporation into SLIs and after 28 days of 
in-vitro release was assessed by SDS-PAGE, showing no noticeable aggregation or 
fragmentation of the protein [167, 176]. The released fractions where further analysed by SE-
HPLC for up to 60 days, confirming that the protein was mainly released in its monomeric form. 
(> 95 %) [167]. These promising results were underlined by a study by Sax et al. demonstrating 
that also a monoclonal antibody can be delivered over 150 days with a consistent monomer 
content [234]. Conversely, SDS-PAGE analysis of extracted brain-derived neurotropic factor 
(BDNF) from a glyceryl tripalmitate matrix revealed the formation of dimers upon incubation for 
1 month [175]. On biological activity of extracted protein or liberated protein fractions was not 
reported.  
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In this chapter, the stability of released protein fractions is described. Three aspects were 
considered: First, released proteins were analysed over a period of 26 weeks (mAb), 18 weeks 
(Ranibizumab), 14 weeks (Aflibercept) and 3 weeks (Bevacizumab), respectively. Fractions 
were collected from in-vitro release experiments from SLIs (chapter IV). Second, fractions 
liberated from PLGA matrices (Resomer® RG 502 and RG 502 H) were collected and analysed 
over 14 weeks. In a third approach, protein released over the first week after a 1 or 3-month 
storage of SLIs at 4°C was performed. Analysing these three aspects assist to obtain 
information on protein stability during long-term release from triglyceride and PLGA matrices 
and on stability while the proteins are incorporated into a highly hydrophobic triglyceride matrix. 
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Table VII-1: Literature overview on controlled release systems for peptides and proteins from lipidic and non-lipidic depots including protein stability evaluations of 
encapsulated and/or released protein. The references provided in table are sorted by year of publication starting from 2015 to 1998. 
LIPID BASED DEPOTS 
Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Ovalbumin SE-HPLC Tsc-extruded 
implants (Chol, 
lecithin, D114) 
 
up to 14 days Even et al. 
(2015) 
[233] 
• 40 % monomer loss after 14 days of release due to 
aggregation 
Interferon-α SDS-PAGE, 
FT-IR 
Tsc-extruded 
implants (H12, D118) 
up to 60 days Schulze et 
al. (2009) 
[181] 
 
• preservation of the protein integrity after manufacturing 
Brain-derived 
neurotrophic factor 
(BDNF), Lysozyme 
SDS-PAGE Compressed implants up to 80 days Koennings 
et al. 
(2007) 
[175] 
• Lysozyme: tendency towards aggregation during 
preparation 
• BDNF: no change directly after preparation, after 1 
month dimers detected 
 
rh-interferon α-2a SE-HPLC, RP-
HPLC 
Compressed tristearin 
implants 
up to 30 days Mohl et al. 
(2006) 
[176] 
• formation of 15 % to 20 % aggregates and up to 16 % 
oxidised protein after 3 weeks of release after implant 
storage 
 
rh-interferon α-2a SDS-PAGE Compressed tristearin 
implants 
up to 30 days Mohl et al. 
(2004) 
[167] 
• slight aggregation during in-vitro release 
NON-LIPIDIC DEPOTS 
Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Single-chain VEGF 
antibody fragment 
SE-HPLC, 
SDS-PAGE 
Semi-solid 
hexylsubstituted 
poly(lactic acid) 
(hexPLA) 
 
up to 98 days Asmus et 
al. (2015) 
[207] 
• antibody structure was kept intact during incorporation 
and release 
fab-fragment IEX, SE-HPLC PLGA-triacetin depot up to 80 days Chang et 
al. (2015) 
[72] 
• 5 % monomer loss and 55 % loss in main peak area 
(IEX)  
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Exenatide RP-HPLC, 
HPLC-MS/MS 
PLGA microspheres 20 days Liang et al. 
(2013) 
[217] 
• rapid acylation of exenatide dependent on water 
content 
Exenatide HPLC-MS/MS, 
optical rotation, 
UV 
 
PLGA solution 
mimicking depot 
incubation 
time: 5 days 
Liang et al. 
(2013) 
[300] 
• formation of non-native conformational changes 
• acylation as main degradation route 
IgG1 mAb SE-HPLC, 
SDS-PAGE, 
IEF-PAGE, CD, 
peptide 
mapping  
 
Silk hydrogels and 
lyogels 
up to 80 days Guziewicz 
et al. 
(2013) [98] 
• slight fragmentation (SE-HPLC), not seen in SDS-
PAGE  
• secondary and tertiary structure unchanged 
• elevated levels of oxidized mAb 
Insulin CD, DSC, SDS-
PAGE, RP-
HPLC, MALDI-
TOF-MS, FT-IR 
Chitosan-Zn-Insulin-
Complex incorporated 
into PLA-PEG-PLA 
copolymer 
up to 84 days Oak et al. 
(2011) [81] 
• formation of non-covalent aggregates upon release 
• FT-IR: significant depletion of α-helix and increase of 
random coils after 60 days of release  
• CD: changes in tertiary structure 
• DSC: dissociation of chitosan-Zn-insulin complex 
• RP-HPLC: complete degradation after 30 days 
• MALDI-TOF-MS: hydrolysis, deamidation; complete 
degradation after 30 days 
 
Octreotide, modified 
with maleic anhydride 
(MA) 
RP-HPLC, LC-
MS 
PLGA microspheres 42 – 56 days Ahn et al. 
(2011) 
[301]  
• 100 % acylation after 56 days of octreotide release 
• MA-octreotide: less acylation but faster release 
(42 days) 
 
Recombinant human 
growth hormone (r-
hGH) 
SDS-PAGE PLGA microparticles up to 28 days Rafi et al. 
(2010) [48] 
• no aggregation or fragmentation over 1 month 
insulin SDS-PAGE pH- and 
thermosensitive 
hydrogel 
 
up to 3 days Shi et al. 
(2010) [82] 
• neither aggregation nor fragmentation of insulin upon 
72 h of release 
Growth hormone-
releasing peptide-6 
(GHRP-6) 
 
RP-HPLC, 
MALDI-TOF-MS 
PLGA microspheres up to 30 days Park et al. 
(2010) 
[229] 
• acylation of GHRP-6 
• after 30 days of release 21 % to 78 % intact peptide 
Lysozyme DSC PLA in situ forming 
depot (triacetin) 
up to 60 days Al-Tahami 
et al. 
(2008) [54] 
• better conformational stability than control (protein in 
buffer) after 2 weeks of release 
• increased polymer concentration stabilise protein 
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Lysozyme, trypsin 
inhibitor 
SE-HPLC Recombinant gelatin 
hydrogel (HU4) 
up to 5 days Sutter et 
al. (2007) 
[302] 
 
• formation of mainly aggregates upon release; slight 
increase in fragment percentage 
BSA, ribonuclease A, 
avidin 
CD Sol-gel derived silica 
gels 
up to 3.5 days Teoli et al. 
(2006) 
[303] 
• no modification of the tertiary structure after entrapment 
Tetanus toxoid (TT), 
Ova, lysozyme 
SDS-PAGE, 
CD, FL 
Monomers of PLGA 
mimicking 
degradation 
incubation 
time: 20 days  
Determan 
et al. 
(2006) 
[304] 
• TT:  aggregation, formation of β-sheets, partial 
unfolding 
• Ovalbumin: no formation of aggregates, increase of α-
helix content and tertiary structure 
• Lysozyme: no aggregate formation, increase of α-helix 
content, tertiary structure unchanged  
 
BSA SDS-PAGE, 
SE-HPLC, FT-
IR 
Release model for 
PLGA depots: acidic 
pH of 2 
 
incubation 
time: 20 days 
Estey et al. 
(2006) 
[253] 
• Rapid aggregation and hydrolysis, secondary and 
tertiary changes 
Insulin RP-HPLC Chitosan 
microspheres 
up to 80 days Wang et al. 
(2006) [79] 
• In dependency of loading method, partially significant 
loss of insulin main peak 
 
BSA SDS-PAGE, CD PLG-amino 
cyclodextrine 
conjugates 
 
up to 28 days Gao et al. 
(2006) [66] 
• No aggregation of released BSA 
• Secondary structure unchanged over 21 days 
Insulin RP-HPLC, LC-
MS 
PLA and PLGA 
microspheres 
6 h Ibrahim et 
al. (2005) 
[49] 
• Insulin mainly destabilized by deamidation rather than 
acylation  
• Observation time: 18 days 
 
BSA CD, FL,  PEG-poly(L-histidine) 
copolymer in PLGA 
microspheres 
 
up to 60 days Kim et al. 
(2005) [43] 
• Rapid unfolding in secondary and tertiary structure 
Diphteria toxoid (Dtxd) SE-HPLC Incubation with PLGA 
microspheres 
incubation 
time: 56 days 
Namur et 
al. (2004) 
[305] 
 
• Monomer loss mainly caused by fragmentation 
Recombinant human 
growth hormone (rHGH) 
FT-IR PLGA microspheres up to 42 days Capan et 
al. (2003) 
[47] 
• Decrease in α-helix content and increase in β-sheet  
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Atrial natriuretic 
peptide (ANP) 
RP-HPLC, 
HPLC-MS 
PLA and PLGA 
solutions mimicking 
PLGA matrix 
 
incubation 
time: 60 days 
Lucke et 
al. (2003) 
[61] 
• Rapid acylation of ANP 
BSA Insoluble and 
soluble residue 
analysis 
 
PLGA implants up to 28 days Kang et al. 
(2002) [52] 
• BSA mostly released as insoluble form 
Insulin-like growth 
factor-I (IGF-I) 
RP-HPLC PLGA microspheres up to 21 days Meinel et 
al. (2001) 
[50] 
 
• Protective effect of various excipients after entrapment 
of IGF-I 
Lysozyme, α-
lactalbumin, BSA, 
VEGF 
SE-HPLC, 
Heparin-affinity 
chromatography 
(HAC) 
 
Semisolid, self-
catalyzed poly(ortho 
ester)s (POEs) 
up to 15 days van de 
Weert et 
al. (2001) 
[306] 
• BSA: increase of soluble aggregates up to 35 % over 
release time frame; occurred also for the other proteins 
(data were not shown) 
 
Human erythropoietin 
(rhEPO) 
SDS-PAGE PLGA microspheres 1 to 2 days Bittner et 
al. (1998) 
[45] 
 
• Substantial aggregate formation after encapsulation 
Erythropoietin SDS-PAGE LPLG-PEO-LPLG 
triblock copolymer 
microspheres 
up to 15 days Morlock et 
al. (1998) 
[44] 
• Rapid and significant reduction in monomer content (up 
to 100 % aggregate formation) 
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Table VII-2: Literature overview on controlled release systems for peptides and proteins from lipidic and non-lipidic depots including protein bioactivity aspects of 
encapsulated and/or released protein. The references provided in the table are sorted by the year of publication starting from 2015 to 2000. 
LIPID BASED DEPOTS 
Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Human 
thymidylatesynthase 
inhibitor peptide 
(octapeptide) 
 
MTT SLNs up to 4 h Sacchetti et al. 
(2015) [140] 
• increase of apoptosis percentage observed 
indicating that SLNs were able to carry the 
peptide efficiently to its enzymatic target 
Apolipoprotein E MTT and LDH 
assays in human 
cerebral 
microvascular 
endothelial cells 
 
SLNs functionalized with 
apolipoprotein E 
not avaiable Neves et al. 
(2015) [252] 
• no toxicity and a 1.5-fold increment in the 
blood-brain-barrier permeability 
Protamine, anionic 
polysaccarides 
Cell viability (CCK-
8 assay) 
SLNs not avaiable Apaolaza et al. 
(2015) [148] 
• partial recovery of retina  
• successful RS1 gene transfer to Rs1h-
deficient animals using non-viral 
nanocarriers demonstrated 
 
Ovalbumin CD4+ and CD8+ T 
cell proliferation, 
IgG titer, IFN-γ and 
IL4 secretion 
 
Tsc-extruded implants 
platform (Chol, lecithin, 
D114) 
up to 7 days Even et al. 
(2014) [186] 
• generation of cellular and humoral immune 
responses 
siRNA, antisense 
oligonucleotides 
Transfection Assay ketal nucleoside lipid 
(KNL) nanoparticles 
not available Luvino et al. 
(2013) [147] 
• siRNA exhibits protein knockdown 
• suitable transfecting reagent for novel 
therapeutic approaches against prostate 
cancer 
 
Bevacizumab ELISA Nanoliposomes not available Abrishami et al. 
(2009) [213] 
• intravitreal injection of liposomes 
• encapsulated bevacizumab was well 
tolerated through 42 days in rabbits  
• clearance of this drug in vitreous from 
liposomal formulations was slower than 
soluble form 
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Brain-derived 
neurotrophic factor 
(BDNF), Lysozyme 
ELISA Compressed implants up to 80 days Koennings et al. 
(2007) [175] 
• Lysozyme: in the first 30 days, 60 % to 
75 % were found in its enzymatically active 
form 
• BDNF: 20 % or 60 % intact protein over 
1 month  
 
Insulin ELISA Triglyceride based 
compressed implants 
up to 14 days Appel et al. 
(2006) [169] 
• Preserved bioactivity of incorporated and 
released protein 
• strong dose-dependent effects on tissue 
engineered cartilage 
 
Interleukin-18 (IL-18) ELISA Compressed implants up to 12 days Koennings et al. 
(2006) [174] 
• progressive integrity loss (down to 20 % to 
40 %) observed with ongoing release 
NON-LIPIDIC DEPOTS 
Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Nel-like molecule-1 
(Nell-1) 
Alkaline 
phosphatase 
activity (ALP) 
Chitosan/hydroxyapatite-
modified tricalcium 
phosphate (TCP) particles 
up to 28 days Zhang et al. 
(2016) [77] 
• About 78 % of the loaded protein’s 
bioactivity was preserved over the period of 
investigation 
 
Coumarin-6, 
fluocinolone 
acetonide (FA), BSA, 
BMP-2 
Alkaline 
phosphatase 
activity (ALP), 
calcium deposition, 
gene expression 
 
Chitosan-graft-poly(lactic 
acid) copolymers 
up to 14 days Niu et al. (2016) 
[70] 
• Enhanced odontogenesis and significantly 
enhanced mineralized tissue regeneration  
• suppressed inflammation  
Connexin43 mimetic 
peptide 
retinal ischaemia–
reperfusion rat 
model 
 
PLGA nano- and 
microparticles 
up to 
120 days 
Chen et al. 
(2015) [208] 
• promising results on Cx43 down-regulation 
and RGC rescue in acute injury mode 
Single-chain VEGF 
antibody fragment 
Surface plasmon 
resonance analysis 
Semi-solid 
hexylsubstituted 
poly(lactic acid) (hexPLA) 
 
up to 98 days Asmus et al. 
(2015) [207] 
• released protein monomer maintained its 
high affinity to human VEGF-A 
Bevacizumab ELISA Silk hydrogel up to 90 days Lovett et al. 
(2015) [96] 
• concentrations in vitreous humor after 
90 days equivalent to those levels for the 
positive control at 1 month 
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Bone morphogenetic 
protein 2 (BMP-2) 
Alkaline 
phosphatase 
activity (ALP) 
 
Hydrogel embedded with 
alginate microspheres 
up to 42 days Zhu et al. (2015) 
[84] 
• released BMP-2 retained bioactivity, 
maintaining of osteogenesis functions 
Platelet-derived 
growth factor (PDGF-
AA) 
ELISA Hydrogel/nanoparticle 
composite 
up to 21 days Elliott Donaghue 
et al. (2015) [63] 
• Released PDGF-AA remained bioactive 
demonstrated by NSPC oligodendrocyte 
differentiation 
 
fab-fragment Antigen binding 
capacity 
PLGA-triacetin depot up to 80 days Chang et al. 
(2015) [72] 
• 80 % remaining binding capacity after 
80 days of release  
Fibroblast growth 
factor 2 (FGF-2), bone 
morphogenetic 
protein 2 (BMP-2) 
Alkaline 
phosphatase 
activity (ALP), 
calcium 
accumulation 
 
Core-shell PLGA 
microspheres 
up to 30 days Lei et al. (2014) 
[51] 
• Accelerated differentiation of stem cells into 
osteogenic lineage 
• Higher calcium accumulation 
Bevacizumab MTT, 3-D 
angiogenesis 
culture 
Thermoresponsive 
hydrogel 
up to 60 days Hu et al. (2014) 
[267] 
• After 1 month of intravitreal injection, the 
histomorphology of a rabbit’s retina was 
preserved 
• Released bevacizumab inhibited anti-
angiogenesis in 3-D cultures 
IgG1  TGFβ induced 
release of IL-11 
Silk hydrogels and lyogels up to 80 days Guziewicz et al. 
(2013) [98] 
• No change in mAb potency represented by 
IL-11 inhibition 
BSA, Lysozyme Enzyme activity dihydroxyacetone-based 
poly(carbonate ester) 
matrices 
 
up to 80 days Weiser et al. 
(2013) [107] 
• Lysozyme: at least 50 % activity over the 
first month of release; 14 % to 16 % 
bioactivity after 60 days 
Insulin Glucose oxidase 
(GOD) assay 
Multi-arm histidine 
copolymer-PLGA 
composite microspheres 
 
up to 30 days Park et al. (2012) 
[68] 
• controlled blood-glucose levels and 
maintained lower glucose levels without a 
loss of body weight  
Nel-like molecule-1 
(Nell-1) 
Alkaline 
phosphatase 
activity (ALP) 
 
β-tricalcium phosphate (β-
TCP) particles 
up to 14 days Hu et al. (2012) 
[307] 
• Bioactivity preserved during loading 
• Bioactivity was preserved over 4 weeks in 
the lyophilized state 
Nel-like molecule-1 
(Nell-1) 
Alkaline 
phosphatase 
activity (ALP) 
 
Chitosan/tripolyphosphate/ 
Chondroitin sulfate 
nanoparticles 
up to 14 days Hou et al. (2012) 
[76] 
• Bioactivity was preserved during 
encapsulating procedure 
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Basic fibroblast 
growth factor (FGF-2) 
ELISA Polyelectrolyte multilayer 
microcapsules 
up to 3 days She et al. (2012) 
[308] 
• Bioactive FGF-2 decreased from 0.6 ng to 
0.4 to 0.1 ng 
Bone morphogenetic 
protein-6 (BMP-6) 
Alkaline 
phosphatase 
activity (ALP) 
 
Chitosan scaffolds up to 7 days Soran et al. 
(2012) [78] 
• Enhanced osteoblastic differentiation of 
bone marrow-derived rat mesenchymal 
stem cells 
Bone morphogenetic 
protein-2 (BMP-2) 
Alkaline 
phosphatase 
activity (ALP) 
 
Core-shell PLLACL-
collagen fibers 
up to 21 days Su et al. (2012) 
[92] 
• Increased ALP activity, mineralization and 
osteoblast marker expression 
Bevacizumab ELISA Nanostructured 
mesoporous silica (SiO2) 
films 
 
up to 30 days Andrew et al. 
(2011) [210] 
• antibody released in its active form over 
1 month; approx. 98 % of drug released 
Fibroplast growth 
factor (FGF) 
Alkaline 
phosphatase 
activity (ALP) 
 
Silica-chitosan hybrid 
coating on Ti 
up to 35 days Jun et al. (2011) 
[309] 
• Improved osteoblast cell response 
Bevacizumab induced choroidal 
neovascularization 
(CNV) in rat eyes 
PLGA nanoparticles not available Pan et al. (2011) 
[276] 
• reduction in CNV area suggests successful 
creation of formulations while retaining 
bevacizumab’s active antiangiogenic 
properties 
Recombinant human 
growth hormone (r-
hGH) 
r-hGH bioactivity on 
rat lymphoma nB2 
cell line 
 
PLGA microparticles up to 28 days Rafi et al. (2010) 
[48] 
• Bioactivity of release protein maintained 
over 4 weeks after single i.m. injection 
Insulin sodium oleate Diabetic rat model PLGA nanoparticles not available Sun et al. (2010) 
[298] 
• plasma glucose level reduced to 23.85 % 
from the initial one 12 h post-administration 
and this continued for 24 h in diabetic rats 
 
Nel-like molecule-1 
(Nell-1) 
Rat spinal fusion 
model 
Biomimetic apatite-coated 
alginate/chitosan 
microparticles 
 
up to 30 days Lee et al. (2009) 
[83] 
• Enhanced spinal fusion rates measured by 
manual palpation, radiographs and µCT 
Lysozyme Enzyme activity Thermosensitive mPEG–
PLGA–mPEG copolymer 
up to 28 days Tang et al. 
(2009) [67] 
• depot preserved lysozyme in its biologically 
active form 
Lysozyme Enzyme activity PLA in-situ forming depot 
(triacetin) 
up to 60 days Al-Tahami et al. 
(2008) [54] 
• Better enzyme activity than control (protein 
in buffer) after 2 weeks of release 
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Peptide or protein 
Analytical 
technique 
Delivery platform 
in-vitro 
release 
Reference Comment 
Lysozyme Enzyme activity PLGA microspheres up to 28 days Taluja et al. 
(2008) [69] 
• Enzymatic activity decreased by approx. 
10 % over 21 days of release 
BSA and nerve growth 
factor (NGF) 
ELISA Nano-fibrous collagen 
microspheres 
up to 28 days 
(only for BSA) 
Chan et al. 
(2008) [310] 
• Released NGF retained most of its 
bioactivity; but no comment on release 
duration of NGF and only 3 to 6 % delivered 
  
Lysozyme Enzyme activity Electrospun poly(ε-
caprolactone) and 
poly(ethylene oxide) fiber 
mesh  
 
up to 12 days Kim et al. (2007) 
[104] 
• Released lysozyme retained sufficient 
bioactivity (90 % after 12 days) 
Insulin Glucose oxidase 
(GOD) assay 
Insulin-phospholipid 
complex  
up to 12 h Cui et al. (2006) 
[311] 
• Reduced plasma glucose levels in diabetic 
rats 
Tetanus toxoid (TT), 
Ovalbumin, lysozyme 
ELISA Monomers of PLGA 
mimicking degradation 
incubation 
time: 20 days  
Determan et al. 
(2006) [304] 
• TT: loss of antigenicity  
• Ovalbumin: increased antigenicity 
• Lysozyme: only little lost in enzymatic 
activity  
 
Diphteria toxoid 
(Dtxd) 
ELISA Incubation with PLGA 
microspheres 
incubation 
time: 56 days 
Namur et al. 
(2004) [305] 
• Complete loss of bioactivity after 56 days 
Lysozyme Enzyme activity Poly(ether–ester) 
multiblock copolymers for 
macro-porous scaffolds 
up to 70 days Sohier et al. 
(2003) [312] 
• Encapsulation of protein into depot did not 
reduced enzyme activity 
• 80 % – 90 % remaining bioactivity after 
60 days of release  
 
Tissue plasminogen 
activator (t-PA) 
Serine protease 
activity 
PLGA implants up to 28 days Kang et al. 
(2002) [52] 
• No activity at all of t-PA after 4 weeks 
Insulin-like growth 
factor-I (IGF-I) 
Radioimmunoassay 
(RIA), fat cell assay 
(FCA) 
 
PLGA microspheres up to 21 days Meinel et al. 
(2001) [50] 
• Partially, up to 50 % less activity already 
after 0.2 days 
Insulin, met-
enkephalin, 
leuprolide, octreotide 
Suppression of 
testosterone by 
Radioimmunoassay 
(RIA) for leuprolide 
DepoFoam™ up to 25 days Ye et al. (2000) 
[313] 
• Prolonged suppression of testosterone 
levels in rats similar to Lupron® Depot after 
a single 1.m. injection 
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VII.2 RESULTS AND DISCUSSION 
VII.2.1 STABILITY OF RELEASED PROTEIN FRACTIONS FROM LIPID IMPLANTS  
VII.2.1.1 ANALYSIS OF SOLUBLE AGGREGATES AND FRAGMENTS 
Released proteins were collected, concentrated and analysed via SE-HPLC.  
 
Figure VII-1: Monomer content of released (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept 
monitored over 3 weeks to 26 weeks. Displayed are the relative percentages of monomer and the relative 
change of retention times compared to reference. 
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Figure VII-1 illustrates the monomer content over the period the proteins were released from 
the lipid matrix. If not otherwise noted, protein lyophilisate was formulated 1:1 [w/w] with HP-β-
CD. Displayed are the relative percentages of the monomer content compared to the reference 
defined as 100 % (reference: protein solution after dialysis and prior to lyophilisation). The 
monomer content of released mAb fractions alternated between 93 % and 98 % over 26 weeks 
(Figure VII-1 A).  
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 week 2 
6 week 4 
7 week 6 
8 week 10 
9 blank 
10 MW Marker 
Figure VII-2: Non-reducing denaturating SDS-PAGE gels using NuPAGE® Novex® 3-8% Tris Acetate Protein 
Gels of released mAb fractions collected between week 2 and week 10. 
 
The decrease in monomer content was caused by fragmentation rather than aggregation of the 
mAb, as observed by non-reducing denaturating SDS-PAGE using silver staining (Figure VII-2 
and Figure VII-3).  
  
460 kDa 
 
268 kDa 
 
238 kDa 
 
171 kDa 
 117 kDa 
 
71 kDa 
 51 kDa 
 44 kDa 
 
31 kDa 
 
#2:136 kDa 
 
#1:258 kDa 
 
#3:111 kDa 
 
#4:86 kDa 
 
#5:57 kDa 
 
#6:45 kDa 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 week 14 
6 week 18 
7 week 22 
8 week 26 
9 blank 
10 MW Marker 
Figure VII-3: Released mAb fractions between 14 and 26 weeks of release analysed with non-reducing 
denaturating SDS-PAGE using NuPAGE® Novex® 3-8% Tris Acetate Protein Gels. 
 
As indicated in Figure VII-2, a monomer band (#2, 136 kDa), and high molecular weight (HMW) 
species (#1, 258 kDa) were present in the released fractions. Compared to the reference, low 
molecular weight (LMW) species were particularly detectable, pointing into the direction of slight 
fragmentation, such as fab-fragments (#6, 45 kDa) or one-armed mAbs (#3, 111 kDa). 
SE-HPLC of Ranibizumab revealed a monomer content of 100 % over the release duration 
(18 weeks) compared to the reference material (Figure VII-1 B). In addition, non-reducing SDS-
PAGE was performed as an orthogonal method. Compared to the reference, additional bands 
were detected after 10 weeks, especially fragments ranging between 16 kDa to 18 kDa (Figure 
VII-4). Further, aggregates were identified having a size of approximately 151 kDa (#5) and 
98 kDa to 109 kDa (#6) after 4 weeks.  
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1 2 3 4 5 6 7 8 9 10 11 12 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 week 2 
6 week 4 
7 week 6 
8 week 10 
9 week 14 
10 week 18 
11 blank 
12 MW Marker 
Figure VII-4: Non-reducing denaturating SDS-PAGE gels using NuPAGE® Novex® 4-12% Bis-Tris Protein Gels 
of released Ranibizumab fractions collected over 18 weeks. 
 
These results were complemented by capillary gel electrophoresis, applying an Agilent 2100 
Bioanalyzer. Capillary gel electrophoresis showed Ranibizumab monomer content ranging 
between 94 % to 96 % (Figure VII-5 A). Additionally, a slight increase in LMW species from 4 % 
to 6 % was identified, HMW species percentage remained constant at 0.2 % over time. 
Therefore, these results are qualitatively in line with SDS-PAGE results. A typical 
electropherogram is displayed in Figure VII-5 B. 
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Figure VII-5: (A): Capillary gel electrophoresis of released Ranibizumab under non-reducing denaturating 
conditions. Shown are (○) monomer content, (●) low molecular weight (LMW) species and (▼) high molecular 
weight (HMW) species over the release period of 18 weeks. (B): typical electropherogram displaying markers, 
system peaks and signals of Ranibizumab.  
 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 reference 
2 blank 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 day 1 
6 day 3 
7 day 7 
8 day 14 
9 day 21 
10 MW Marker 
Figure VII-6: Non-reducing denaturating SDS-PAGE gels using NuPAGE® Novex® 3-8% Tris Acetate Protein 
Gels of released Bevacizumab fractions collected over 3 weeks of release. 
 
460 kDa 
 
268 kDa 
 
238 kDa 
 
171 kDa 
 117 kDa 
 
71 kDa 
 
51 kDa 
 44 kDa 
 
31 kDa 
 
#3:120 kDa 
 
#2:136 kDa 
 
#5:85 kDa 
 
#7:45 kDa 
 
#6:57 kDa 
 
#1:266 kDa 
 
#4:112 kDa 
 
STABILITY OF RELEASED PROTEIN FRACTIONS FROM LIPID AND PLGA MATRICES 
147 
The monomer content of Bevacizumab substantially dropped by 15 % within the first 3 weeks, 
highlighting the high sensitivity of Bevacizumab compared to the other proteins (Figure VII-1 C). 
Non-reducing SDS-PAGE underlined these results, pointing into the direction of aggregation 
(physical instability) and fragmentation (chemical instability) as displayed in Figure VII-6.  
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 week 2 
6 week 4 
7 week 6 
8 week 10 
9 week 14 
10 MW Marker 
Figure VII-7: Non-reducing denaturating SDS-PAGE gels using NuPAGE® Novex® 3-8% Tris Acetate Protein 
Gels of released Aflibercept fractions collected over 14 weeks. 
 
Figure VII-1 D displays the monomer content of Aflibercept over 14 weeks, illustrating a 
continuous decrease from 100 % to nearly 85 % compared to the reference. The loss of 
monomer is caused by the formation of aggregates having a size of 219 kDa (#1), 335 kDa (#6) 
and 500 kDa (#7), respectively, which were already detectable at week 4 as indicated by non-
reducing SDS-PAGE (Figure VII-7).  
In literature, protein stability after incorporation into lipid matrices has already been discussed 
for smaller and less complex molecules like ovalbumin [233], rh-interferon α-2a [176, 181], 
lysozyme [175] or brain-derived neuropathic factor (BDNF) [175]. All references reported on no 
changes in the aggregation/fragmentation profile after incorporation and were assessed by 
SDS-PAGE. Used lipids were mainly triglycerides (C12 to C18) and additives like PEG or 
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trehalose processed within the protein lyophilisate were used. These observations are in line 
with our results, as no protein instabilities were observed after incorporation into the lipid matrix. 
In terms of stability of released protein, Koennings et al. [175] described the dimerisation of 
BDNF during release from lipid depots measured after 1 month by SDS-PAGE. In contrast, Mohl 
et al. [176] observed only a minimal increase of rh-interferon α-2a aggregates (approximately 
1 %) from compressed lipid implants comprising D118, PEG or trehalose over 20 days of 
release. Also, neither aggregation nor fragmentation of released rh-interferon α-2a after 28 days 
was observed. Rh-interferon α-2a was identified to be stable after 6-month storage of the SLIs 
when formulated with HP-β-CD as lyophilisate stabiliser. The aggregation level of released 
fractions over the first 3 weeks after 6 months remained constant at approximately 3 %. In 
addition, Schulze et al. reported that rh-interferon α-2a monomer content, delivered from a 
binary triglyceride matrix, stayed at 95 % over a release period of up to 60 days [181]. However, 
all studies mentioned reported on aggregation – if any - rather than fragmentation as main 
degradation pathway. This stands in contrast to our results most likely due to the different 
proteins used. 
VII.2.1.2 CHEMICAL STABILITY OF PROTEINS 
To determine possible chemical changes of the proteins, IEX methods for mAb and 
Bevacizumab were developed (III.2.6.5). Using this method, the separation of acidic and basic 
species from the main charge variant is possible by applying a salt or pH gradient for separation 
[247, 314-328]. Figure VII-8 A illustrates that the main charge variant of mAb decreased from 
initially 100 % (relative to reference) to 84 % over 26 weeks. Simultaneously, the percentage of 
acidic subspecies continuously increased whereas the level of basic residues stayed constant 
(Appendix, Figure XII-8 A). The retention time of the main charge variant stayed constant over 
26 weeks pending between 98 % and 102 % compared to retention time of the reference. 
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Figure VII-8: Relative change of the main charge variant area of (A) mAb and (B) Bevacizumab assessed by 
IEX. Retention time of the main peak eluting from the column relative to reference material is displayed as 
black dots. 
 
As illustrated in Figure VII-8 B, the relative percentage of Bevacizumab’s main charge variant 
decreased substantially and continuously over 3 weeks by 40 %. At once, more acidic 
subspecies eluting earlier than the main charge variant were identified (Appendix, Figure 
XII-8 B). Retention times did not change considerably throughout the 21 days of release.  
Chemical degradation products from Ranibizumab and Aflibercept were identified and 
quantified by a HIC method (III.2.6.6) developed for each protein. HIC allows the separation of 
differently charged protein species and has already been described in literature [329-336]. As 
Figure VII-9 A demonstrates, the main charge variant of Ranibizumab decreased from 100 % 
to 90 %. The chromatograms of Ranibizumab did not change noteworthy during the first 
6 weeks; a notable change occurred firstly after 10 weeks. Analysis of the chromatograms 
showed an increase of subspecies eluting later than the main peak, therefore signifying the 
formation of more hydrophobic residues. More hydrophilic residues (eluting faster than the main 
peak) were not detected (Appendix, Figure XII-9 A). Noticeably, the retention time of the main 
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charge variant shifted towards shorter elution times, highlighting that more hydrophilic 
subspecies were formed which were not separated by the gradient. 
 
Figure VII-9: Relative change of the main charge variant area of (A) Ranibizumab and (B) Aflibercept as 
assessed by HIC. 
 
The main charge variant of Aflibercept decreased by 8 % over 14 weeks as displayed in Figure 
VII-9 B. The formation of more hydrophobic rather than hydrophilic residues was detected. 
Additionally, the retention time of the main charge variant changed towards higher retention 
times, indicating that residues of slightly elevated hydrophobicity were formed. 
To obtain more detailed information with respect to chemical stability, capillary gel 
electrophoresis was performed under reducing denaturating conditions to detect possible 
covalent bonds, e.g. disulfide bonds. Samples taken at each predetermined time point were 
compared to reference material as shown in Figure VII-10. For mAb, the percentage of heavy 
chain, light chain, LMW species and HMW species stayed rather constant over 26 weeks 
designating no formation of covalent bonds (Figure VII-10 A). In contrast, for Ranibizumab the 
heavy chain percentage slightly increased by 2 % over 18 weeks whereas the level of light chain 
decreased by 2.5 %. Levels of other sized fragments did not change (Figure VII-10 B). For 
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Bevacizumab, the percentage of the heavy chain declined from 69 % (day 1) to 58 % (day 21). 
In the same course, the percentages of the light chain, small sized and larger sized residues 
increased pointing into the direction of covalent bond formation (Figure VII-10 C). 
 
Figure VII-10: Capillary gel electrophoresis applying the 2100 Bioanalyzer under reducing denaturating 
conditions of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept released fractions. Shown are 
the () light chain and () heavy chain percentages as well as the amount of () LMW and () HMW species 
over the specific release durations. 
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Figure VII-10 D displays the results obtained for Aflibercept: the percentage of heavy and light 
chain decreased by 5% and 10%, respectively. Concurrently, the formation of LMW and HMW 
species can be observed. 
IEX and HIC analysis revealed formation of differently charged subspecies (IEX) or subspecies 
having a different hydrophobicity (HIC). Thus, more chemical degradation than physical 
degradation of proteins was observed when released from a hydrophobic matrix over time. 
Possible reactions forming acidic species are deamidation (asparagine, glutamine, c-terminal 
amides), cleavage of disulfide bonds, oxidation (proline, phenylalanine, o-tyrosine, tryptophan), 
conversation of arginine and hydrolysis [337]. Chemical subspecies of Ranibizumab and 
Aflibercept were measured by HIC, whereby exclusively subspecies were found being more 
hydrophobic than the main charge variant (Figure VII-9). This can be explained by the potential 
formation of disulfide bonds caused by oxidation, isomerisation of asparagine to succinimide 
[337] or unfolding of the protein. During partial unfolding of the protein, hydrophobic areas are 
turning to proteins` surface generating hydrophobic patches. While this happens, chemical 
reactions are not obligatory necessary.  
In addition, a decrease in heavy chain percentage measured under reducing conditions 
(especially for Bevacizumab and Aflibercept) might have occurred due to the formation of 
covalent disulfide bonds. The disulfide bonds formed new linkers between protein helices where 
there were none before. The reducing agent DTT cleaved those bonds leading to more fractions 
being smaller in size than before. 
In literature, little information is provided on chemical stability of proteins delivered from lipidic 
matrices. The chemical stability of released rh-interferon α-2a from compressed lipid matrices 
comprising the triglyceride D118 has already been discussed by Mohl et al. [176]. Oxidized 
species levels were measured using RP-HPLC taking also into account the storage of loaded 
implants prior to in-vitro release. For rh-interferon α-2a formulated with HP-β-CD, the level of 
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oxidized species did not change over release duration of 22 days. After 6-month storage prior 
to release, the level increased after 2 weeks of release from 1 % to 2 %. 
VII.2.1.3 CONFORMATIONAL STABILITY OF PROTEINS 
FT-IR is a well-established and widely used method to determine protein secondary structure 
[338-343] and was therefore used to obtain information on the conformational status of released 
protein. FT-IR spectra at every single predetermined time point were measured. For a better 
visualisation, only spectra of reference and selected samples, representing the progress upon 
release, are displayed in Figure VII-11. It should be noted, that the sample concentration of 
1.0 mg/ml was at the lower end of instrument sensitivity. This fact may explain the not perfectly 
matching overlays.  
Figure VII-11 A displays the FT-IR spectra of mAb between 1600 cm-1 and 1700 cm-1. The 
amide I band, which is mainly generated by C=O stretching vibrations, represents the β-sheet 
band structure [340, 343] and can be identified between 1635 cm-1 and 1645 cm-1. Apparently, 
the single peak present at the reference (1635 cm-1 to 1637 cm-1) turned into a split peak with a 
left side shoulder at 1645 cm-1 starting at week 6. Additionally, an increase in band intensity at 
1680 cm-1 and 1615 cm-1can be observed, being characteristic for protein unfolding events 
[341]. Shifts towards higher wavenumbers represent unordered random coil like structures 
[341]. On the expense of regular structures, the formation of intermolecular hydrogen-bonded 
antiparallel β-sheet structures are pointing into the direction of partial unfolding of the mAb [344]. 
Changes in secondary structure of mAb might have arisen due to the hydrophobic environment 
(triglycerides) the antibody was exposed to. 
Ranibizumab FT-IR spectra are shown in Figure VII-11 B, including the reference and the 
samples of week 4, 10 and 18, respectively. The spectra are characterised by a pronounced 
amide I band at 1636 cm-1. Intensity of the amide I band slightly decreased over time whereas 
the band at 1678 cm-1 became more prominent. Overall, Ranibizumab is present in its native 
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state over the complete release period. Compared to mAb, the better conformational stability is 
most likely due to the less complex structure of the fab-fragment. 
 
Figure VII-11: FT-IR spectra of collected released fractions from (A) mAb, (B) Ranibizumab, (C) Bevacizumab 
and (D) Aflibercept. 
 
Figure VII-11 C shows the FT-IR spectra of Bevacizumab reference and released fractions 
collected over 21 days. The reference comprised a weak amide I single band at 1636 cm-1. After 
STABILITY OF RELEASED PROTEIN FRACTIONS FROM LIPID AND PLGA MATRICES 
155 
3 days, the spectra changed dramatically, pointing into the direction of substantial changes in 
secondary structure. The amide I band was shifted towards 1640 cm-1 (day 21), representing 
more unordered random coil like structures and band intensity at 1690 cm-1 increased (protein 
unfolding).  
Aflibercept reference material is characterised by an amide I band consisting of two peaks: the 
main band having a maximum at 1640 cm-1 and a right-side shoulder band at 1630 cm-1 (Figure 
VII-11 D). While the protein was released, the band intensity of the amide I band at 1630 cm-1 
declined considerably. Moreover, an increase in band intensities at 1680 cm-1 and 1697 cm-1 
was observed.  
Schulze et al. was the first assessing the conformational status of a protein after encapsulation 
into a lipid matrix, showing that the protein (lysozyme) was still in its native state [181]. To the 
best of our knowledge, our study is the first describing the conformational status of three 
different protein formats released from SLIs. 
 
VII.2.2 STABILITY OF RELEASED PROTEIN FRACTIONS FROM PLGA MATRICES  
PLA and PLGA polymers provide a biodegradable system for sustained release of protein drugs, 
but erosion/degradation of the polymer is associated with a drop in pH and an increase in 
osmotic pressure (particularly inside the matrix), which may result in degradation products 
caused by acylation, deamidation or aggregation [49, 253, 254].  
Within our study, released protein from a PLGA matrix (Resomer® RG 502 or Resomer® RG 
502 H) was collected over 12 weeks to investigate protein stability and compare these results 
to data obtained from SLIs (VII.2.1). The pH of the release medium was measured accordingly.  
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Figure VII-12: Displayed are the pH values of incubation medium in which protein loaded Resomer® RG 502 H 
matrices were incubated. The course of pH was monitored for extrudates containing () no protein, () mAb, 
() Ranibizumab, and () Aflibercept. 
 
When completely exchanging the release medium at predetermined time points (as it was 
performed for in-vitro release studies), the measured pH described a curve with a minimum of 
pH 2 after 4 weeks (Figure VII-12). Since the pH was around 3 from week 3 to week 7, an 
incubation study at pH 3 was performed to hedge that possible instabilities were due to the pH 
drop and osmotic pressure increase inside the PLGA matrix. Therefore, proteins were incubated 
in PBS pH 3.0 for 4 weeks at 37°C in a horizontal shaker (40 rpm). Samples were analysed 
after 2 weeks and 4 weeks.  
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VII.2.2.1 ANALYSIS OF SOLUBLE AGGREGATES AND FRAGMENTS 
SE-HPLC data were obtained for released mAb and Ranibizumab over 12 weeks. The monomer 
content of reference, pH 3 incubated samples, released fractions from SLIs after 12 weeks and 
from a Resomer® matrix (Figure VII-13) were compared. Monomer content of mAb declined to 
86 % after 4 weeks of incubation at pH 3. After 4 weeks of release from the PLGA matrix, 
monomer content was measured with 72 % (Figure VII-13 A). The lower value can be explained 
by the acidic microenvironment generated while PLGA eroded, namely a drastic change in pH 
and elevated osmotic pressure. Unfortunately, data from other time points were not available 
due to the very small amount of protein released within this time frame (IV.2.7).  
 
Figure VII-13: Monomer content of (A) mAb and (B) Ranibizumab of reference, pH 3 incubated samples, 
released fractions from SLIs after 12 weeks and released fractions from a Resomer® matrix. 
 
The incubation at pH 3 did not affect the monomer content of Ranibizumab. Therefore, it can 
be assumed that incubation for even longer time would not negatively affect the monomer 
content. A head to head comparison of Ranibizumab released from SLIs after 12 weeks 
(100.1 %) and Resomer® RG 502 H (4.4 %) clearly showed that the PLGA matrix (and its 
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degradation products) degraded Ranibizumab dramatically. These results also highlight that 
SLIs provide an outstanding delivery matrix for proteins.  
Additionally, non-reducing denaturating SDS-PAGE was performed for mAb, Bevacizumab and 
Aflibercept (for Ranibizumab capillary gel electrophoresis was performed and will be discussed 
in the following).  
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 pH3_week 2 
6 pH3_week 4 
7 
Resomer® RG 
502_week 4 
8 
Resomer® RG 
502_week 6 
9 
Resomer® RG 
502_week 12 
10 MW Marker 
Figure VII-14: Non-reducing denaturating SDS-PAGE of mAb. Shown is the head-to-head comparison of 
samples being incubated at pH 3 and those which were released from a PLGA matrix. 
 
Illustrated in Figure VII-14, SDS-PAGE of mAb revealed a pH-induced degradation resulting in 
the formation of aggregates with a size of 250 kDa (#6) and 200 kDa (#7) and fragments being 
51 kDa (#8) and 48 kDa (#9) in size compared to the reference (lane 2, 5 and 6). Interestingly, 
between week 2 and week 4 of incubation in the acidic solution, qualitatively no more 
degradation of mAb was observed leading to the conclusion that the pH-induced degradation 
was already complete after 2 weeks. Results for the released fractions of mAb from a Resomer® 
RG 502 matrix can be seen at lane 7 to 9. Comparable additional bands can be detected as it 
was the case for the pH 3 incubated samples. Moreover, intensity of fragment bands increased 
while the monomer band was less intense. After 12 weeks, the mAb was completely degraded 
and only bands with a MW of 37 kDa (#11) to 41 kDa (#10) were present pointing into the 
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direction of complete fragmentation. MAb fractions released from the PLGA matrix were much 
more degraded than the samples incubated at pH 3. Thus, it can be concluded that the instability 
of mAb was mainly caused by chemical interactions with PLGA and its degradation products. 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 pH3_week 2 
6 pH3_week 4 
7 
Resomer® RG 
502_week 4 
8 
Resomer® RG 
502_week 12 
9 blank 
10 MW Marker 
Figure VII-15: Non-reducing denaturating SDS-PAGE gel of released Bevacizumab fractions from a Resomer® 
RG 502 matrix. Due to the very incomplete release of Bevacizumab, only samples taken after 4 weeks and 
12 weeks were accessible for analysis. 
 
Figure VII-15 displays the results for separation of MW species of the pH 3 study (lane 5 and 6) 
and the released fractions of Bevacizumab from a Resomer® RG 502 matrix (lane 7 and 8). Due 
to the very incomplete release of Bevacizumab, only samples taken after week 4 and week 12 
were accessible for analysis. Surprisingly, after a 2-week incubation at pH 3, no additional bands 
were detected; only slightly more intense HMW aggregates and fragment bands were observed. 
No obvious differences between the samples taken after 2 and 4 weeks of incubation at pH 3 
were found. For the sample taken after 4 weeks of release from the PLGA matrix, no apparent 
differences in band patterns are noticeable (compared to the pH 3 samples), thereby 
demonstrating that Bevacizumab was not further degraded by the PLGA matrix. This result was 
surprising because in previous studies (VII.2.1) Bevacizumab was the most sensitive protein. 
After 12 weeks of release, a clear and distinct tendency towards fragmentation was observed: 
the monomer band almost completely disappeared and was replaced by a broad spectrum of 
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bands ranging in a size of 50 kDa to 150 kDa (#7). In addition, intense bands at 45 kDa and 
30 kDa were present. In case of Bevacizumab, a concluding answer if the acidic pH of the 
incubation media or the acidic microclimate inside the PLGA matrix were responsible for its 
degradation, remains unanswered. 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 pH3_week 2 
6 pH3_week 4 
7 
Resomer® RG 
502_week 6 
8 
Resomer® RG 
502_week 8 
9 blank 
10 MW Marker 
Figure VII-16: Non-reducing denaturating SDS-PAGE gel of Aflibercept samples incubated at pH 3 and of 
released fractions of Aflibercept from a Resomer® RG 502 matrix. 
 
The results for the recombinant fusion protein Aflibercept are displayed in Figure VII-16. The 
reference material was characterised by weak bands at approximately 246 kDa (#1), most likely 
aggregates, whereas bands at 129 kDa (#2) represented the monomer in its glycosylated form; 
an additional band was identified at 106 kDa (#3) which was probably the deglycosylated form. 
After 2 weeks at pH 3 (lane 5), bands already seen for the reference became more intense; very 
weak bands around 37 kDa (#4) and 34 kDa (#5) were also identified. Qualitatively, the 
aggregation profile did not change between week 2 and week 4 upon incubation at pH 3, 
meaning that a further degradation of Aflibercept would be unlikely. Lane 7 and 8 are illustrating 
the degradation profile of released fractions taken after 6 and 8 weeks. The monomer band 
disappeared almost completely and was replaced by strong bands in the MW region of 20 kDa 
to 30 kDa. A similar profile can be seen after 8 weeks. These results proof, that Aflibercept was 
460 kDa 
 268 kDa 
 
238 kDa 
 
171 kDa 
 
117 kDa 
 
71 kDa 
 51 kDa 
 44 kDa 
 
31 kDa 
 
#6 
 
#1 
 
#5 
 
#4 
 
#3 
 
#2 
 
STABILITY OF RELEASED PROTEIN FRACTIONS FROM LIPID AND PLGA MATRICES 
161 
mainly degraded by products formed due to the PLGA erosion. Degradation took also place 
upon incubation at pH 3, but the differences between the sample at lane 6 (4 weeks at pH 3) 
and lane 7 (6 weeks of release) were substantial. Consequently, the major degradation can be 
reduced to PLGA erosion. 
Table VII-3: Non-reducing denaturating capillary gel electrophoresis of Ranibizumab samples. 
 LMW species [%] Monomer [%] HMW species [%] 
reference 2.05 (±0.49) 97.85 (±0.64) 1.10 (±0.14) 
week 2_pH 3 1.47 (±0.15) 98.47 (±0.21) 0.06 (±0.12) 
week 4_pH 3 1.60 (±0.36) 98.03 (±0.25) 0.03 (±0.06) 
week 12_lipid matrix 2.10 (±0.14) 97.90 (±0.14) 0.00 (±0.00) 
week 12_Resomer® RG 502 31.65 (±0.92) 65.85 (±2.05) 2.50 (±1.13) 
week 12_ Resomer® RG 502 H 27.75 (±0.78) 64.05 (±3.04) 8.20 (±2.26) 
 
Table VII-3 displays the results from non-reducing capillary gel electrophoresis of Ranibizumab. 
No difference can be observed between the reference and the samples incubated at pH 3 as 
the monomer content stays constant at 98 %. Released Ranibizumab from both Resomer® 
polymers (ester terminated and free COOH-group), showed 28 % to 32 % fragments and up to 
8 % aggregates were formed. This clearly illustrates that not the low pH of the incubation 
medium predominantly caused protein degradation, rather the direct chemical interaction of 
Ranibizumab and PLGA/PLGA degradation products inside the matrix as reported previously 
[49, 253].  
Finally, it was possible to confirm that the degradation of the proteins was mainly driven by the 
erosion of the PLGA matrix and the direct interaction of the proteins with PLGA and its 
degradation products rather than the acidic pH of the surrounding incubation medium. This 
statement holds true for mAb, Aflibercept and Ranibizumab whereby it was not possible to 
unequivocally answer this question for Bevacizumab. 
CHAPTER VII 
162 
VII.2.2.2 CHEMICAL STABILITY OF PROTEINS 
Samples were further analysed towards chemical stability. IEX and HIC was not applicable due 
to the very little sample volume. Instead, capillary gel electrophoresis under reducing conditions 
was executed to detect possible covalent bonds potentially formed (Figure VII-17). Shown are 
the percentages of light and heavy chain as well as of LMW and HMW species for samples 
incubated at pH 3 for 2 weeks and 4 weeks and of released protein after 12 weeks from lipid 
implants and from Resomer® RG 502 and RG 502 H matrix as head-to-head comparison of both 
delivery platforms.  
Figure VII-17 A illustrates the results for mAb. Upon incubation at pH 3, a significant increase 
in LMW species can be detected by a similarly decrease of the heavy chain percentage already 
after 2 weeks. The light chain percentage increased by 10 %. No major differences between 
samples taken after 2 weeks and after 4 weeks were detected, meaning that the chemical 
degradation of mAb took place rapidly and was complete already after 2 weeks of incubation. 
Interestingly, no significant differences were identified between the reference and the released 
mAb from SLIs after 12 weeks pointing out, that no additional covalent bonds were formed 
during release. Contrarily, released mAb from Resomer® RG 502 was characterised by a drastic 
increase in LMW species and light chain at the expense of heavy chain percentage. MAb 
released from Resomer® RG 502 H was almost exclusively present as LMW species in the 
range of molecular weight of the light chain (no single peaks were isolated; more a multi-peak 
region was observed). The difference in degradation profile of mAb between both PLGAs can 
be explained by the acidic end group Resomer® RG 502 H is equipped with promoting the 
cleavage of the peptide bonds. 
STABILITY OF RELEASED PROTEIN FRACTIONS FROM LIPID AND PLGA MATRICES 
163 
 
Figure VII-17: Reducing denaturating capillary gel electrophoresis of (A) mAb, (B) Ranibizumab, (C) 
Bevacizumab and (D) Aflibercept samples incubated at pH 3 for 2 and 4 weeks and of released fractions from 
both lipid and PLGA matrices after 12 weeks of release.  
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In case of Ranibizumab, the incubation in acidic PBS buffer did not lead to any alterations in 
light chain and heavy chain percentage, thereby showing the remarkable stability of 
Ranibizumab (Figure VII-17 B). The released Ranibizumab from SLIs did not revealed any 
changes, which indicates that no covalent bonds were formed during release. In contrast, no 
heavy chain was detected released from Resomer® RG 502, but instead an increase of about 
60 % of smaller sized fragments was found. Even more (approximately 75 %) LMW species 
were measured for Ranibizumab samples released from Resomer® RG a carboxyl group). Both 
PLGAs heavily promoted the formation of additional covalent bonds whereas for the samples 
released from SLIs no differences compared to the reference were apparent. 
As it was already the case for SE-HPLC analysis, Bevacizumab samples were not available for 
all time points due to the short release duration (for SLIs) of only 3 to 4 weeks or the very small 
amount released which was the case for the Resomer® matrices. Therefore, the data set 
presented at Figure VII-17 C gives no conclusive results and will not be further discussed. 
Aflibercept samples are illustrated in Figure VII-17 D. Upon incubation in PBS at pH 3, the 
formation of LMW species was observed after 2 weeks; even more LMW species were formed 
after 4 weeks of incubation indicating that additional covalent bonds were formed also after a 
longer incubation period. Similarly, the heavy chain and light chain percentage dropped over 
the time. Collected and concentrated Aflibercept liberated from SLIs was distinguished by slight 
changes in the chain profile compared to the reference. In contrast, once released from both 
Resomer® matrices, the fraction of LMW species (approximately 60 % more compared to 
reference) increased dramatically whereas almost no heavy chain was detectable anymore.  
In summary, it was demonstrated that the formation of additional covalent bonds was mainly 
driven by erosion of the PLGA matrix. But also, a shift in chain profile upon incubation at pH 3 
was detectable, meaning that also the pH of the incubation medium promoted partially the 
formation of chemical alterations. However, proteins were chemically modified more intensively 
when released from PLGA, even differences between Resomer® RG 502 and RG 502 H were 
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observed, which can be explained by the different end groups the polymers are equipped with. 
Contrarily, only slight changes - if any - were noticed when proteins were released from SLIs 
highlighting the benefit of this delivery platform. For Bevacizumab, it was not possible to 
unmistakably answer this question due to the limited sample available.  
Other reports in the literature also addressed the topic of chemical protein stability during 
release from PLGA based depots [44, 46]. Estey et al. [44] reported on BSA stability under 
acidic conditions (pH 2) by modelling the microclimate within PLGA matrices. BSA monomer 
dropped to 0 % within 14 days to 28 days due to the formation of aggregates and fragments 
measured by SE-HPLC and SDS-PAGE. The chemical degradation (mainly deamidation) of 
insulin from PLGA microspheres [49, 345] over 18 days [49] or the acylation of atrial natriuretic 
peptide (ANP) has been described. The acylation of ANP over 60 days has also been described 
by Lucke et al. modelling the microclimate within PLGA matrices by lactic acid solutions [254]. 
The same holds true for exenatide as reported by Liang et al. [217] with the additional 
background of water uptake onto PLGA microspheres. Chang et al. [72] measured the main 
peak area of a released fab-fragment by IEX from PLGA-triacetin depots over 80 days showing 
a continuous decrease from almost 100 % to approximately 50 %. In our study, for SLIs (Table 
VII-3) the main charge variant of Ranibizumab dropped only by 10 % over 18 weeks of release. 
All references reported on a fast and distinct chemical degradation, which was not the case in 
our study, highlighting the benefit of lipid based depots in terms of chemical protein stability.  
 
VII.2.3 STABILITY OF RELEASED PROTEIN FRACTIONS AFTER STORAGE OF LIPID 
IMPLANTS 
Besides the stability analysis performed with protein released from freshly prepared implants, it 
was also analysed if mAb and Ranibizumab show sufficient stability when stored for up to 
3 months within the highly hydrophobic lipid matrix. SLIs were stored at 4°C after production for 
4 weeks and 12 weeks prior to in-vitro release. The protein fraction released over the first 7 days 
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after storage was then collected, concentrated and analysed. For this study, the 3:1 
protein:cyclodextrine [w/w] lyophilisate formulation was used. 
 
Figure VII-18: Monomer content of (A) mAb and (B) Ranibizumab released within the first 7 days after storage 
of lipid implants for 0, 4 and 12 weeks at 4°C. Displayed is the variation relative to the reference. 
 
In Figure VII-18, SE-HPLC results are displayed showing the monomer content of the reference 
and samples directly after production (week 0) and after storage of 4 and 12 weeks, 
respectively. For mAb, the monomer content remained unchanged ranging from 96.9 % to 
100.9 % relative to the reference also after a 12-week storage. Non-reducing denaturating SDS-
PAGE was performed orthogonally showing slightly more intense bands of stored samples at 
276 kDa (#6) and 178 kDa (#7) (aggregates) and bands of different sized fragments (45 kDa, 
64 kDa) compared to reference (Appendix, Figure XII-10).  
Ranibizumab monomer content was measured with 98.1 % to 98.9 % relatively to the reference, 
also showing no decrease after storage. Orthogonally, capillary gel electrophoresis was 
performed as illustrated in Table VII-4. The monomer content slightly decreased by 1 % 
between week 0 and week 12. A significant change in HMW and LMW upon storage was not 
detected. 
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Table VII-4: Results of non-reducing denaturating on-chip gel electrophoresis of Ranibizumab fractions 
stored for 12 weeks at 4°C prior to release compared to reference. 
 Reference Week 12 
LMW species [%] 2.05 (±0.49) 1.90 (±0.00) 
Monomer [%] 97.85 (±0.63) 97.00 (±0.00) 
HMW species [%] 0.10 (±0.14) 0.10 (±0.00) 
 
Regarding chemical stability, the percentage of mAb’s main charge variant decreased by 
approximately 5 % upon storage while the percentages of acidic (+6 %) and basic species 
increased (+0.7 %) (Figure VII-19 A). For Ranibizumab, exclusively more hydrophobic 
subspecies were formed (+2 %) upon storage equivalent to a decrease in main charge variant 
by 2 % (Figure VII-19 B). 
In addition to IEX and HIC, reducing denaturating capillary gel electrophoresis was performed 
(Table VII-5). The heavy chain percentage of mAb decreased by 3 % after a 12-week storage 
whereas slightly more LMW and HMW species were detected compared to the reference. The 
percentage of light chain stayed constant. Ranibizumab samples also showed a slight reduction 
in heavy chain percentage (1.5 %) as well as a minor increase of light chain and LMW species 
(together 1.5 %). 
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Figure VII-19: Chemical stability of (A) mAb and (B) Ranibizumab released within the first 7 days after storage 
of lipid implants for 0, 4 and 12 weeks at 4°C.  
 
Table VII-5: Reducing denaturating capillary gel electrophoresis of mAb and Ranibizumab released fractions 
after a 12-week storage. Displayed are the light and heavy chain percentages as well as the amount of LMW 
and HMW species compared to reference. 
 mAb Ranibizumab 
 Reference Week 12 Reference Week 12 
LMW species [%] 0.95 (±0.00) 1.80 (±0.14) 0.30 (±0.28) 1.15 (±0.35) 
Light chain [%] 29.10 (±0.14) 28.85 (±0.92) 34.50 (±0.14) 34.66 (±1.98) 
Heavy chain [%] 67.90 (±0.00) 64.75 (±0.49) 64.55 (±0.35) 63.00 (±1.41) 
HMW species [%] 2.05 (±0.07) 2.70 (±0.14) 0.65 (±0.07) 1.40 (±0.00) 
 
The FT-IR spectra of mAb and Ranibizumab samples are given in Figure VII-20. Spectra of the 
reference and of the released protein after 0, 4 and 12 weeks are illustrated. The amide I band 
region (1635 cm-1 to 1645 cm-1) of mAb samples did not alter in band maxima but band intensity 
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differed. Furthermore, increasing band intensities were noticed at 1680 cm-1 and 1615 cm-1, 
leading to the conclusion that unfolding events must have taken place. FT-IR spectra of 
Ranibizumab samples did not show any deviations including band intensity and wavenumber of 
band maxima (Figure VII-20 B). Compared to mAb, the better conformational stability was due 
to the less complex structure of the fab-fragment [346]. 
 
Figure VII-20: FT-IR spectra of released (A) mAb and (B) Ranibizumab samples collected over the first 7 days 
of release. Lipid implants were stored at 4°C for 0, 4 or 12 weeks prior to in-vitro release. 
 
When stored in the dry state at 4°C, mAb and Ranibizumab showed very good stability even 
after a period of 3 months. Both proteins were more stable compared to the stability profile 
obtained after 12 weeks of release. This can easily be explained by the elevated temperatures 
during incubation and the aqueous environment which are well-known triggers for protein 
degradation [347-351]. 
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VII.3 CONCLUSION 
Within this chapter, the stability of four different proteins was analysed, including three 
commercial products.  
The stability of the proteins was assessed released either from lipid or PLGA depots. As a model 
protein, an IgG1 antibody (mAb) was used which was characterised by an adequate stability 
over more than 6 months (26 weeks) when released from SLIs. Monomer content stayed 
between 93 % and 98 % over the release duration, even though major chemical and 
conformational instabilities were detected. Ranibizumab was delivered over 18 weeks, showing 
excellent physical, chemical and conformational stability over the complete release period. 
Therefore, Ranibizumab was the most promising therapeutic. Aflibercept comprised an 
acceptable stability profile over 14 weeks, therefore being an additional candidate for further 
studies. Only Bevacizumab was characterised by poor stability and comparatively short release 
durations.  
The stability of released protein from a PLGA matrix was assessed as well. All proteins showed 
a rapid and substantial degradation – physically and chemically – which was mainly caused by 
the micro environment within the PLGA matrix rather than the pH of the incubation medium. 
These results are in line with reports in the literature (Table VII-1). 
For fractions released from SLIs, such promising protein stability data have - to the best of our 
knowledge - not yet been published (Table VII-1), neither regarding the period of release nor 
the variety of proteins, most of them being therapeutically relevant proteins. Various publications 
have already addressed this topic describing the stability of peptides [301], small sized proteins 
[43, 45, 49, 253] or fab-fragments [72], but none of them reported over such long release 
durations and comprehensive stability data, irrespective of the delivery platform. Compared to 
other delivery platforms described in literature such as PLGA [43, 49] or chitosan [79], the lipid 
based depot described here provides an adequate stability for at least the mAb and 
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Ranibizumab over a long-term release period of 18 weeks to 26 weeks as well as after storage 
of the implants.  
Overall, the benefit of lipid based systems was demonstrated, as it can retain the stability of the 
incorporated protein during long-term release and storage. Especially the excellent stability 
profile of Ranibizumab is promising basis for future work. 
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VIII. TRIGLYCERIDE-PROTEIN-INTERACTION 
STUDIES 
VIII.1 INTRODUCTION 
Within chapter IV and chapter VII, release patterns and stability profiles of two IgG1 antibodies, 
the fab-fragment Ranibizumab (Lucentis®) and the fusion protein Aflibercept (Eylea®) were 
described. However, the complexity of the lipid depot systems in particular with regard to lipid-
protein interactions has not been studied. In this chapter, experiments were performed to study 
possible interactions between the proteins and triglycerides with the aim to identify if the lipids 
may potentially be accountable for the different release profiles and protein instability issues 
observed. Considering such interactions is crucial since lipid based depots are not considered 
to be inert. Even et al. already described the interactions between differently charged peptides 
and lipids including D114, soy lecithin and cholesterol [187]. The interactions between interferon 
β-1b and the triglycerides H12 and D118 has been addressed by Neuhofer [185]. 
Interactions between proteins and lipids have been studied extensively before, but exclusively 
phospholipids have been analysed. In such studies, the focus was mainly on interactions at a 
cellular level, for instance interactions of proteins with membranes [352-368], or between 
proteins and liposomes [185], or hexosomes [369] using methods like surface plasmon 
resonance (SPR), isothermal titration calorimetry (ITC), dynamic scanning calorimetry (DSC), 
dynamic light scattering (DLS) or flow cytometry.  
However, triglycerides differ from phospholipids by structure, solubility, hydrophobicity and 
charge [125, 370]. To our knowledge, Neuhofer was the first describing interactions between a 
pharmaceutical protein and triglycerides, namely H12 and D118, which have also been used in 
this study [185]. Interactions have been studied by performing incubation studies with native 
and PEGylated interferon β-1b and the relevant triglycerides. Neuhofer described that in the 
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presence of lipids, interferon β-1b formed soluble aggregates and oxidized subspecies. 
Furthermore, the biological activity of the protein decreased in presence of triglycerides. At the 
same time, protein recovery was significant lower upon incubation with triglycerides. 
Triglyceride-protein-interactions were further investigated by using QCM to study adsorption 
and desorption events of interferon β-1b on tristearin coated chips. Additionally, Neuhofer 
observed substantial different release patterns of native and PEGylated interferon β-1b released 
from the same lipid depot. This raised the question, if such interactions may influence protein 
release from lipidic depots in addition to diffusion and erosion which are well-known release 
mechanisms. 
The present chapter describes how two IgG1 antibodies, the fab-fragment Ranibizumab and the 
fusion protein Aflibercept behave upon contact with H12, D118 or Resomer® RG 755 S, 
respectively. The aim was to identify possible interactions between the different compounds 
Therefore, rods consisting of pure H12, D118 or RG 755 S, respectively, were extruded and 
incubated with protein solutions to study possible interactions. After an 8-week incubation period 
at 35°C, the protein was analysed with regards to colloidal, chemical and conformational 
stability. Additionally, raw material and extruded rods were tested for the presence of heavy 
metals. Heavy metals could potentially be introduced into the lipid matrix during the 
manufacturing process and may be a cause for protein instabilities [371-373]. 
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VIII.2 RESULTS AND DISCUSSION 
VIII.2.1 INCUBATION STUDY OF PROTEIN SOLUTIONS WITH TRIGLYCERIDE AND 
PLGA RODS 
To study possible interactions between proteins and the depot forming materials used within 
this work, lipid and PLGA rods were extruded and incubated with the proteins for 8 weeks at 
35°C and 40 rpm in a horizontal shaker. Implants were extruded consisting of 100 % H12 
(extrusion temperature 35°C), 100 % Dynasan® D118 (extrusion temperature 60°C) or 100 % 
Resomer® RG 755 S (extrusion temperature 70°C), respectively, using a ZE-5 mini-extruder. 
Resomer® RG 755 S was chosen, as it has a degradation time frame of approximately 6 months. 
Thereby, it was ensured that during an 8-week incubation study no erosion of the RG 755 S rod 
occurred, which could have caused elevated particle counts or could have otherwise interfered 
with protein analysis. Extruded implants had a size of 2.0 mm x 15 mm, resulting in a surface of 
approximately 100 mm2. Rods were placed in 2.0 ml micro-centrifuge tubes (VWR, Radnor, PA, 
USA) and 1.0 ml protein solution was added at a concentration of 2.0 mg/ml (protein stock 
solutions comprising 10 mg/ml in 50 mM sodium phosphate buffer pH 6.2 were diluted with 
0.22 µm filtered PBS pH 7.4). As a negative control, proteins were also incubated in PBS pH 
7.4 for 8 weeks without any additives. After 2, 4 and 8 weeks, samples were taken for each 
incubation protocol (incubation protocol: the material the protein was exposed to) and analysed 
using the following techniques: Light obscuration (LO), turbidity, SE-HPLC, electrophoretic 
techniques (SDS-PAGE and capillary gel electrophoresis under reducing and non-reducing 
conditions), protein recovery, IEX, HIC, cIEF, extrinsic fluorescence and FT-IR. 
In the following, the results of the incubation study will be discussed separately in terms of 
colloidal, chemical and conformational stability. Furthermore, the phenomena of possible 
protein absorption onto lipids/PLGA surfaces will be discussed. Therefore, it is clearly stated, 
that the behaviour of the proteins will be evaluated covering two completely different aspects 
(protein stability and adsorption phenomena) in the presence of lipids/PLGA.  
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VIII.2.1.1 COLLOIDAL STABILITY OF PROTEINS 
The colloidal stability of incubated proteins was measured using different methods covering the 
formation of subvisible particles (LO, turbidity) and soluble aggregates (SE-HPLC, non-reducing 
denaturating electrophoresis). In previous studies, an incubation temperature of 37°C had been 
applied as it mimics the physiological temperature. Here, the incubation temperature was set to 
35°C due to the low Tonset (36.8°C) of the extrudates consisting of 100 % H12 as it was expected 
that an incubation temperature of 37°C would lead to a complete disintegration of the H12 rods. 
LIGHT OBSCURATION (LO) AND TURBIDITY 
The results of LO measurements are displayed in Figure VIII-1. The particle count of the 
negative controls (rods incubated in PBS) after 8 weeks of incubation was well below 
100 counts indicating that an elevated particle count at the protein containing samples was not 
due to disintegration (particle formation) of the rods. However, at the negative control of the H12 
rods, about 500 particles were counted pointing into the direction of a slight disintegration of the 
H12 rod even though the incubation temperature was below its Tonset. Nevertheless, particle 
counts of protein solutions were higher. It can therefore be hypothesised that the elevated 
particle count measured was based on protein aggregates. The mechanism and kinetics of 
particle formation is highly relevant and would deliver additional information [348, 349, 351, 374-
386], however, this aspect was not further investigated as it was beyond the scope of this work. 
As a control, protein solutions were incubated without any lipids/PLGA rods (Figure VIII-1). 
Particle counts were found to comprise the lowest levels; in maximum 650 particles were 
measured for Bevacizumab after 8 weeks of incubation. Turbidity measurements confirming this 
observation as the values were found to be the lowest ones for each protein ranging between 
0.73 (±0.07) and 1.07 (±0.08) (Table VIII-1). 
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Figure VIII-1: Cumulative particle count (> 1 µm) of protein solutions incubated with H12, D118 and RG 755 S 
rods and without any additives (PBS, negative control) after 8 weeks at 35°C and 40 rpm.  
 
Upon incubation with D118 and PLGA rods, both particle count and turbidity were very low for 
all proteins as illustrated by Figure VIII-1 and Table VIII-1. Merely, slightly elevated particle count 
and turbidity can be seen for Bevacizumab containing solutions. 
The highest particle counts can be identified when proteins were incubated with H12 rods. 
Particle counts for the protein containing samples were between 850 particles/ml (mAb) up to 
77.000 particles/ml for Aflibercept. Regarding the Aflibercept containing samples, the high 
particle count was caused by the complete disintegration of the H12 rods. Interestingly, 
disintegration of the H12 rod only occurred when Aflibercept was present. For mAb, 
Ranibizumab and Bevacizumab, H12 rods did not fully disintegrated although a partial 
«softening» and disintegration was observed. If incubated without any proteins (negative 
control), the H12 rods remained solid. Turbidity values were in line with particle measurements: 
for all proteins turbidity of protein solutions incubated with H12 showed the highest values 
ranging from 1.07 (±0.02) to 24.56 (±1.21). Again, the high value for Aflibercept samples 
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incubated with H12 rods (24.56 FNU ±1.21 FNU), was caused by the total disintegration of the 
H12 rod which was only observed for this protein.  
Table VIII-1: Turbidity of samples incubated with H12, D118 and RG 755 S rods and without any additives 
(PBS, negative control) after 8 weeks at 35°C and 40 rpm. Results are given in FNU. 
 PBS mAb Ranibizumab Bevacizumab Aflibercept 
PBS 0.53 (±0.03) 0.73 (±0.07) 0.73 (±0.01) 0.74 (±0.05) 1.07 (±0.08) 
H12 1.09 (±0.11) 1.07 (±0.02) 1.25 (±0.05) 2.36 (±0.14) 24.56 (±1.21) 
D118 0.56 (±0.03) 0.79 (±0.13) 1.13 (±0.03) 0.91 (±0.08) 1.35 (±0.09) 
RG 755 S 0.58 (±0.02) 0.89 (±0.05) 0.94 (±0.16) 1.01 (±0.12) 1.02 (±0.10) 
 
Both particle count and turbidity for proteins incubated with PLGA rods were comparatively low. 
That signifies that PLGA is more inert than the triglycerides tested here from a colloidal stability 
perspective. However, it should not be forgotten that proteins were incubated with the 
lipids/PLGA rather than encapsulated within the matrix material.  
When comparing H12 and D118 head-to-head, it is striking that both cumulative particle count 
and turbidity are clearly higher for H12 than for D118 for all proteins tested. As the particle count 
for H12 rods incubated in PBS (negative control) revealed less counts, a disintegration of the 
H12 rod due to the incubation close to Tonset was most likely not the cause for the elevated 
particles observed. In fact, it can be concluded that an interaction between proteins and H12 
took place. 
Based on these results, it can be assumed that even the protein itself might has an impact on 
lipid disintegration due to its amphiphilic character. For Aflibercept, even a complete 
disintegration of the H12 rods was observed.  
As additional factors, pH and surface-active additives (residues from the marketed formulations 
which were not removed by the dialysis) can possibly lead to disintegration of the H12 rods. As 
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the pH represents a critical parameter, the pH was monitored over 8 weeks and is displayed in 
the Appendix, Table XII-1. For all proteins, the pH value stayed constant (a change of a 
maximum of 0.12 was observed) over the complete incubation time. Furthermore, the pH of the 
protein containing samples was measured between 6.79 (Bevacizumab) and 7.00 
(Ranibizumab) at week 8. These results pointing into the direction that a different pH as possible 
source of H12 rod disintegration can be excluded. Since all proteins (except mAb) were 
originally formulated with PS 20 (III.1.1), the presence of surface-active additives should be 
considered. Although all marketed formulations were dialysed, small amounts of PS 20 were 
most likely still present within all formulations. Therefore, the disintegration of the H12 rods was 
probably not caused by surface-active additives. These theories were not further investigated 
and need to be thoroughly studied in future experiments. For instance, to distinguish between 
protein aggregates and particles with a lipidic origin, microflow imaging (MFI) would be a 
suitable method.  
Elevated particle count and turbidity could be explained by a potential partial unfolding of the 
proteins in presence of the highly hydrophobic surfaces the proteins were exposed to [387]. It 
is known, that partially unfolded proteins can act as nuclei for protein aggregation [350, 380, 
388] and therefore for the formation of small soluble and large insoluble aggregates. The surface 
charge distribution and presence of hydrophobic patches at proteins’ surface are also factors 
influencing the propensity to unfold. For instance, that could be a reason for the comparable 
high particle count for Bevacizumab samples. It has the highest tendency to interact with 
hydrophobic surfaces probably due to its propensity to unfold. This is caused by hydrophobic 
patches present at Bevacizumab`s surface. HIC analysis revealed the longest retention time for 
Bevacizumab, signifying the highest hydrophobicity of this protein compared to the other 
proteins. This would also explain the incomplete release patterns of Bevacizumab observed 
during in-vitro release studies described in chapter IV. 
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SE-HPLC AND ELECTROPHORETIC ANALYSIS 
The percentage of monomer content was monitored in samples collected after 0 (before 
incubation started), 2, 4 and 8 weeks. For the detailed course of monomer depletion upon 
incubation with lipid/PLGA rods, please see Appendix Figure XII-11. Protein recovery was 
assessed as well but will be discussed separately within VIII.2.1.4 as it is an indication for 
adsorption of proteins onto lipid/PLGA surfaces.  
Table VIII-2: SE-HPLC results of mAb incubated with H12, D118 and RG 755 S rods and without any additives 
(PBS, negative control) after 0 weeks (reference) and 8 weeks at 35°C and 40 rpm. Results are given in %. 
 Reference Week 8 
 Aggregates  Monomer  Fragments  Aggregates  Monomer  Fragments  
PBS 
1.11 (±0.13) 98.19 (±0.06) 0.69 (±0.07) 
0.63 (±0.16) 95.05 (±0.39) 4.34 (±0.22) 
H12 0.43 (±0.12) 89.88 (±0.29) 9.69 (±0.19) 
D118 0.45 (±0.16) 94.21 (±1.07) 5.34 (±0.98) 
RG 755 S 0.46 (±0.10) 93.61 (±0.17) 5.93 (±0.20) 
 
Table VIII-2 provides an overview of the monomer content of mAb upon incubation. 
Interestingly, the monomer content after 8 weeks of incubation with H12 rods dropped down to 
90 % compared to 93 % to 95 % if incubated with D118 or PLGA rods, respectively. The 
monomer loss for all incubation protocols was due to fragmentation but approximately 5 % more 
fragments were observed upon incubation with H12 rods. Formation of soluble aggregates was 
not detected. However, these differences were not seen by non-reducing denaturating SDS-
PAGE (Appendix, Figure XII-12). 
  
TRIGLYCERIDE-PROTEIN-INTERACTION STUDIES 
181 
Table VIII-3: SE-HPLC results of Bevacizumab incubated with H12, D118 and RG 755 S rods and without any 
additives (PBS, negative control) after 0 weeks (reference) and 8 weeks at 35°C and 40 rpm. Results are given 
in %. 
 Reference Week 8 
 Aggregates  Monomer  Fragments  Aggregates  Monomer  Fragments  
PBS 
2.90 (±0.04) 96.73 (±0.09) 0.38 (±0.11) 
4.25 (±0.16) 94.06 (±0.10) 1.69 (±0.06) 
H12 3.79 (±0.03) 94.16 (±0.23) 2.04 (±0.24) 
D118 4.34 (±0.08) 93.91 (±0.14) 1.75 (±0.06) 
RG 755 S 3.93 (±0.13) 94.26 (±0.11) 1.81 (±0.17) 
 
For Bevacizumab, the monomer content ranged between 93.9 % to 94.3 % after an 8-week 
incubation without any differences between lipids, PLGA and PBS, respectively (Table VIII-3). 
In contrast to mAb, the monomer loss can be traced back to the formation of soluble aggregates 
rather than the formation of fragments. Again, major differences between the 
aggregation/fragmentation profile as a function of the incubation protocol was not noticed as it 
was also confirmed by SDS-PAGE (Appendix, Figure XII-13).  
Table VIII-4: SE-HPLC results of Ranibizumab incubated with H12, D118 and RG 755 S rods and without any 
additives (PBS, negative control) after 0 weeks (reference) and 8 weeks at 35°C and 40 rpm. Results are 
displayed in %. 
 Reference Week 8 
 Aggregates  Monomer  Fragments  Aggregates  Monomer  Fragments  
PBS 
0.00 (±0.00) 98.66 (±0.31) 1.34 (±0.31) 
0.00 (±0.00) 97.93 (±0.35) 1.96 (±0.25) 
H12 0.00 (±0.00) 98.40 (±0.05) 1.60 (±0.05) 
D118 0.00 (±0.00) 99.06 (±0.21) 0.94 (±0.21) 
RG 755 S 0.00 (±0.00) 97.20 (±0.80) 2.80 (±0.80) 
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The monomer content of Ranibizumab after an incubation for 8 weeks in the presence of lipid 
or PLGA rods ranged between 97.2 % to 99.1 % meaning no differences were observed. If any, 
slightly more fragmentation might be observed (2.80 %) upon incubation with PLGA compared 
to the lipid rods (in maximum 1.60 %).  
Table VIII-5: SE-HPLC results of Aflibercept incubated with H12, D118 and RG 755 S rods and without any 
additives (PBS, negative control) after 0 weeks (reference) and 8 weeks at 35°C and 40 rpm. Results are given 
in %. 
 Reference Week 8 
 Aggregates  Monomer  Fragments  Aggregates  Monomer  Fragments  
PBS 
0.71 (±0.02) 99.29 (±0.02) 0.00 (±0.00) 
0.52 (±0.02) 99.48 (±0.02) 0.00 (±0.00) 
H12 2.56 (±0.00) 97.44 (±0.06) 0.00 (±0.00) 
D118 0.52 (±0.03) 99.48 (±0.03) 0.00 (±0.00) 
RG 755 S 0.54 (±0.07) 99.46 (±0.07) 0.00 (±0.00) 
 
The same scenario as described for mAb was also observed for Aflibercept: the monomer 
content stayed constant at 99.5 % for all incubation protocols except for samples incubated with 
H12 rods (decrease to 97.4 %), which was due to aggregation rather than fragmentation (Table 
VIII-5). These results were not confirmed by non-reducing denaturating SDS-PAGE (Appendix, 
Figure XII-14). 
In conclusion, for two proteins – mAb and Aflibercept - a H12 promoted monomer loss was 
noticeable. Interestingly, for mAb the monomer loss was caused by an elevated formation of 
fragments (Table VIII-2) whereas for Aflibercept the formation of soluble aggregates was the 
reason for enhanced monomer loss (Table VIII-5). However, fragmentation and aggregation, 
respectively, could not be confirmed by non-reducing denaturating SDS-PAGE (Appendix, 
Figure XII-12 and Figure XII-14). The reason for the monomer loss promoted by H12 rods 
remains to be investigated further. Another possibility could be impurities or contaminations of 
the H12 raw material with heavy metals which are known for their potency to induce protein 
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aggregation [371-373, 389-394]. To answer this question, ICP-AES analysis of all raw materials 
and extruded implants were analysed towards their heavy metal impurities (VIII.2.1.4). 
Neuhofer [185] already performed an incubation study with the same triglycerides used here 
but using another protein. He investigated native interferon (nIFN) and PEGylated interferon β-
1b. In terms of aggregation, he stated that «The formation of aggregates is slightly more 
pronounced in the presence of lipids in comparison with the pure buffer […]. In PBS buffer pH 
7.4 +0.1 % SDS a slight trend towards the formation of soluble aggregates is visible with 
increased incubation time. Also the presence of placebo extrudates slightly promotes the 
formation of aggregates […]» [185]. This is in accordance with our results even though interferon 
is different by molecular weight and structure compared to the proteins used within our study.  
VIII.2.1.2 CHEMICAL STABILITY OF PROTEINS 
In addition to physical stability analysis, proteins were also analysed towards chemical changes 
by IEX, HIC, reducing capillary gel electrophoresis, and cIEF.  
ION EXCHANGE CHROMATOGRAPHY (IEX) 
An IEX method was developed for the separation of the charge variants of mAb and 
Bevacizumab as described previously (III.2.6.5). As indicated in Figure VIII-2 A, the fingerprint 
of mAb was divided into 5 subspecies, whereas the signal of Bevacizumab was classified into 
4 different charge variants (Figure VIII-2 B). 
Table VIII-6 displays the results obtained after an 8-week incubation in PBS (negative control) 
or in presence of H12, D118, or RG 755 S rods, respectively. MAb`s main peak area was slightly 
more reduced upon incubation with the lipid/PLGA rods with lowest percentage upon incubation 
with D118 rods (approximately 2.5 % less compared to samples incubated for 8 weeks in PBS). 
The same was true for Bevacizumab: main charge variant showed the most decrease upon 
incubation with D118 rods (approximately 3 %).  
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Figure VIII-2: Exemplary chromatographic profile of (A) mAb and (B) Bevacizumab using a WCX column for 
separation of charge variants upon incubation in PBS at 35°C over 8 weeks. As indicated, the fingerprint of 
mAb was divided into 5 subspecies whereas the signal of Bevacizumab was classified into 4 different charge 
variants.  
 
The main charge variant of both proteins decreased distinctly upon incubation compared to the 
reference material: for mAb and Bevacizumab the percentage of main charge variant was 
halved after incubation. This result was expected, as an 8-week incubation at 35°C and 40 rpm 
represents relatively harsh environmental conditions leading to degradation [315, 395]. For both 
proteins, the retention time of the main peak was monitored additionally. A constant retention 
time underlines that the separation method was suitable to isolate differently charged 
subspecies which were formed during the incubation. Contrarily, a shift in retention time would 
point into the direction of differently charged subspecies which were not isolated by the 
separation method. In terms of mAb and Bevacizumab, the retention time of the main peak was 
found be to constant after 8 weeks of incubation irrespectively of the incubation protocol 
compared to the reference (Table VIII-6). 
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Table VIII-6: Area and retention time of the main charge variant of mAb and Bevacizumab after 8 weeks of 
incubation with H12, D118, or RG 755 S rods and in PBS (negative control) compared to the reference. 
 mAb Bevacizumab 
 
Main charge 
variant [%] 
Retention time 
main peak [min] 
Main charge 
variant [%] 
Retention time 
main peak [min] 
Reference 37.44 (±0.69) 29.95 (±0.05) 62.77 (±0.29) 28.88 (±0.01) 
PBS_week 8 20.36 (±0.05) 29.86 (±0.02) 39.40 (±0.70) 28.87 (±0.03) 
H12_week 8 19.56 (±0.10) 29.80 (±0.00) 38.47 (±0.57) 28.92 (±0.01) 
D118_week 8 17.86 (±0.20) 29.78 (±0.01) 36.45 (±0.12) 28.92 (±0.01) 
RG 755 S_week 8 19.21 (±0.14) 29.80 (±0.00) 37.81 (±1.16) 28.88 (±0.01) 
 
In general, both IgG1 antibodies formed more acidic rather than basic subspecies as shown in 
the chromatographic fingerprint (Figure VIII-2). Those chemical alterations include deamidation 
(asparagine, glutamine, c-terminal amides), cleavage of disulfide bonds, oxidation of proline, 
oxidation of phenylalanine to o-tyrosine, oxidation of tryptophan (formation of oxindolyalanine, 
dioxindolyalanine, kynurenine, N-formylkynurenine), conversion of arginine to ornithine and/or 
citrulline or hydrolysis [337]. For both proteins, the formation of covalent bonds was not detected 
as measured by reducing capillary gel electrophoresis (Appendix, Figure XII-15 A and B). 
However, most degradation was seen at the D118 incubated samples. 
HYDROPHOBIC INTERACTION CHROMATOGRAPHY (HIC) 
Charge variants of Ranibizumab and Aflibercept were analysed applying HIC (III.2.6.6). The 
signal of Ranibizumab was sectioned into two areas (Figure VIII-3 A). Area 1, the area of the 
main charge variant, decreased marginally over the incubation time, whereas a minimal 
increase of area 2 was observable.  
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Figure VIII-3: Exemplary chromatographic profile of (A) Ranibizumab and (B) Aflibercept applying a 
MAbPac™ HIC-10 column for separation of charge variants upon incubation in PBS for 8 weeks at 35°C. As 
indicated, the fingerprint of Ranibizumab and Aflibercept was divided into 2 species. 
 
The formation of hydrophilic isoforms eluting at approximately 9.5 min was noticeable. In 
addition, a shift of the main peak to shorter retention times pointed into the direction of more 
hydrophilic isoforms. The signal of Aflibercept featured by a shift to longer retention times, 
representing more hydrophobic variants arisen between week 2 and week 4 (Figure VIII-3 B). 
Table VIII-7 displays the percentages of Ranibizumab`s main charge variant after the 8-week 
incubation. After 8 weeks, the main charge percentage decreased by 8 % in average compared 
to the reference. A difference upon incubation with lipids, PLGA or PBS was not detected as 
the percentage of the main charge differed less than 1 % from each other. However, the elution 
of the main peak shifted to shorter retention times from 18.48 min (reference) to 17.13 min and 
17.89 min after incubation. The main peak eluted earliest upon incubation with D118 rods.  
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Table VIII-7: Area and retention time of the main charge variant of Ranibizumab and Aflibercept after 8 weeks 
of incubation with H12, D118, or RG 755 S rods and in PBS (negative control) compared to the reference. 
 Ranibizumab Aflibercept 
 
Main charge 
variant [%] 
Retention time 
main peak [min] 
Main charge 
variant [%] 
Retention time 
main peak [min] 
Reference 99.26 (±0.11) 18.48 (±0.01) 96.89 (±0.44) 12.25 (±0.01) 
PBS_week 8 92.18 (±0.10) 17.89 (±0.11) 93.78 (±0.43) 12.91 (±0.12) 
H12_week 8 91.87 (±0.36) 17.74 (±0.02) 96.06 (±0.45) 12.73 (±0.01) 
D118_week 8 91.41 (±0.47) 17.13 (±0.08) 96.16 (±0.80) 12.82 (±0.03) 
RG 755 S_week 8 91.25 (±0.26) 17.58 (±0.13) 96.44 (±0.27) 12.71 (±0.03) 
 
Conversely, the main charge percentage of Aflibercept had the lowest percentage when 
incubated in PBS without any additives - approximately 3 % less compared to the samples 
incubated with the lipid/PLGA rods (93 % versus 96 %). However, the retention time of the main 
peak shifted to longer retention times from 12.25 min (reference) to 12.8 min in average (Table 
VIII-7). This demonstrates the formation of more hydrophobic subspecies interacting more with 
the hydrophobic column material.  
Interestingly, Ranibizumab and Aflibercept behaved completely different. The Ranibizumab 
chromatographic peak migrated to shorter retention times, especially for samples incubated with 
D118 (Figure VIII-3, Table VIII-7). This could be due to possible chemical reactions triggered by 
D118, for instance oxidation (tryptophan, methionine, proline, histidine, phenylalanine), 
isomerisation (e.g. aspartic acid isomerisation), N- and O-glycosylation, serine fucosylation, 
deamidation (e.g. asparagine, glutamine, C-terminal amides), hydrolysis or β-elimination [337]. 
Contrarily, the main peak of Aflibercept shifted to longer retention times, which is an indicator 
for the formation of more hydrophobic subspecies which can be possibly promoted by chemical 
alterations or partial unfolding. When the protein unfolds, hydrophobic patches arise at the 
surface of the protein, thereby changing its overall surface charge and making it more 
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hydrophobic [346, 350, 380, 396-403]. However, unfolding was not detected by FT-IR (see also 
VIII.2.1.3). Alternatively, chemical reactions like oxidation (formation of disulfide bonds) or 
isomerisation (e.g. asparagine to succinimide) [337] are conceivable. For Aflibercept, results 
from reducing denaturating capillary gel electrophoresis suggests the formation of disulfide 
bonds in presence of the PLGA rod: a higher percentage of LMW species and less heavy chain 
percentage was found (Appendix, Figure XII-15 D).  
Finally, the question raises if the slight differences which were observed were caused by the 
different triglycerides/PLGA the proteins were exposed to. Interestingly, the main peak area for 
mAb, Bevacizumab and Ranibizumab decreased most in presence of D118. 
CAPILLARY ISOELECTRIC FOCUSSING (CIEF) 
The investigations towards chemical modifications using IEX and HIC revealed slightly more 
chemically modified subspecies when proteins were incubated with D118 rods. To verify the 
obtained data, cIEF was applied for Ranibizumab and Bevacizumab as an orthogonal method, 
as it is a more precise and more sensitive method than IEX and HIC and has been widely used 
in protein characterisation [404-408].  
The Ranibizumab signal was classified into an acidic isoform, the main isoform (main peak) and 
a single basic isoform, whereas for Bevacizumab, two different acidic isoforms were identified. 
As Figure VIII-4 A illustrates, the 8-week incubation promoted the formation of mainly more 
acidic subspecies by a simultaneous depletion of the main peak. Addition of lipid/PLGA rods to 
the Ranibizumab containing solution resulted in more acidic isoforms upon incubation with D118 
rods (approximately 5 %); all other results were comparable to each other. Consequently, it can 
be concluded that D118 promoted the formation of acidic isoforms. The percentage of basic 
isoforms was not affected. These data confirm the results obtained by HIC, where the shortest 
retention time of the main peak (more hydrophilic subspecies) was observed for samples 
incubated with D118 rods. It can be speculated that these changes were caused by deamidation 
or oxidation [337]. For Bevacizumab, Figure VIII-4 B illustrates that the area of the basic isoform 
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was more pronounced (approximately 4 %) in the presence of H12 rods. This finding contrasts 
with the obtained IEX results, where D118 was identified to promote most chemical alterations. 
Besides H12 and D118 rods, Ranibizumab and Bevacizumab were incubated with RG 755 S 
rods as well. For both proteins, levels of acidic and basic isoforms were in the same course as 
measured for both lipids and the negative control.  
Overall, for both proteins differences in areas between the different incubation protocols are 
negligible. A decrease in main charge variant on account of more acidic isoforms compared to 
the reference was detected but differences between samples incubated with lipids/PLGA or 
PBS were not observed. 
 
Figure VIII-4: Results of cIEF measurements of (A) Ranibizumab and (B) Bevacizumab. Protein containing 
solutions were incubated over 8 weeks in presence of H12, D118, or RG 755 S rods, respectively, or without 
any additives (PBS, negative control).  
 
Neuhofer already addressed the chemical stability of proteins upon incubation with lipids. The 
level of oxidized IFN β-1b in presence of lipids was investigated applying RP-HPLC. Within his 
work, he demonstrated that up to 20 % more oxidized species were formed upon the incubation 
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with lipid rods consisting of H12 and D118 in comparison to PBS. To clarify the origin of the 
elevated oxidation levels, he incubated nIFN β-1b with H12, D118 and paraffin wax rods over 
7 days. The highest oxidation levels were found upon incubation with D118 rods. This is in 
accordance with the results reported by us even though the proteins used were completely 
different by structure.  
The lipid-induced oxidation of proteins has already been described in literature. During 
peroxidation of lipids, unsaturated lipid species can form peroxides or radicals which can react 
with proteins. For instance, lipoxidation [409] is an important factor in atherosclerosis [410, 411]. 
It is well known that lipoxidation is often catalysed by metal impurities, as described by Wills 
[412] where oxidized unsaturated fatty acids inhibited specific enzymes. The lipids used within 
the present work were all saturated C12 to C18 triglycerides and therefore not prone to oxidation 
or lipoxidation. It was proven that even at high temperatures, an oxidation of saturated fatty 
acids (and their corresponding esters) did not correlate with the chain length of the triglycerides 
[185]. This means that the chemical changes, which were observed upon incubation with D118 
rods (consisting of tristearin), were not due to a preferred autoxidation of stearic acid. However, 
most chemical changes were observed in the presence of D118. In summary, it could be 
speculated that the presence of impurities was the reason for the increase in protein oxidation. 
As this is only speculative, it would be worth to invest more efforts to answer this question. As 
a follow-up study to the presented results, the presence of heavy metal was analysed as 
described in VIII.2.1.4. 
VIII.2.1.3 CONFORMATIONAL STABILITY OF PROTEINS 
Secondary structure analysis applying FT-IR was performed. Spectra were recorded of the bulk 
material (defined as reference) and of the samples after 8-week incubation in PBS (negative 
control) or in the presence of H12, D118, or RG 755 S rods, respectively.  
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Figure VIII-5: FT-IR spectra of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept recorded after 
8 weeks of incubation in PBS (negative control) or with H12, D118 or RG 755 S rods compared to reference. 
 
FT-IR spectra of Ranibizumab and Aflibercept did not show any deviations, neither in band 
intensity nor in band wavenumber, therefore suggesting that the proteins were conformationally 
stable over the incubation period and that the presence of lipids or PLGA did not promoted 
unfolding (Figure VIII-5 B, Figure VIII-5 D).  
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Figure VIII-5 A shows the FT-IR spectra of mAb recorded between 1600 cm-1 and 1700 cm-1. 
The amide I band, representing the β-sheet structure [340, 343], can be identified between 
1635 cm-1 and 1645 cm-1. The single peak present at the reference (1635 cm-1) turned into a 
split peak with a left side shoulder at approximately 1645 cm-1 which was most pronounced for 
the samples which had been in contact with RG 755 S. Additionally, the band intensity at 
1680 cm-1 and 1615 cm-1 indicated protein unfolding events [339]. Shifts towards higher 
wavenumbers represent unordered random coil like structures [338]. On the expense of regular 
structures, the formation of intermolecular hydrogen-bonded antiparallel β-sheet structures 
indicated partial unfolding of the mAb [342]. Changes in the secondary structure of mAb were 
also apparent when incubated with H12 and D118, but most pronounced for RG 755 S. In 
particular, an additional band at 1645 cm-1 was observed.  
Conformational changes were also observed for Bevacizumab. In Figure VIII-5 C, the FT-IR 
spectra of Bevacizumab reference and samples measured after 8 weeks incubated with H12, 
D118 or RG 755 S rods are given. Bevacizumab`s secondary structure changed slightly but a 
difference between the differently incubated samples was not observed.  
As an orthogonal method, extrinsic fluorescence was utilised using a Bis-ANS assay. In theory, 
Bis-ANS interacts with hydrophobic patches present at the protein surface, which leads to an 
increased fluorescence signal [380, 413-417]. If an enhanced signal is observed, it can be 
concluded that hydrophobic patches were formed upon partial unfolding. However, extrinsic 
fluorescence measurements did not confirm FT-IR results, as an enhanced signal was only 
measured for the positive control (proteins were exposed to 80°C and 400 rpm for 10 min) 
(Appendix, Figure XII-16). 
VIII.2.1.4 ADSORPTION OF PROTEINS ONTO LIPID/PLGA SURFACES 
To study absorptive effects of proteins on lipid/PLGA surfaces, protein recovery was measured 
via SE-HPLC assessing the AUC of the protein signal including the signal of soluble aggregates, 
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monomer and fragments. For the detailed course of protein recovery upon incubation with 
lipid/PLGA rods, please see Appendix Figure XII-17. 
The recovery of mAb did not change during incubation irrespective of the material the protein 
was exposed to (Table VIII-8). Recovery was measured with 101 % in general, therefore, no 
absorption of the mAb to the lipid/PLGA rods was observed.  
The protein recovery of Ranibizumab was characterised by a loss of recovery during incubation, 
especially if incubated with D118 rods (84.6 %). But also, protein recovery at the negative 
control decreased to 92 % within 8 weeks.  
Table VIII-8: Protein recovery of mAb, Ranibizumab, Bevacizumab, and Aflibercept after an 8-week incubation 
in PBS (negative control) or with H12, D118 or RG 755 S rods, respectively, measured by SE-HPLC. 
 PBS H12 rods D118 rods RG 755 S rods 
mAb 101.84 (±3.88) 101.75 (±1.80) 101.52 (±1.73) 102.83 (±0.13) 
Ranibizumab 91.99 (±0.44) 98.99 (±1.49) 84.56 (±1.57) 96.27 (±1.27) 
Bevacizumab 101.56 (±0.64) 94.08 (±0.82) 99.13 (±1.79) 100.59 (±1.53) 
Aflibercept 96.36 (±2.53) 80.65 (±2.18) 95.40 (±1.37) 95.16 (±0.42) 
 
Protein recovery for Bevacizumab and Aflibercept remained rather constant over 8 weeks 
regarding D118 and RG 755 S rods. More importantly, the recovery for both proteins was found 
to be 94 % (Bevacizumab) and 81 % (Aflibercept) when exposed to H12 rods.  
Neuhofer also addressed protein recovery within his studies, showing a correlation between 
hydrophobicity of the protein (interferon β-1b in its native state and PEGylated interferon) and 
protein recovery. A loss of protein recovery of nIFN β-1b of 50 % already after 7 days of 
incubation with lipid rods was demonstrated [185]. He also measured protein recovery of nIFN 
β-1b after incubation with H12/D118 rods, and rods consisting of pure H12 and D118. After 
7 days of incubation with H12/D118, recovery was only 50 % compared to the rods consisting 
of pure H12 (20 % loss) and D118 (25 % loss). 
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Lipid-protein-interactions were also studied by Even focussing on interactions of peptides 
(having different charges and hydrophobicity) and the lipids D114 (trimyristin), soybean lecithin 
and cholesterol [186]. Even concluded that neither the size nor the hydrophobicity of the 
peptides allows to predict the release behaviour or the interactions with the lipids, assuming that 
the three-dimensional protein structure should also be taken into account. 
Especially for Bevacizumab and Aflibercept, distinct adsorptive phenomena were observed. As 
the same phenomenon can be observed for different protein formats described by Neuhofer 
and us, it can be speculated that adsorption of proteins to triglyceride surfaces might be a 
function of protein hydrophobicity. When considering adsorptive phenomena, the isoelectric 
point of the proteins is of special interest as it provides information on the surface charge of a 
protein at a given pH [418-421]. The theoretical isoelectric points of the studied proteins were 
given with 8.3 (mAb), 8.8 (Ranibizumab), 8.8 (Bevacizumab) and 8.2 (Aflibercept) according to 
Hirvonen et al. [422]. The authors calculated the theoretical values using ExPASy. For mAb, the 
isoelectric point was determined experimentally via isoelectric focusing. Since the isoelectric 
points of the proteins were very similar, it can be considered that they were all positively charged 
at the incubation pH of 7.4. Therefore, differences in the overall net charge of the surface were 
most likely not responsible for the different behaviour. Rather than the net charge of the overall 
surface, isolated hydrophobic areas on the protein surface (hydrophobic patches) might be a 
driving factor for protein adsorption. These «hydrophobic patches» have a higher density of 
hydrophobic amino acids (alanine, leucine, isoleucine, phenylalanine, tryptophane) than other 
regions of the protein and are not affected by the surrounding pH in their hydrophobicity. To 
verify this hypothesis, further experiments would be needed facing the three-dimensional 
structure of the proteins. 
It should be stated that beyond diffusion and erosion, also the adsorption and desorption of the 
proteins to the highly hydrophobic lipid matrix should be considered also possibly explaining the 
different sustained release patterns observed (chapter IV). For instance, Ranibizumab is more 
hydrophobic than Aflibercept because it interacts more with the hydrophobic stationary phase 
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during HIC (Figure VIII-3, Table VIII-7). This might be a reason for a more sustained release of 
Ranibizumab compared to Aflibercept (Figure IV-11), even though Ranibizumab is smaller in 
size. 
 
VIII.2.2 METAL IMPURITIES AND THEIR IMPACT ON PROTEIN STABILITY  
During the preparation process of implants, many sources could theoretically act as an origin 
for possible contaminations of the material with traces of heavy metals. For instance, extruder 
parts, being in contact with the material during extrusion, are possible sources for metal 
abrasions. It is well-known that heavy metals can promote protein degradation [389, 390, 393]. 
In the present study, the level of diverse metals (Al, Co, Cr, Cu, Fe, Mn, Ni, Pb, Zn) was 
measured within the raw material (lipids, HP-β-CD), protein lyophilisates and extruded implants 
manufactured with both extruders (Table VIII-9). The samples were analysed according to 
III.2.6.12 using ICP-AES. Levels of titanium (serves as a catalyst during the bleaching step of 
triglyceride production) were not evaluated, as it is regularly monitored by Cremer Oleo. The 
certificates provided by Cremer Oleo showed that the titanium content was less than 1 ppm 
measured by a suitable method included in the European Pharmacopoeia (Ph. Eur. 2.2.23). 
The results of the ICP-AES analysis are displayed in Table VIII-9 as milligram heavy metal per 
gram of sample. Levels for all elements were below the limit of detection (LOD) and are therefore 
not displayed in Table VIII-9, except for aluminium, were traces were identified. Within 
Ranibizumab, Bevacizumab and Aflibercept protein lyophilisates, aluminium was detected. 
Aluminium was also found in Witepsol H12. Consequently, aluminium was also found in all 
extruded implants, with the highest amount of 3 µg aluminium per implant. 
To clarify if aluminium was a driving force for protein degradation within the lipid implants, 
protein solutions were incubated with highest aluminium content found (0.111 µg aluminium per 
mg protein). 
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Table VIII-9: Overview of samples analysed towards metal content with ICP-AES. Only results for aluminium 
content are displayed as for all other metals the level was below the LOD. Results are given in mg/g.  
Sample code Sample description 
Concentration aluminium 
[mg/g] 
#1 Lyophilisate mAb < LOD 
#2 Lyophilisate Ranibizumab 0.0348 
#3 Lyophilisate Bevacizumab 0.0233 
#4 Lyophilisate Aflibercept 0.2350 
#5 HP-β-CD < LOD 
#6 H12 < LOD 
#7 H12A < LOD 
#8 Witepsol H12 0.0051 
#9 Dynasan® D118 < LOD 
#10 SLI produced on a MiniLab® extruder (mAb) 0.0088 
#11 SLI produced on a MiniLab® extruder (Ranibizumab) 0.0685 
#12 SLI produced on a MiniLab® extruder (Bevacizumab) 0.0870 
#13 SLI produced on a MiniLab® extruder (Aflibercept) 0.1045 
#14 SLI produced on a ZE-5 mini-extruder (mAb) 0.1080 
#15 SLI produced on a ZE-5 mini-extruder (Ranibizumab) 0.0585 
#16 SLI produced on a ZE-5 mini-extruder (Bevacizumab) 0.0560 
#17 SLI produced on a ZE-5 mini-extruder (Aflibercept) 0.0435 
 
According to Table VIII-9, the highest aluminium content was found to be 0.1080 mg/g. Based 
on the average weight of an SLI (dimensions of 1.5 mm x 15 mm considered), which is 30.7 mg, 
in theory 3.2 µg aluminium per SLI were found. This amount aluminium is equal to 0.1 µg 
aluminium per mg protein (protein formulated 1:1 [w/w] with HP-β-CD). To evaluate, if an 
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aluminium content of 3.2 µg per SLI can cause protein degradation and therefore provide an 
explanation for protein instability observed during release (chapter VI), an incubation study with 
different aluminium concentrations was performed. Even though the study was performed in the 
liquid state, which cannot be transferred 1:1 to the dry state (protein lyophilisate incorporated 
into SLIs and not being released), it shall provide a first impression what could have happened 
within the SLIs. Protein solutions at a concentration of 1.0 mg/ml (diluted from stock solutions 
comprising 10 mg/ml in 50 mM sodium phosphate buffer pH 6.2 with PBS pH 7.4) were spiked 
with aluminium (as AlCl3*6H20) to obtain a final concentration of 0.1 µg/ml (maximum level found 
by ICP-AES) and 1.0 µg/ml (positive control). As negative control, non-spiked protein solutions 
were incubated. Samples were incubated for 4 weeks at 37°C in a horizontal shaker (40 rpm) 
and samples were analysed applying LO, SE-HPLC, IEX and HIC. 
At a concentration of 0.1 µg/ml Al3+, particle count was not elevated for all proteins compared 
to negative control (PBS). At the ten times higher concentration of Al3+ (positive control), particle 
count was higher for all proteins pointing towards metal induced formation of subvisible 
particles. 
Table VIII-10: Cumulative particle count (> 1 µm) of protein solutions spiked with different concentrations of 
Al3+ incubated over 4 weeks at 37°C and 40 rpm. 
 mAb Ranibizumab Bevacizumab Aflibercept 
PBS 380 (±203) 141 (±104) 806 (±175) 397 (±138) 
0.1 µg/ml 241 (±42) 153 (±34) 607 (±110) 276 (±12) 
1.0 µg/ml 489 (±110) 2134 (±189) 1899 (±240) 1166 (±168) 
 
The monomer content of all tested proteins did not differ after 4 weeks upon incubation with 
Al3+. Even in the positive control, no impact of aluminium to monomer content was observed.  
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Protein recovery of mAb and Ranibizumab were unaffected, whereas protein recovery of 
Bevacizumab and Aflibercept decreased to 77 % and 57 %, respectively, already at 
concentrations of 0.1 µg/ml Al3+. 
 
Figure VIII-6: (A) Monomer content and (B) protein recovery of proteins spiked with different concentrations 
of Al3+ incubated over 4 weeks at 37°C and 40 rpm. 
 
Supplemental to particle count and SE-HPLC, IEX and HIC were applied to detect possible 
metal induced chemical alterations compared to the negative control (Table VIII-11). For all 
proteins, the percentage of main peak area was not negatively affected by the addition of Al3+, 
not even for the positive control with the ten times higher aluminium concentration. 
In summary, aluminium-induced protein degradation was not observed; neither elevated particle 
count, nor higher rates in monomer loss were detected. Likewise, more pronounced chemical 
degradation was not detected. 
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Table VIII-11: Main peak area in % of proteins spiked with different concentrations of Al3+ incubated over 
4 weeks at 37°C and 40 rpm. As control, samples were incubated in PBS. For mAb and Bevacizumab, main 
peak percentage was assessed by IEX whereby main peak area for Ranibizumab and Aflibercept was 
assessed using HIC. 
 mAb Ranibizumab Bevacizumab Aflibercept 
Reference 35.61 (±0.18) 99.26 (±0.11) 62.77 (±0.29) 96.89 (±0.44) 
PBS 30.13 (±0.36) 94.46 (±0.08) 53.70 (±0.68) 98.63 (±0.12) 
0.1 µg/ml 30.89 (±0.44) 95.47 (0.17) 54.79 (±1.61) 96.08 (±1.40) 
1.0 µg/ml 33.35 (±0.35) 96.48 (±0.13) 53.28 (±0.35) 95.68 (±0.69) 
 
On the contrary, protein recovery of Bevacizumab and Aflibercept decreased to 77 % 
(Bevacizumab) and 57 % (Aflibercept), respectively, compared to the negative control. As no 
elevated particle count was observed at this aluminium level, metal induced formation of large 
sized and insoluble aggregates forming precipitates was most likely. Those precipitates 
precipitated out of the solutions and were therefore not measured by LO. Metal induced 
aggregation (also forming large sized particles) has already been described in literature [373, 
394], which supports our explanation. Our explanation was further confirmed by the observation 
of milky sediments. 
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VIII.3 CONCLUSION 
Triglyceride-protein-interactions were studied within an incubation study, where extruded rods 
consisting of 100% H12, D118, or Resomer® RG 755 S were incubated with protein solutions 
over 8 weeks at 35°C and 40 rpm. Proteins were characterised towards colloidal, chemical and 
conformational stability as well as adsorptive effects upon incubation with either triglycerides or 
PLGA rods.  
If incubated with H12 rods, elevated particle count and turbidity were observed for all proteins, 
especially for Aflibercept. H12 rods partially disintegrated upon incubation with proteins (total 
disintegration upon incubation with Aflibercept). It can be therefore speculated that the 
disintegration of the H12 rod could be due to the amphiphilic character of the proteins. For mAb 
and Aflibercept, monomer content decreased upon contact with H12, contrarily, monomer 
content of Ranibizumab and Bevacizumab stayed constant. For Bevacizumab and Aflibercept, 
protein recovery decreased over time, resulting in a recovery of 94 % (Bevacizumab) and 81 % 
(Aflibercept) after 8 weeks. This points into the direction of protein adsorption onto H12. 
Interestingly, for these two proteins highest particle count (suggesting the formation of subvisible 
particles) was observed. Regarding chemical and conformational stability, no differences were 
observed. Finally, it can be concluded that proteins partly interacted with H12 resulting in the 
formation of subvisible particles, the loss of monomer and adsorptive effects.  
For D118 rods, another picture can be drawn. In terms of physical and conformational stability, 
no distinct differences between the proteins were noted. However, mAb and Ranibizumab 
comprised more chemical isoforms on the account of a loss of main charge variant in the 
presence of D118 (not seen upon contact with H12). It is noteworthy, that exclusively 
Ranibizumab recovery decreased (84.6 % after 8 weeks) compared to the other proteins. Since 
no elevated particle count or turbidity was observed, it can be assumed that the loss in protein 
recovery was due to adsorption onto D118 rather than formation of particles. Overall, interaction 
between D118 and proteins was less compared to H12.  
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Proteins were incubated with rods consisting of Resomer® RG 755 S. Overall, proteins revealed 
no reduced physical, chemical and conformational stability. Additionally, protein recovery was 
not affected. These results are in a strong contrast to the results described within chapter 
VII.2.2. There, substantial physical and chemical instabilities were observed when proteins were 
encapsulated within a PLGA matrix. Here, proteins were incubated with placebo PLGA rods for 
sure not fully mimicking the environment within a PLGA matrix.  
Studies towards heavy metal impurities revealed detectable levels only of aluminium within the 
protein lyophilisates and H12 and consequently also in extruded SLIs. However, particle 
formation, monomer content and main charge variant were not negatively affected by the 
presence of Al3+ at a concentration of 3.2 µg per implant (highest Al3+ concentration found). 
However, protein recovery of Bevacizumab and Aflibercept decreased in the presence of Al3+. 
Finally, it can be concluded that proteins interacted most with H12 but also partly with D118. 
Thereby, the observed instabilities were not caused by heavy metal impurities of the raw 
materials. Other impurities possibly being present at the lipid raw material (peroxides or 
aldehydes) could be a further reason for protein degradation. 
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IX. PRESSURE MEASURMENT AS A NEW 
ANALYTICAL TOOL FOR TWIN-SCREW 
EXTRUSION OF SOLID LIPID IMPLANTS 
IX.1 INTRODUCTION 
This chapter is aimed to systematically investigate the extrusion process on a ZE-5 mini-
extruder. The formulation comprising 10 % protein lyophilisate and a lipid matrix consisting of 
50 % H12 and 50 % D118 (from now on referred to as 50:50 lipid composition) was used as 
starting point. The mAb as model protein for in-vitro release was used. The ZE-5 mini-extruder 
was equipped with a resistance strain gauge located at the outlet plate of the extruder barrel as 
an online pressure monitoring tool. This allows to measure extrusion forces in real time. The 
impact of process parameters such as extrusion speed, temperature, and lipid composition on 
implant properties was studied. Bending strength, true density and microscopic appearance of 
extruded implants was assessed. Extrusion temperature (33°C to 42°C), screw speed (40 rpm 
to 80 rpm) and the lipid composition (30 % to 70 % of each triglyceride) were modified. 
Furthermore, SLIs were double-extruded to evaluate this technique as a potential tool to further 
modify implant properties.  
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IX.2 DISTINCTION BETWEEN HOT MELT EXTRUSION (HME) AND SOLID LIPID 
EXTRUSION (SLE) 
It is important to differentiate between HME and SLE. Generally, synthetic polymers such as 
EVA, PEO, PLA, or PLGA are used for HME, and processing takes place at temperatures far 
above 100°C [423]. This is normally performed at 15°C to 60°C above the Tm or Tg [424] of the 
used material. At these process temperatures, the material is completely molten and in a liquid-
like state. For SLE, mainly fatty acids (myristic acid, stearic acid), polyoxylglycerides (Gelucire, 
Compritol) or acylated glycerides (Dynasan, Imwitor, Precirol ATO) [425] have been used. 
Irrespective of the lipid, the extrusion temperature is below the Tm of the components, which 
leads to a semi-solid state of the material.  
Regarding HME, the process has been thoroughly characterised and the impact of process 
parameters – mixing [426], shape of screws [427], impact of degassing [428], screw speed, 
effect of plasticisers, process temperature - on product properties has been described within 
numerous publications [424, 429]. 
For SLE, research focused on release profiles and underlying release mechanisms [155, 157, 
158, 182, 299, 430], the solid-state behaviour [161, 163], effect of release modifiers [149, 160, 
177, 178] or in-vivo-in-vitro correlations [168] for various drugs [163, 182, 236, 299] including 
pharmaceutical relevant proteins such as rh-interferon-α [178] and interleukin-18 [174]. 
However, the extrusion process in pharmaceutical applications itself has not been investigated 
in depths until now.  
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IX.3 RESULTS AND DISCUSSION 
IX.3.1 ANALYSIS OF PRESSURE-TIME CURVES DURING EXTRUSION  
Pressure curves were recorded for each batch produced on the extruder. A representative 
pressure profile is displayed in Figure IX-1, illustrating the course of pressure during an 
extrusion run of a 50:50 composition at 35°C and 60 rpm. The pressure profile can be separated 
in four different phases, namely the feeding phase (I), compacting phase (II), implant formation 
phase (III) and termination of implant formation (IV). During section I, the material is fed via a 
feeding tube and pestle to the inlet of the barrel (Figure III-6 C). During this step, no pressure 
at the outlet plate is measured because the material did not yet reach the outlet plate. During 
this time, the components are merged, melted, admixed, and pre-compressed as a function of 
screw speed, extrusion temperature and extrudates’ formulation.  
 
Figure IX-1: Representative extrusion pressure profile of a 50:50 lipid composition extruded at 35°C and 
60 rpm. The extrusion run can be divided into four different phases, namely (I) feeding, (II) compacting, (III) 
implant formation and (IV) termination of implant formation. 
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In phase II, the material has reached the end of the extruder barrel. The material has been 
transported to the space between the end of the screws and the outlet plate. Due to this, first 
little pressure peaks can be observed (Figure IX-1, phase II). While the pressure is increasing, 
lipid strand formation already started. 
During the plateau phase, lipid strand formation takes place (Figure IX-1, phase III). An initial 
pressure peak can be observed followed by a phase where the extrusion pressure reaches a 
steady-state plateau. When no further material is fed to the inlet of the barrel, the steady-state 
is no longer maintained, which is indicated by a continuous decrease in pressure until it reaches 
a plateau again. Once the pressure started to decrease, implant formation started to slow down 
and stopped subsequently. The low plateau represents the end of the extrusion run (Figure IX-1, 
phase IV). For calculation of the average extrusion pressure, the mean values measured during 
the steady-state plateau were taken. The comparatively low remaining pressure after the run 
has been completed (approximately 500 kPa for the run depicted in Figure IX-1) is generated 
by the remaining material left behind within the barrel. 
 
IX.3.2 INVESTIGATION OF INNER-STRAND HOMOGENEITY 
The inner-strand homogeneity was assessed by extruding a 50:50 lipid composition at 35°C 
and 40 rpm, which represents the standard extrusion settings within this study (Figure IX-2). 
The resulting lipid strand had a total length of approximately 130 cm to 140 cm. For this run, 
implant formation (phase III) started after approximately 40 sec and lasted for 40 sec which 
equates an extrusion speed of 3.4 cm/sec. The last 15 cm to 20 cm were discarded and not 
further analysed since the implant strand formed during this phase (phase IV) was 
inhomogeneous and lipid strand formation was non-continuous. Thus, the first 120 cm were 
divided into four sections, each 30 cm in length. From each section four replicates (15 mm in 
length) were taken randomly.  
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Each phase was analysed towards true density, mechanical properties, and in-vitro release of 
the mAb. The average extrusion pressure was calculated by taking all pressure values into 
consideration measured during the steady-state plateau. For this particular run, the average 
pressure was calculated between 50 sec and 80 sec (Figure IX-2) resulting in an average 
pressure of 975 kPa ±74 kPa. Even if the pressure reaches a constant level during the implant 
formation section, it is not self-evident that the characteristics of the implants formed during this 
period comprise the same properties, e.g. true density or release patterns. Importantly, it should 
be noted that the first section (0 cm to 30 cm) was produced while the extrusion pressure 
plateau was not yet reached (45 to 50 sec, Figure IX-2) whereas all other sections (30 cm to 
120 cm) were extruded during the steady-state phase (between 50 sec and 80 sec of the run). 
  
Figure IX-2: Representative extrusion pressure profile of a 50:50 lipid composition extruded at 35°C and 
60 rpm. 
 
As shown in Table IX-1, both true density and bending strength measurements had lower values 
for the first section (0 cm to 30 cm) compared to the following three sections. The sections taken 
between 30 cm to 120 cm were comparable in terms of true density and bending strength. 
Additionally, cumulative release of the mAb was monitored over 4 weeks. Release from SLIs 
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taken from section 30 cm to 120 cm was comparable ranging from 45.62 % to 46.21 % after 
4 weeks. Release from the first section (0 cm to 30 cm) was faster (64.66 % after 4 weeks). 
Consequently, within the following experiments, the first 30 cm were discarded and not used for 
further analysis. 
Table IX-1: Summary on true density, bending strength, and release of mAb for the different sections of the 
lipid strand. 
Section 
True density 
[g/cm3] 
Bending strength  
[N] 
Cumulative release of mAb 
after 4 weeks [%] 
0 cm to 30 cm 0.974 (±0.004) 0.757 (±0.169) 64.66 (±2.89) 
30 cm to 60 cm 1.032 (±0.002) 1.967 (±0.220) 45.86 (±1.83) 
60 cm to 90 cm 1.031 (±0.002) 2.090 (±0.381) 45.62 (±3.23) 
90 cm to 120 cm 1.030 (±0.001) 2.064 (±0.387) 46.21 (±2.25) 
 
The low standard deviation, especially with regards to the in-vitro release, indicated that the 
protein was homogenously distributed within the lipid matrix. This means that the preparation 
technique provides an adequate distribution of the individual components even though the 
screws are rather short and were not equipped with any special mixing and kneading zones. 
Additionally, a pre-melting or full melting of the lipids is not necessary either.  
Generally, it is important to consider that implant formation already started during the 
compacting phase (phase II). Collecting the lipid strand therefore started approximately after 
40 sec of the corresponding run (Figure IX-2). The differences between the first (0 cm to 30 cm) 
and the following sections (30 cm to 120 cm) can be explained by the fact that during the very 
first formation of the lipid strand, the pressure did not reach completely the steady-state plateau 
as illustrated in Figure IX-2 at phase II. Consequently, the lipid strand showed macroscopic 
irregularities, e.g. a very rough surface or even gaps and cut-outs. This goes in line with a more 
porous implant. By this, the faster release is plausible as well because incubation medium can 
penetrate faster into the micro-pores and channels running through the lipid matrix. After the 
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steady-state phase (phase III), extrusion pressure decreased and lipid strand formation 
subsequently ended.  
Throughout all experiments, the standard deviations of average extrusion pressures between 
independent runs (triplicates) were low which indicates a good reproducibility of the extrusion 
runs and a low batch to batch variety of the resulting lipid implant. Especially at lower extrusion 
temperatures, standard deviations ranged between 2 % to 5 %. Nevertheless, within a single 
run, isolated pressure peaks were observed as it is displayed in Figure IX-2.  
 
IX.3.3 IMPACT OF PROCESS PARAMETERS ON EXTRUDATE CHARACTERISTICS 
IX.3.3.1 EXTRUSION TEMPERATURE 
The impact of extrusion temperature was evaluated using the 50:50 lipid composition. Three 
different extrusion temperatures were chosen, covering the complete temperature range where 
this specific formulation is extrudable (33°C to 37°C).  
Figure IX-3 illustrates the pressure profiles at extrusion temperatures of 33°C, 35°C and 37°C, 
respectively. The lower the extrusion temperature the higher the steady-state pressure is: at 
33°C 2373 kPa (±48 kPa) was measured, whereas 975 kPa (±74 kPa) and 487 kPa (±240 kPa) 
were measured when extrusion was performed at 35°C and 37°C, respectively (Figure IX-4 A). 
At 37°C, the formulation was problematic to extrude, as the lipid melt resulted in implant 
irregularities and a non-constant implant formation. Moreover, isolated pressure peaks, a less 
constant steady-state, and relatively high standard deviations were observed. 
In addition to measuring the steady-state extrusion pressure, also the time of implant formation 
varied substantially. The speed at which implants were formed was strongly dependent on 
extrusion temperature.  
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Figure IX-3: Representative extrusion pressure profiles of a 50:50 lipid composition extruded at 33°C, 35°C, 
and 37°C at 40 rpm. 
 
 
Figure IX-4: (A) Average extrusion pressure, (B) bending strength, and (C) cumulative release of mAb after 
4 weeks of a 50:50 lipid composition as a function of extrusion temperature ranging from 33°C to 37°C 
extruded at 40 rpm. 
 
As shown in Figure IX-3, at 33°C a steady-state plateau was present for approximately 50 sec, 
whereas this time was reduced to 30 sec at 37°C. Considering that the formed lipid strand had 
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a length of 120 cm, the extrusion speed can be calculated with 2.4 cm/sec at 33°C, 3.4 cm/sec 
at 35°C and 4.0 cm/sec at 37°C. 
Mechanical properties of SLIs were highly dependent on the extrusion temperature as it can be 
seen in Figure IX-4. A strong correlation for extrusion pressure and bending strength can be 
observed: both decreasing with higher extrusion temperature. 
In contrast to bending strength, release kinetics did not directly correlate with average extrusion 
pressure. Figure IX-4 C displays the cumulative released amount of mAb after 4 weeks as a 
function of the extrusion temperature. Compared to the standard extrusion temperature (35°C), 
release rates were comparably faster when extrusion temperature was either elevated (37°C) 
or reduced (33°C), as illustrated in Figure IX-4 C.  
In Figure IX-5, microscopic appearance of SLIs in dependence of the extrusion temperature is 
depicted. At lower extrusion temperatures of 33°C (Figure IX-5 A) and 35°C (Figure IX-5 C), 
implants had a smooth surface with no irregularities (e.g. pores). At 37°C, a rather rough and 
uneven surface is noticeable (Figure IX-5 E). The micro-structure of the implants was affected 
by the extrusion temperature as well. At 33°C, needle-like structures are present with sharp 
edges and well-defined forms (Figure IX-5 B). In contrast, if 35°C or 37°C were applied, 
platelets-like structures instead of needles were observed (Figure IX-5 D and Figure IX-5 F), 
possibly due to the higher extrusion temperatures which were very close to the Tonset of H12 
(36.8°C).  
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Figure IX-5: SEM micrographs of lipid implant surfaces consisting of a 50:50 lipid composition, which were 
extruded at (A, B) 33°C, (C, D) 35°C and (E, F) 37°C. Micrographs were taken at a magnification of (A, C, E) 
80x, and (B, D, F) 2000x, respectively. 
 
DISCUSSION 
Within this experiment, the impact of extrusion temperature on implant properties was 
investigated for a 50:50 lipid composition which was extruded at 33°C, 35°C and 37°C at 40 rpm. 
At 33°C, the average extrusion pressure was nearly five times higher compared to pressure 
measured at 37°C (Figure IX-3 and Figure IX-4 A). Additionally, implant formation speed was 
practically doubled (2.4 cm/sec at 33°C versus 4.0 cm/sec at 37°C.). At temperatures close to 
the Tonset of H12 (36.8°C), the lipid is in a waxy condition rather than in a solid state, which 
creates a lower resistance and rigidity during feeding to the extruder inlet. For this reason, H12 
is easier to compact because the waxy H12 is pressed between the interspace of non-molten 
A B 
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D118 particles more easily. Thus, the overall resistance and rigidity of the formulation generated 
less pressure, hence resulting in lower average extrusion pressure and a faster implant 
formation speed. Bending strength measurements support this explanation. Due to less 
compaction at higher extrusion temperatures, the material was less compacted resulting in a 
lower mechanical stability (2.21 N at 33°C compared to 1.31 N at 37°C).  
At an extrusion temperature of 35°C, a perfect balance between waxy H12 and non-molten 
material (D118) resulted in the slowest release. The non-molten material (D118) acted as the 
solid phase; the waxy H12 served as a «kit» between the solid lipid platelets of the D118 during 
extrusion. Thereby, a tight and dense lipid matrix was formed. At lower extrusion temperatures 
than 35°C, less waxy H12 was present. Consequently, the solid lipid platelets of the D118 were 
less interconnected by molten H12. Thus, compression rather than melt extrusion might be the 
predominant implant formation process at this temperature. At higher extrusion temperatures 
than 35°C, no suitable implant was formed due to low compaction force.  
No change in lipid modifications were observed neither due to the extrusion process nor upon 
incubation as monitored by differential scanning calorimetry (data not shown).  
In conclusion, a correlation of extrusion pressure, mechanical stability and extrusion 
temperature was observed: the higher the extrusion temperature, the lower the average 
extrusion pressure associated with a faster implant formation. Mechanical stability decreased 
as a function of extrusion pressure. Contrarily, in-vitro release data did not correlate with 
extrusion temperature. The slowest release was observed for implants prepared at 35°C. In 
summary, both sufficient pressure and adequate molten material is needed to form a suitable 
implant. 
IX.3.3.2 SCREW SPEED 
In a next step, the impact of different screw speeds on implant properties was studied. For this 
approach, the lipid matrix consisted of the 50:50 lipid composition. Extrusion temperatures were 
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set to 33°C, 35°C, and 37°C. Additionally, screw speed was varied between 40 rpm and 80 rpm, 
respectively.  
The resulting extrusion pressure profiles are given in Figure IX-6. At all extrusion temperatures, 
a strong relationship between extrusion pressure, duration of steady-state and screw speed can 
be observed. At 33°C, a steep onset and offset of pressure curves was noticeable. Further, at 
higher screw speeds the onset occurred earlier and consequently the steady-state plateau was 
reached faster. At 35°C, a steep onset and offset was observed for 60 rpm and 80 rpm, whereas 
the onset of the 40 rpm-pattern increased slower. Additionally, the steady-state plateau of the 
40 rpm-pattern showed isolated peaks. Pressure curves recorded for 40 rpm and 60 rpm at 
37°C were characterised by an even slower increase in pressure onset compared to 33°C and 
37°C. Moreover, a higher degree of oscillation during the steady-state plateau was noticeable, 
especially at 40 rpm. 
 
Figure IX-6: Representative extrusion pressure profiles of lipid implants consisting of a 50:50 lipid 
composition applying various screw speeds at an extrusion temperature of (A) 33°C, (B) 35°C, and (C) 37°C. 
Please note that the extrusion pressure axis is scaled differently. 
 
Figure IX-7 A provides a summary of average extrusion pressures measured for all screw 
speeds at the different extrusion temperatures. For example, at 35°C, the average extrusion 
pressure increased from 975 kPa (±74 kPa) at 40 rpm to 2830 kPa (±539 kPa) at 80 rpm, which 
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represents a threefold increase by doubling the screw speed. This relationship was also valid 
for the other extrusion temperatures.  
 
Figure IX-7: (A) Average extrusion pressures, (B) bending strength and (C) cumulative release after 4 weeks 
of a 50:50 lipid composition extruded at various screw speeds (40, 60 and 80 rpm) and different extrusion 
temperatures ranging from 33°C to 37°C. 
 
Regarding the mechanical properties of SLIs, a tendency towards decreasing bending strength 
as a function of screw speed was observed (Figure IX-7 B). Moreover, slightly lower values can 
be detected for SLIs extruded at 35°C compared to 33°C. At 37°C, no differences in bending 
strength were observed between the applied screw speeds.  
The cumulative release of the mAb was monitored over 4 weeks and is displayed in Figure 
IX-7 C as a function of extrusion temperature and screw speed. Release rates depended on the 
screw speed, although to a different extent. Generally, a slower screw speed resulted in slower 
release rates. 
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Figure IX-8: SEM micrographs of lipid implant cross sections taken at a magnification of 80x. Implants were 
composed of a 50:50 lipid composition and were extruded at (A, B) 33°C, (C, D) 35°C and (E, F) 37°C. Shown 
SLIs were manufactured with a screw speed of (A, C, E) 40 rpm or (B, D, F) 80 rpm.  
 
SEM micrographs were acquired to determine the impact of different screw speeds on implant 
morphology (Figure IX-8). As demonstrated in Figure IX-8 A and Figure IX-8 B, at an extrusion 
temperature of 33°C implants contained more pores when extruded at 80 rpm compared to SLIs 
manufactured at 40 rpm, where a rather dense matrix can be noticed. At 35°C, only very small 
and isolated pores can be observed irrespectively of the applied screw speed (Figure IX-7 C). 
More pronounced pore formation was observed at 37°C. At 40 rpm, a few isolated pores were 
present, whereas at 80 rpm numerous pores and even channels running through the cross 
section can be noted. This is also in accordance with acquired in-vitro release data, since the 
fastest release was observed when implants were extruded at 80 rpm (Figure IX-7 C).  
A B 
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DISCUSSION 
Within this experiment, the impact of screw speed on the implants´ mechanical stability and 
release patterns at three different extrusion temperatures was investigated. Higher screw speed 
resulted in higher extrusion pressure for all extrusion temperatures (Figure IX-7 A). Due to the 
higher screw speed, more material is transported per time interval. Therefore, at a constant 
implant diameter, the pressure during the compacting phase (phase II) of the extrusion process 
(where the sensor is located) is higher. Logically, once the compacting phase is completed, a 
faster screw speed results in faster lipid strand formation (Figure IX-6).  
Interestingly, the higher pressures did not correlate with increased mechanical stability, as the 
bending strength decreased with increased screw speed for implants extruded at 33°C and 
35°C. This can be explained by the retention period of the material within the barrel: faster 
transported material was less molten which resulted in lower bending strength. By this, the faster 
in-vitro release can be explained as well. Consequently, it can be concluded that the material 
requires a minimum time period to allow sufficient energy transfer from the barrel and screws. 
Only after this minimum retention time is reached, higher screw speed would lead to higher 
mechanical stability and lower release rates. This can easily be realized by a longer barrel 
during upscaling. 
Additionally, it can be speculated that once the lipid strand is pressed through the outlet, it 
expands again (cavitation). This phenomenon has already been described during extrusion of 
PLGA-lipid blends using a RAM-extruder [431]. This effect might be more pronounced the faster 
the screws rotate, which is underlined by more porous implants (Figure IX-8) and a lower 
bending strength (Figure IX-7 B). This would also explain in-vitro release data, as the incubation 
medium can penetrate faster into more porous implants. 
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IX.3.3.3 LIPID COMPOSITION 
Above, for the 50:50 lipid composition the impact of different screw speeds and extrusion 
temperatures on implant properties was described. Next, the impact of the lipid composition 
itself on implant properties was studied. The lipid composition was varied between 30 % (30:70 
lipid composition) to 70 % of H12 (70:30 lipid composition) with the corresponding portions of 
D118 (70 % to 30 %); lyophilisate percentage was kept constant at 10 %. Implants were 
extruded at 33°C, 35°C and 37°C at a fixed screw speed of 40 rpm. The 30:70 lipid composition 
was additionally extruded at 39°C and 42°C.  
 
Figure IX-9: Representative extrusion pressure profiles of different lipid compositions extruded at (A) 33°C 
(B) 35°C and (C) 37°C. Lyophilisate percentage was kept constant at 10 %. Please note that the y-axis is 
scaled differently. 
 
The pressure curves of the different compositions extruded at 33°C, 35°C and 37°C are 
displayed in Figure IX-9. For the 30:70 lipid composition, the average steady-state pressure was 
2-3 times higher as the average steady-state pressure measured for the 50:50 and 70:30 lipid 
composition at all extrusion temperatures. The pressure patterns of the 50:50 and 70:30 lipid 
composition were comparable with respect to the duration of the plateau phase. However, the 
average steady state pressure (Figure IX-10 A) was lower for the 50:50 lipid composition 
compared to the 70:30 lipid composition for implants extruded at 33°C and 35°C. For the 
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implants extruded at 37°C, no difference in average steady-state pressure between the 50:50 
and 70:30 lipid composition was detectable (Figure IX-10 A).  
Furthermore, it should be noted that the plateau phase of the 30:70 lipid composition was almost 
twice as long and increased steadily, whereas a constant pressure was not reached (for all 
extrusion temperatures). Further, the pressure peak (most pronounced at 35°C) right at the 
beginning of the plateau phase and the irregular, oscillating course of the pattern was 
noticeably. For the 30:70 lipid composition, an approximately four times higher remaining 
pressure was determined compared to the other compositions for all extrusion temperatures 
(Figure IX-9). 
 
Figure IX-10: (A) Average extrusion pressure and (B) bending strength of implants consisting of different 
lipid compositions (30 % to 70 % H12) at various extrusion temperatures ranging from 33°C to 42°C.  
 
Bending strength results are depicted in Figure IX-10 B. No noticeable trend with respect to the 
lipid composition at the different extrusion temperatures was determined.  
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Figure IX-11: SEM micrographs of cross sections of lipid implants consisting of different lipid compositions. 
Micrographs (A) and (C) show implants consisting of the 30:70 lipid composition extruded at (A) 33°C and 
(C) 37°C. The right-hand side micrographs depict the 70:30 lipid composition extruded at (B) 33°C and (D) 
37°C, respectively. The magnification was set to 80x. 
 
The impact of lipid compositions on implant morphologies are illustrated in Figure IX-11. 
Exemplarily, micrographs of the 30:70 and 70:30 lipid compositions extruded at 33°C at 37°C 
are depicted, as they represent the «extreme cases» of this experiment. For the 30:70 lipid 
composition, the different extrusion temperatures did not impact implant microstructure as in 
both cases a dense matrix can be observed (Figure IX-11 A and Figure IX-11 C). Regarding the 
70:30 lipid composition, differences in the microstructure were apparent: at an extrusion 
temperature of 33°C, tiny pores and channels were present (Figure IX-11 B). At 37°C, larger 
pores and channels running through the complete cross section were observed thereby 
generating an interconnected pore-network (Figure IX-11 D). 
A 
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Figure IX-12: Cumulative release of mAb over 4 weeks in PBS pH 7.4 at 37°C. Lipid implants were prepared 
at different extrusion temperatures ranging from 33°C to 42°C. Additionally, lipid compositions were varied: 
(A) 30:70, (B) 50:50, (C) 70:30. 
 
A detailed insight into in-vitro release is provided in Figure IX-12 illustrating the release profiles 
of all tested compositions over 4 weeks. For the 30:70 lipid composition, release was slower the 
higher the extrusion temperature. After 14 days, release of the implants extruded at 39°C and 
42°C of the 30:70 lipid composition started to level off, already suggesting that release would 
stop rather early. SLIs prepared at 33°C, 35°C or 37°C provided a constant release. (Figure 
IX-12 A). The 70:30 lipid composition showed this trend after 14 days, even more considerably, 
also for the higher extrusion temperatures of 35°C and 37°C (Figure IX-12 C). Regarding the 
50:50 lipid composition, Figure IX-12 B signifies that no levelling occurred at all extrusion 
temperatures.  
In summary, formulations comprising slowest and most steady release were composed of 30:70 
lipid composition extruded at 35°C and 37°C and 50:50 lipid composition extruded at 35°C 
(which was the lead formulation described earlier).  
DISCUSSION 
As expected, the highest extrusion pressures were observed for the 30:70 lipid composition 
comprising 70 % D118, because of the higher amount of solid D118. The higher pressure during 
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extrusion also resulted in more compact (less porous) implants, which was confirmed by SEM 
micrographs (Figure IX-11). According to this fact (higher solid D118 content leads to higher 
pressures), our findings of the higher extrusion pressure for the 70:30 lipid composition instead 
of the 50:50 lipid composition are controversy (for 33°C and 35°C). At this point of knowledge, 
it can only be speculated that dependent on the amount of molten lipid other effects, e.g. change 
from a laminar flow towards a more turbulent flow could have contributed to the extrusion 
pressure measured with our setup. Overall, more molten material within the 70:30 lipid 
composition caused more interaction and higher viscosity than a lower amount of molten 
material (30:70 lipid composition) with dispersed solid D118. 
The detected differences in duration and course of the plateau phase between the 30:70 and 
50:50 or 70:30 lipid composition, respectively, correlates with our observations during the 
extrusion process: the formation of the lipid strand of the 30:70 lipid composition took twice as 
long as for the other two lipid compositions (in all cases 3 g were processed) which was reflected 
by the longer plateau phase. The irregular, oscillating course of the pressure pattern during the 
«plateau phase» of the 30:70 lipid composition correlates to a non-continuous strand formation 
noticed during extrusion. This was true for all extrusion temperatures from 33° to 42°C. 
With respect to the microstructure, it would have been expected, that at higher D118 
percentages more pores were generated due to a lack of waxy H12 (as described in IX.3.3.1), 
therefore resulting in a faster release. However, SEM micrographs showed a dense matrix, most 
likely caused by compression rather than melt extrusion, which is in accordance with the 
comparatively high extrusion pressures. The dense matrix also explains the slow release rates. 
Further, the observed decrease in release for higher extrusion temperatures (less pressure) can 
be explained by a change from compression to melt extrusion as a function of extrusion 
temperature. It can be assumed that melt extrusion leads to a more permanent connection of 
the lipids compared to compression. Thus, melt extrusion could be the reason for the slower 
and levelling off release of implants produced at higher extrusion temperatures. 
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At percentages of 70 % H12, a dense and compact matrix was expected as the solid D118 
would be completely surrounded by molten H12. In contrast, SEM micrographs showed a 
porous matrix. The micrographs indicated even more and larger pores for implants processed 
at higher extrusion temperatures. From the very low pressures measured using this setup, it 
can be assumed that not enough solid D118 was present to generate the minimum extrusion 
pressure, which is necessary to compact the material. Thus, no proper strand was formed 
(Figure IX-11 B and Figure IX-11 D). Having this in mind, it would have been expected that the 
release of the 70:30 lipid composition would have been faster compared to the non-porous 
matrix of the other composition. However, the measured slow release could be caused by a 
change in microstructure (from porous to dense) due to the incubation temperature of 37°C. 
This assumption was supported by the fact that the implant deformed upon incubation.  
 
IX.3.4 DOUBLE TSC-EXTRUSION 
Now, the aim was to study how extrusion pressure, implants´ mechanical properties and release 
patterns are changing when the same material was extruded twice. Lipid implants were extruded 
(first extrusion run), then ground and sieved (< 180 µm) prior to the second extrusion run. For 
all extrusions described in this section, the batch size was set to 3 g and screw speed was 
adjusted to 40 rpm.  
Three different approaches were tested. First, extrudates comprising the 50:50 lipid composition 
(10 % lyophilisate) were extruded at 35°C and 40 rpm. The ground and sieved material was 
then extruded a second time at 33°C, 35°C, or 37°C, respectively. In a second approach, a 
formulation comprising 20 % lyophilisate and 80 % D118 was first extruded at 65°C (named 
«20% in 0:100» in Table IX-2). Afterwards, the strand was ground and sieved (< 180 µm), H12 
was added to obtain a ratio of 50:50 and the second extrusion was performed at 35°C. Third, 
within the first extrusion run a formulation consisting of 20 % lyophilisate and 80 % H12 was 
extruded at 35°C (named «20% in 100:0» in Table IX-2). D118 was then added to the ground 
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and sieved (< 180 µm) material to obtain a 50:50 lipid composition which was then extruded at 
35°C. 
Table IX-2: Overview over formulations and settings applied for the different double tsc-extrusion 
experiments. 
 First extrusion Second extrusion 
 Formulation Settings Formulation Settings 
10% in 50:50/35°C_33°C 
10% lyophilisate, 
50:50 lipid matrix 
35°C 
10% lyophilisate, 
50:50 lipid matrix 
33°C 
10% in 50:50/35°C_35°C 35°C 35°C 
10% in 50:50/35°C_37°C 35°C 37°C 
20% in 0:100/65°C_35°C 
20% lyophilisate, 
D118 lipid matrix 
65°C 35°C 
20% in 100:0/35°C_35°C 
20% lyophilisate, 
H12 lipid matrix 
35°C 35°C 
 
Figure IX-13 A provides a summary of the average extrusion pressures measured during the 
first and second extrusion runs. Within the first approach, the 50:50 lipid composition was 
extruded at 35°C providing an average pressure of 975 kPa (±74 kPa). Within the second 
extrusion run, temperature was set to 33°C, 35°C and 37°C which resulted in an average 
pressure of 3085 kPa (±251 kPa), 907 kPa (±115 kPa) and 334 kPa (±97 kPa), respectively. 
The pressure values measured were similar to those already observed previously (Figure 
IX-4 A).  
An average pressure of 4438 kPa (±83 kPa) was measured for the extrusion of 20 % lyophilisate 
embedded within a pure D118 matrix (second approach). During this extrusion run, temperature 
was set to 65°C. This was the optimal extrusion temperature, as it is close to the Tonset of D118 
(70.0°C). After H12 was added to give a lipid ratio of 50:50, a pressure of 1531 kPa (±168 kPa) 
was measured during the second extrusion. Throughout the third approach, both extrusion runs 
comprised comparable average extrusion pressures (1065 kPa and 1247 kPa). 
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Figure IX-13: (A) Average extrusion pressure measured during the first and second extrusion run of the 
different approaches described above. (B) displays the average extrusion pressure only during the second 
extrusion run in comparison to the pressure values from the same formulations only extruded once. 
 
Within Figure IX-13 B, the average extrusion pressures during the second extrusion run were 
compared to the pressure values of the same formulations only extruded once (single 
extrusion). Only at 33°C, different extrusion pressures can be observed. A 24 % higher extrusion 
pressure was recorded (2373 kPa compared to 3085 kPa) when the formulation was extruded 
twice compared to a single extrusion using the same settings. For extrusions performed at 35°C 
and 37°C, respectively, average extrusion pressures were comparable. 
Mechanical properties were assessed by bending strength determination (Appendix, Table 
XII-2) and true density measurements (Appendix, Table XII-3). Regarding the first approach, 
bending strength stayed constant at approximately 2 N for all different approaches. True density 
values were found to correlate with average extrusion pressures as true density considerably 
decreased with decreasing temperature during the second run. This relation can also be 
described concerning the second approach. For lipid implants consisting of 100 % D118, true 
CHAPTER IX 
226 
density was measured at 1.086 g/cm3. After H12 was added to a give a 50:50 lipid composition, 
true density decreased to 1.057 g/cm3, which is in accordance with the reduced pressure. For 
the third approach, extruded implants consisting of 100 % H12 demonstrated a substantial 
softness indicated by the low bending strength of 0.87 N (±0.35 N). After D118 was added in a 
defined quantity, bending strength increased again to 1.42 N (±0.19 N), while true density 
reached the value as measured for the second approach. 
 
Figure IX-14: Cumulative release over the first 4 weeks of SLIs manufactured with the different double 
extrusion approaches compared to the lead formulation extruded only once. For a better visualisation, y-
axis was scaled to 60 %. 
 
As illustrated in Figure IX-14, cumulative release of mAb from double extruded implants was 
measured over 4 weeks. As a benchmark, release of mAb from the lead formulation (which was 
only extruded once) is shown additionally. When following the first approach, independent of 
the extrusion temperature during the second extrusion, release rates were slowed down clearly 
compared to the lead formulation: 40.3 % (±4.1 %) mAb was released from the lead formulation, 
compared to 24.0 % to 27.4 % released from double extruded SLIs after 4 weeks. Thus, release 
rates were almost halved.  
PRESSURE MEASUREMENT DURING TSC-EXTRUSION OF SOLID LIPID IMPLANTS 
227 
Concerning the release patterns of SLIs prepared by the second and third approach, the release 
rates were comparable to the single extruded lead formulation (41.5 % compared to 47.6 %). 
Hence, a further retardation of release was not achieved. 
DISCUSSION 
The first approach of double extrusion did not influence average extrusion pressure much 
compared to a single extrusion run (Figure IX-13 B). The mechanical properties of double 
extruded SLIs were comparable to those only extruded once. Although, bending strength and 
true density were slightly higher, which is plausible because the material was extruded (and 
thereby compressed) twice (Appendix, Table XII-2 and Table XII-3).  
Interestingly, release was slowed down almost by one half when the same formulation was 
extruded twice (Figure IX-14). This observation was most likely caused by changes within the 
microstructure of the lipid matrix. However, SEM micrographs showed comparable dense 
matrices in all cases and did not provide any additional information (data not shown). The 
protein was more thoroughly embedded within the lipid matrix by double extrusion, because the 
lipid material was compressed twice. True density measurements support this explanation 
(Appendix, Table XII-3). Consequently, this resulted in a slower release. To prove this 
assumption, a labelling of protein with fluorescence dyes might be beneficial. If a more effective 
encapsulation of the mAb was the reason for the slower release, it should be considered that 
the mAb could theoretically be encapsulated irreversibly into lipid cavities.  
Release was not further slowed down by the second and third approach compared to the lead 
formulation (single extrusion), but release rates were within the same corridor. This leads to the 
conclusion that the double extrusion technique in general results in SLIs with very slow release 
rates.  
In summary, very promising sustained release data were generated by a rather simple 
adjustment of the established extrusion process.  
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IX.4 CONCLUSION 
Within this chapter we described the thorough investigation on process monitoring to 
understand solid lipid extrusion using a tsc-extruder for lipid protein depots. 
A pressure measurement tool allowed us to monitor the process online. Thereby, we could 
describe and characterise an extrusion run in four different phases: feeding (I), compacting (II), 
implant formation (III) and end of implant formation (IV). Implant formation took place mainly 
during the steady-state phase (phase III). We would recommend discarding the first 30 cm of 
formed lipid strand and the parts which were formed during phase IV. In general, up to 100 cm 
product was manufactured utilising a batch size of 3 g. 
Furthermore, the preparation process can ensure both a homogenous distribution of the protein 
encapsulated within the lipid matrix and consistent mechanical properties of SLIs (first 30 cm 
formed are not considered). Additionally, a low batch to batch variety demonstrated the good 
reproducibility and robustness of the extrusion process. 
Insights into how a change of process parameters affects extrusion pressure, mechanical 
properties and release kinetics were gained. By changing process parameters, e.g. screw 
speed, mechanical properties of SLIs can be adjusted. Furthermore, it is now possible to 
estimate how and to which extent a change of a certain process parameter will impact 
mechanical properties or release patterns of SLIs. This allows us to assess if an extrusion 
process is either susceptible or robust against process parameter changes.  
It should be pointed out, that an independent systematical investigation of extrusion temperature 
and screw speed could not completely be realized due to the short screws resulting in short 
retention times and incomplete heat transfer. The two parameters will be studies fully 
independent from each other with an elongated extruder barrel in the course of future scale up 
work.  
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The double extrusion technique slowed down mAb release by almost one half. This process 
reveals a great potential because versatile parameters can be adjusted creating a wide range 
of possible product features. 
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X. FINAL SUMMARY AND OUTLOOK 
 
Within this thesis, solid lipid implants were manufactured by twin-screw extrusion and were 
evaluated with respect to their potential for intraocular use. The study included investigations 
on long-term release of different therapeutic protein formats (monoclonal antibody, fab-fragment, 
fusion protein), the in-vivo performance of SLIs which have been intravitreally administered in 
rabbit eyes, and the stability profile of both encapsulated and released protein. Also, the 
biological activity of released protein was evaluated. Triglyceride-protein interactions were 
further examined to study the influence of these interactions on the protein stability and release 
profile. Towards a better understanding of the extrusion process, a pressure measurement 
system was set up and the extrusion pressure was measured online. SLIs were analysed in 
terms of mechanical properties, morphology and release patterns to correlate those 
characteristics with extrusion parameters.  
 
Chapter I and II include the general introduction and the objective of the thesis. In chapter III, 
the materials and methods are described. 
 
In chapter IV, investigations on improving in-vitro release kinetics were described. In-vitro 
release for up to 120 days of different protein formats from implants being only 1.5 mm x 15 mm 
in size was achieved. The formulation developed ensured a constant release without any burst 
release by a load of 3.00 mg protein per implant. The avoidance of the precipitant PEG as a 
possible source for protein degradation represents a major improvement. The extrusion process 
was established on a ZE-5 mini-extruder, allowing to extrudate very small batch sizes (only 
500 mg) at gentle temperatures of 35°C. It was also ensured that extruded lipid implants can be 
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stored for at least 3 months without any negative impact on the release patterns, thermal 
properties, and status of crystallinity, respectively.  
To further prolong the release duration, triglycerides were pre-melted prior to extrusion. Release 
duration of mAb was prolonged to up to 200 days (increase of approximately 63 %) and 
Ranibizumab release was extended to circa 160 days (40 % longer release duration), compared 
to conventional extrusion. Since the release was substantially different after SLI storage in this 
case, more research is required to elucidate these aspects further.  
For comparison, proteins were also incorporated into PLGA matrices by tsc-extrusion having 
the same dimensions as SLIs. In general, release was, if at all observed, very slow (maximum 
15 % over 98 days). Even after matrix degradation no burst release was noticed, which 
underlines the problems with protein degradation when using PLGA.  
 
The in-vivo performance of Ranibizumab (Lucentis®) loaded SLIs was evaluated within a 3-
month in-vivo study in rabbit eyes using a choroidal neovascularisation model (CNV) and is 
reported in chapter V. We showed that biocompatibility was excellent throughout the 3 months 
of observation. Unfortunately, a partial break-up of implants was observed which was the reason 
for a faster in-vivo release compared to the release observed in-vitro. In-vivo release was 
measured over 3 months, but generally no more Ranibizumab was released after 8 weeks. It 
was identified that the formulation was mechanically sensitive, which was the cause for the 
break-up of implants. Possible reasons were: the relatively high percentage of H12 and the 
temperature within the rabbit eye. Even though the results did not fulfil the expectations, once 
the problem of mechanical stability can be solved, SLIs still represent an interesting depot for 
intravitreal delivery of pharmaceutical proteins.  
The marketed products available for intravitreal applications should be taken into consideration 
as a benchmark. The depots Retisert® (5 mm x 2 mm x 1.5 mm), Ozurdex® (0.45 mm x 6.5 mm) 
and Iluvien® (0.37 mm x 3.5 mm) are all smaller in size compared to SLIs described here. 
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Therefore, investigating smaller sized SLIs by ensuring an adequate protein load should be 
considered for further work. Nevertheless, the size of SLIs used in this work was already suitable 
for intravitreal use.  
 
Chapter VI was intended to extend our technology to other protein formats. For this, the in-vitro 
release of the complement factor H (mini-FH) and determination of its biological activity over a 
period of 98 days was reported. Even after 98 days, the mini-FH released from SLIs still 
exhibited biological activity.  
 
The stability of both encapsulated and released proteins was reported in chapter VII. Moreover, 
the stability of proteins delivered from PLGA implants was assessed and compared to those of 
proteins delivered from SLIs. The IgG1 monoclonal antibody was characterised by an adequate 
stability over more than 6 months, even though minor chemical and conformational instabilities 
were observed. This is a unique finding, since a delivery duration of 6 month of a protein 
therapeutic displaying such a good stability over the complete time frame can rarely be found 
in literature. Released Ranibizumab showed excellent physical, chemical and conformational 
stability over 4 months. Furthermore, Aflibercept stability was monitored over 3 months. 
Instabilities with respect to physical, chemical and conformational stability started approximately 
after 1 month and increased continuously. Bevacizumab instability was already observed after 
1 week, and at the end of the observation time (1 month), the antibody was fully chemically and 
conformationally degraded. 
In addition, the stability of mAb and Ranibizumab was assessed upon storage. For that, loaded 
SLIs were stored for 3 months at 4°C prior to in-vitro release in the dry state. MAb and 
Ranibizumab showed perfect stability after 3-month of storage.  
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The stability of released protein from a PLGA matrix was also assessed in chapter VII. For all 
proteins, a rapid and substantial degradation was observed, being in accordance with literature 
[49, 217, 300]. SE-HPLC and SDS-PAGE results revealed a distinct monomer loss of released 
proteins mainly caused by fragmentation (VII.2.2.1). For instance, comparing Ranibizumab 
monomer content released from SLIs after 12 weeks (100.1 %) and Resomer® RG 502 H 
implants (4.4 %) underlines this. Also, analysis towards chemical stability (IEX, HIC, reducing 
capillary gel electrophoresis) pointed into the direction of rapid degradation of all tested proteins 
in PLGA matrices. Especially higher percentages of LMW species and light chain were 
observed. These results highlight that SLIs provide an outstanding delivery matrix for proteins, 
as the stability of the incorporated protein during long-term release and storage was retained 
compared to the PLGA implants used here.  
 
In chapter VIII, studies on triglyceride-protein-interactions are described. Incubation studies 
were performed, where extruded rods consisting of 100 % H12, D118, or Resomer® RG 755 S 
were incubated with solutions of mAb, Ranibizumab, Bevacizumab and Aflibercept over 
8 weeks. Colloidal, chemical and conformational stability of proteins were assessed at 
predetermined time points. Elevated particle counts, monomer loss and less protein recovery 
upon incubation with H12 rods were observed. This was especially the case for Aflibercept and 
Bevacizumab, whereas for the other proteins the increase in particle counts was smaller. 
Neither H12 nor D118 were identified as trigger for inadequate release patterns or chemical 
degradation.  
It was also tested if possible heavy metal impurities of the raw materials could cause protein 
degradation. Only aluminium was found by ICP-AES, which did not promote chemical 
instabilities. Other impurities possibly being present in the lipid raw material, e.g. peroxides or 
aldehydes, could be the reason for protein degradation. This should be further investigated. 
Lastly, it should be noted that adsorption phenomena play a major role affecting sustained 
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release of proteins form triglyceride based depots that should be more extensively examined in 
future.  
 
Within chapter IX, the extrusion process was studied with regards to process parameters and 
how changing these parameters affected the properties of the lipid matrices. For this, a custom-
made resistance strain gauge was designed and established to measure the pressure within 
the barrel during an extrusion run. The impact of process parameters such as extrusion speed, 
temperature, and lipid composition on implant properties was investigated systematically. 
Bending strength, true density and microscopic appearance of extruded implants was assessed. 
Furthermore, in-vitro release profiles were addressed using a monoclonal antibody. This 
allowed to characterise an extrusion run which can be defined into four different phases: 
feeding, compacting, implant formation, and end of implant formation. Additionally, the inner-
strand homogeneity was investigated displaying a homogenous distribution of the protein within 
the lipid matrix. The batch to batch variation was very low, demonstrating good reproducibility 
and robustness of the extrusion process.  
It was possible to correlate implant properties to the different process parameters (extrusion 
temperature, screw speed, lipid composition). In summary, we now know that both sufficient 
extrusion pressure and an appropriate ratio of molten to solid lipid is needed to form a suitable 
implant. 
Furthermore, double extrusion was investigated as an additional preparation method. By this, 
the release rate of mAb was almost halved over the first 4 weeks by simply performing the 
extrusion twice with slightly different extrusion temperatures or even the same settings. 
Therefore, it reveals a great potential, because versatile parameters can be adjusted creating a 
great scope for further research. As lipids are exposed to extrusion temperatures twice, possible 
re-crystallisation of the triglycerides should be taken into consideration for further research. 
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XI. ADDENDUM 
XI.1 LIST OF ABBREVIATIONS 
AAV   adeno-associated virus 
AMD   age related macular degeneration 
ANP   atrial natriuretic peptide 
AP   alternative pathway 
AUC   area under the curve 
BDNF   brain derived neurotropic factor 
bFGF   basic fibroblast growth factor 
BMP-2   bone morphogenetic protein-2 
BSA   bovine serum albumin 
CD   circular dichroism 
CDR   capsule drug ring 
cIEF   capillary isoelectric focussing 
CNV   choroidal neovascularisation 
CPP   central precocious puberty  
DDS   drug delivery system 
DLS   dynamic light scattering 
DNA   deoxyribonucleic acid 
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DR   diabetic retinopathy 
DSC   differential scanning calorimetry 
DTT   dithiothreitol 
EDTA   ethylene diamine tetra acetic acid 
ELISA   enzyme-linked immunosorbent assay 
EPO   erythropoietin 
EVA   ethylene vinyl acetate 
Fab   fragment antigen binding 
Fc region  fragment crystallisable region 
FDA   food and drug administration 
FFF   front face fluorescence 
FNU   formazine nephelometric unit 
FT-IR   fourier transform infrared spectroscopy 
GLP   glucagon-like-peptide 
GnRH   gonadotropin releasing hormone 
HCl   hydrochloride 
HEMA   hydroxyethyl methacrylate 
HES   hydroxyethyl starch 
HIC   hydrophobic interaction chromatography 
HME   hot melt extrusion 
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HMW   high molecular weight 
HNO3   nitric acid 
HP-β-CD  hydroxypropyl-beta-cyclodextrine 
HRP   horseradish peroxidase 
IC50    half maximal inhibitory concentration 
ICP-AES  inductively coupled plasma atomic emission spectroscopy 
IEX   ion exchange chromatography 
IgG   immunoglobulin G 
ITC   isothermal titration calorimetry 
KOH   potassium hydroxide 
LMW   low molecular weight 
LO   light obscuration 
LOD   limit of detection 
mAb   monoclonal antibody 
MC    methylcellulose 
MFI   microflow imaging 
mPEG   monomethoxy polyethylene glycol 
MQ water  milli-Q water 
MW   molecular weight 
MWCO  molecular weight cut off 
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NELL-1  NEL-like molecule-1 
nIFN   native interferon 
NIR   near-infrared 
NMP   N-methyl-2-pyrrolidon 
PBS   phosphate buffered saline 
PCL   poly(ɛ-caprolactone) 
PDGF   platelet-derived growth factor 
PEG   polyethylene glycol 
PEO   polyethylene oxide 
pI   isoelectric point 
PLA   poly-lactic acid 
PLGA   poly-lactic-co-glycolic acid 
PNH   paroxysmal nocturnal hemoglobinuria 
PVA   poly vinyl acetate 
QCM   quartz crystal microbalance 
rRBCs   reagent red blood cells 
RNA   ribonucleic acid 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate poly acryl gel electrophoresis 
SE-HPLC  size exclusion high performance liquid chromatography 
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SEM   scanning electron microscopy 
siRNA   small interfering ribonucleic acid 
SLE   solid lipid extrusion 
SLI   solid lipid implant 
SLM   solid lipid microparticle 
SLN   solid lipid nanoparticle 
SPR   surface plasmon resonance 
Tg`   glass transition temperature 
TMPE-TL  trimethylopropane ethoxylated-ethyl 2-mercaptoproprionate 
TMPE-TG  trimethylopropane ethoxylated ethyl thioglycolate 
Tsc    twin screw 
UV-VIS  ultraviolet-visible spectrophotometry 
VEGF   vascular endothelial growth factor 
WCX   weak cation exchange 
XRPD   X-ray powder diffraction 
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XII. APPENDIX 
 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng 
4 BSA 0.36 ng 
5 week 0 
6 week 4 
7 week 8 
8 week 12 
9 week 24 
10 MW Marker 
Figure XII-1: Non-reducing denaturating SDS-PAGE of reconstituted mAb lyophilisates after a storage period 
of 0, 4, 8, 12 and 24 weeks at 4°C. 
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2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 week 0 
6 week 4 
7 week 8 
8 week 12 
9 week 24 
10 blank 
11 blank 
12 MW Marker 
Figure XII-2: Non-reducing denaturating SDS-PAGE of reconstituted Ranibizumab lyophilisates after a 
storage period of 0, 4, 8, 12 and 24 weeks at 4°C. 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng 
4 BSA 0.36 ng 
5 week 0 
6 week 4 
7 week 8 
8 week 12 
9 week 24 
10 MW Marker 
Figure XII-3: Non-reducing denaturating SDS-PAGE of reconstituted Bevacizumab lyophilisates after a 
storage period of 0, 4, 8, 12 and 24 weeks at 4°C. 
 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 reference 
3 BSA 1.80 ng 
4 BSA 0.36 ng 
5 week 0 
6 week 4 
7 week 8 
8 week 12 
9 week 24 
10 MW Marker 
Figure XII-4: Non-reducing denaturating SDS-PAGE of reconstituted Aflibercept lyophilisates after a storage 
period of 0, 4, 8, 12 and 24 weeks at 4°C. 
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Figure XII-5: Cumulative release of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept from SLIs 
manufactured with pre-melted lipids. Lipid implants were produced with different percentages of protein 
lyophilisate in a 1:1 [w/w] formulation with HP-β-CD resulting in a final protein load of 5 %, 7.5 % and 10 % 
per implant.  
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Figure XII-6: Diffraction patterns of SLIs produced with conventional extrusion technique. SLIs were stored 
for 0, 4 and 12 weeks at 4°C. 
 
 
Figure XII-7: Diffraction patterns of SLIs extruded with pre-melted lipids. SLIs were stored for 0, 4 and 
12 weeks at 4°C. 
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Figure XII-8: Chromatogram of (A) mAb and (B) Bevacizumab using a Dionex ProPac® WCX-10 column for 
separation of charge variants. For mAb, samples were analysed after 6, 14 and 26 weeks of release. Released 
Bevacizumab was analysed after 3, 14 and 21 days. For both proteins, the main charge variant decreased 
while the percentage of acidic subspecies increased. 
 
 
Figure XII-9: Chromatograms of (A) Ranibizumab and (B) Aflibercept using a Dionex MAbPac™ HIC-10 
column for separation of charge variants. For Ranibizumab, samples were analysed after 4, 10 and 18 weeks 
of release. Released Aflibercept was analysed after 4, 10 and 14 weeks. For both proteins, the main charge 
variant shifted to shorter retention times upon incubation. 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
  
1 MW Marker 
2 reference 
3 BSA 1.80 ng  
4 BSA 0.36 ng 
5 blank 
6 week 0 
7 week 4 
8 week 12 
9 blank 
10 MW Marker 
Figure XII-10: Non-reducing denaturating SDS-PAGE gel of released mAb fractions from the first week of 
release after different storage times (0 weeks to 12 weeks). Only samples comprising the 3:1 [w/w] 
lyophilisate are displayed. 
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Table XII-1: Overview of pH of samples incubated with H12, D118 and RG 755 S rods and without any 
additives (PBS, negative control) after 0 weeks and 8 weeks at 35°C and 40 rpm. 
 PBS H12 rods D118 rods PLGA rods 
 week 0 week 8 week 0 week 8 week 0 week 8 week 0 week 8 
PBS 7.40 
(±0.02) 
 
7.37 
(±0.01) 
 
7.40 
(±0.02) 
 
7.37 
(±0.01) 
 
7.40 
(±0.02) 
 
7.37 
(±0.01) 
 
7.40 
(±0.02) 
 
7.37 
(±0.01) 
 
mAb 6.89 
(±0.11) 
 
6.94 
(±0.01) 
 
6.94 
(±0.05) 
 
6.90 
(±0.00) 
 
6.96 
(±0.07) 
 
6.91 
(±0.00) 
 
6.88 
(±0.03) 
 
6.83 
(±0.08) 
 
Ranibizumab 6.99 
(±0.02) 
 
7.07 
(±0.02) 
 
6.98 
(±0.07) 
 
7.01 
(±0.02) 
 
6.99 
(±0.04) 
 
7.04 
(±0.01) 
 
7.00 
(±0.03) 
 
7.06 
(±0.01) 
 
Bevacizumab 6.78 
(±0.02) 
 
6.91 
(±0.02) 
 
6.84 
(±0.06) 
 
6.89 
(±0.01) 
 
6.87 
(±0.05) 
 
6.90 
(±0.01) 
 
6.79 
(±0.03) 
 
6.92 
(±0.01) 
 
Aflibercept 6.88 
(±0.03) 
6.89 
(±0.01) 
6.89 
(±0.05) 
6.87 
(±0.02) 
6.89 
(±0.02) 
6.89 
(±0.02) 
6.89 
(±0.06) 
6.89 
(±0.01) 
 
CHAPTER XII 
260 
 
Figure XII-11: Monomer content of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept upon 8-
week incubation in PBS (negative control) or with H12, D118 and RG 755 S rods. 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
 
1 MW Marker 
2 BSA 1.80 ng  
3 BSA 0.36 ng 
4 reference  
5 PBS_week 8 
6 H12_week 8 
7 D118_week 8  
8 RG 755 S_week 8 
9 blank 
10 MW Marker 
Figure XII-12: Non-reducing denaturating SDS-PAGE gel of mAb incubated for 8 weeks with H12, D118 and 
RG 755 S rods or in PBS (negative control) at 35°C. 
 
1 2 3 4 5 6 7 8 9 10 No. Sample name 
   1 MW Marker 
2 BSA 1.80 ng  
3 BSA 0.36 ng 
4 reference  
5 PBS_week 8 
6 H12_week 8 
7 D118_week 8  
8 RG 755 S_week 8 
9 blank 
10 MW Marker 
Figure XII-13: Non-reducing denaturating SDS-PAGE gel of Bevacizumab incubated for 8 weeks with H12, 
D118 and RG 755 S rods or in PBS (negative control) at 35°C. 
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1 2 3 4 5 6 7 8 9 10 No. Sample name 
  
1 MW Marker 
2 BSA 1.80 ng  
3 BSA 0.36 ng 
4 reference  
5 PBS_week 8 
6 H12_week 8 
7 D118_week 8  
8 RG 755 S_week 8 
9 blank 
10 MW Marker 
Figure XII-14: Non-reducing denaturating SDS-PAGE gel of Aflibercept incubated for 8 weeks with H12, D118 
and RG 755 S rods or in PBS (negative control) at 35°C. 
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Figure XII-15: Capillary gel electrophoresis applying a 2100 Bioanalyzer under reducing denaturating 
conditions of (A) mAb, (B) Ranibizumab, (C) Bevacizumab, and (D) Aflibercept samples after an 8-week 
incubation with H12, D118 or RG 755 S rods. The protein bulk is defined as reference whereby incubation in 
PBS without any rods served as negative control. 
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Figure XII-16: Extrinsic fluorescence measurements of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) 
Aflibercept samples after an 8-week incubation with H12, D118 or RG 755 S rods. The protein bulk is defined 
as reference whereby incubation in PBS without any rods served as negative control. As positive control, 
proteins were exposed to 80°C and 400 rpm for 10 min. 
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Figure XII-17: Protein recovery of (A) mAb, (B) Ranibizumab, (C) Bevacizumab and (D) Aflibercept upon 8-
week incubation in PBS (negative control) or with H12, D118 or RG 755 S rods, respectively, measured by 
SE-HPLC. 
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Table XII-2: Overview of bending strength measured after the first and the second extrusion in comparison 
to single extrusion. 
Extrusion settings Bending strength [N]  
 First extrusion Second extrusion Single extrusion 
10% in 50:50/35°C_33°C 
2.025 (±0.39) 
1.978 (±0.43) 2.212 (±0.14) 
10% in 50:50/35°C_35°C 2.393 (±0.10) 2.025 (±0.39) 
10% in 50:50/35°C_37°C 1.966 (±0.38) 1.312 (±0.22) 
20% in 0:100/65°C_35°C 1.448 (±0.29) 1.458 (±0.33) - 
20% in 100:0/35°C_35°C 0.875 (±0.34) 1.424 (±0.19) - 
 
Table XII-3: True density of lipid implants measured after the first and second extrusion run applying different 
extrusion settings in comparison to single extrusion. 
Extrusion settings True density [g/cm3]  
 First extrusion Second extrusion Single extrusion 
10% in 50:50/35°C_33°C 1.031 (±0.002) 1.050 (±0.002) 1.049 (±0.002) 
10% in 50:50/35°C_35°C 1.031 (±0.002) 1.048 (±0.002) 1.031 (±0.002) 
10% in 50:50/35°C_37°C 1.031 (±0.002) 0.977 (±0.002) 1.008 (±0.005) 
20% in 0:100/65°C_35°C 1.086 (±0.002) 1.057 (±0.004) - 
20% in 100:0/35°C_35°C 1.080 (±0.001) 1.056 (±0.002) - 
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